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Dr. Ka Kit Edmond CHAN 
Abstract  
Kidney transplantation significantly improves quality of life and survival in patients with advance d 
renal failure and it has become the treatment of choice. Long-term immunosuppressants following 
transplantation are associated with an increased risk of infection, malignancy and diabetes. 
Therefore, transplant physicians endeavour to reduce long-term maintenance of the 
immunosuppression burden and aim to reduce the risk of developing these complications.  This has 
been made possible in the last decade with the introduction of biological induction agents, namely 
Campath 1H. 
Campath (Campath-1H) is a humanised rat monoclonal antibody directed against the CD52 antigen, 
which is one of the most abundant antigens on human lymphocytes. Activation of CD52 antigen 
causes profound cell lysis and cytokines release. This was thought to be crucial in the mechanism of 
developing a partial tolerance in transplant recipients. 
A great interest has developed in its use in transplantation since the first reported use of Campath-
1M in solid organ transplantation in the late 1980s and humanised Campath 1H in 1998. Campath 
had been used as an induction agent together with varying maintenance regimes with different 
results. 
In this thesis, I am going to present a brief history of kidney transplantation and a literature review 
on the use of Campath in transplantation. I will follow by presenting the results and discussions on 
clinical studies that I developed during my study: the pilot study of Campath induction with 
tacrolimus monotherapy; CamTac study - a randomised controlled study; the prospective long-term 
outcomes study; the retrospective cohort dose-finding study; further studies developed to examine 
the incidence and risk related to long-term immunosuppression – causes of graft loss, long-term 
allograft pathology, infection, malignancy, haematological profile; and a detailed study on 
lymphocyte proliferation and rejection following Campath induction.  
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1 Introduction 
The incidence of end-stage renal failure [ESRF] in the United Kingdom has been slowly rising over 10 
years. The UK renal registry estimated that the incidence of ESRF in the UK has risen from 566 per 
million populations [pmp] in 2002 to 794 pmp in 2009 (1). Treatment options in patients with ESRF 
are somewhat limited. Death is almost inevitable without treatment. There is a substantial 
improvement in survival with each treatment option; however, it comes with significant trade-offs.  
Haemodialysis is the commonest renal replacement modality; (1) Patients are required to attend a 
specialised unit for dialysis three times a week, and duration of each session is approximately four 
hours. Even with this length of dialysis, this form of renal replacement therapy [RRT] only managed 
to offer a minimal renal support. This form of RRT has a detrimental impact on a patient’s quality of 
life (2), as well as increased risk of infection, bleeding from anticoagulation required for dialysis, 
cardiovascular risk, and amyloid. 
Peritoneal dialysis is an alternative to haemodialysis; this form of RRT requires patients to perform 
dialysis at home using pre-prepared fluid. This is a viable option for patients who seek RRT away 
from hospital settings; however, this form of dialysis requires patients’ ability to commence dialysis 
as well as a considerate amount of storage space for the disposables. Furthermore, there is growing 
evidence that this form of dialysis is associated with incurable complications in the long term (3).  
Either of the dialysis modalities provides bare minimum renal support to patients with ESRF, and has 
an adverse impact on patients’ quality of life because of the nature of dialysis.  
Kidney Transplantation from either a living or deceased donor would be a good alternative to dialysis 
in patients with ESRF. Transplantation improves mortality, quality of life and general well-being. 
However, this is not without risk and complication, which I will discuss further. 
Patients with ESRF have a substantially poor mortality. The renal registry highlighted a 50% 5-year 
survival rate in patients aged between 55 and 64. (1) NHS statistics showed that patients with 
chronic kidney disease have an almost 100-fold increase in mortality. It has long been established 
that transplantation improves mortality in the long term (4). Data from the UNOS database shows 5-
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year patient survival of 85% after transplantation compared to the dismal survival of 67% reported in 
the renal registry.  
1.1 History of renal transplantation 
Renal transplantation is widely accepted as the treatment of choice in patients with advanced renal 
failure; it had been shown that transplantation significantly improves patients’ quality of life and 
long-term survival. The effort and experimentation in development in organ transplantation started 
in the early 1900s and the development of clinical transplantation remains one of the most 
fascinating stories in clinical medicine and immunology. 
The concept of transplanting organs between human beings and animals was not alien in historic 
literature. In Homer’s The Odyssey, in the 9th century BC, he described an animal Chimera weaved 
together by supernatural forces with a lion, goat and dragon.  A Chinese literature in the 4th century 
BC described Tsin Yue-Jen, a surgeon who switches the hearts of two soldiers – one had a strong 
spirit but weak will and the other had a weak spirit but strong will. A Roman Catholic story from 3rd 
century AD described St Cosmos and Damian replacing a patient’s gangrenous leg with one from a 
recently deceased Ethiopian man. Although these stories are fictional, they certainly spark the 
curiosity of clinicians and the public towards transplantation.  
The first documented transplantation was by James Blundell (5, 6). A British obstetrician transfused 
4 ounces of blood from a man to his wife; during the time, a postpartum haemorrhage was common 
and associated with a marked mortality. He then attempted a transfusion in 10 other women, of 
which 5 survived. During his experiment, Blundell observed an immediate transfusion reaction with 
a few transfusion recipients. It is now clear that this is due to a circulatory antibody against a 
different blood group and this problem remains a major barrier in solid organ transplantation. 
Experimentation on organ transplantation continues. The first successful bone transplantation was 
reported in 1878, attempts on bone marrow transplantation were made in 1896 and the first 
successful skin graft was in 1881 (7). 
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In 1902, Hungarian surgeon Emerich Ullmann and French surgeon Alexis Carrel began separately 
experimenting with kidney transplantation in dogs. Ullmann transplanted a dog’s kidney into 
another dog’s neck, whereas Carrel transplanted the dog’s own kidney onto its neck. Although 
Ullmann’s experiment failed soon after transplantation due to rejection, their experiments 
established a successful way for blood vessel anastomosis to be achieved. Carrel continued his 
experiment further by transplanting between dogs and discovered that transplantation between 
animals inevitably fails; he termed this effect “biological incompatibility”, the most important barrier 
in transplantation, and this becomes the foundation of modern immunology. 
There were many unsuccessful attempts to transplant kidneys between humans and animals and 
between humans between the early 1900s and mid-1950s. The first successful kidney 
transplantation in humans was performed between identical twins in 1954 in Boston, led by Joseph 
Murray (8). The donor and recipient were 23-year-old twins, one of whom was suffering from 
advanced glomerulonephritis. The transplant was successful: the recipient returned to work and led 
a normal life. Murray reported a further 6 successful cases of living donor transplantation. 
However, transplantations were limited to homozygote twins until the idea of immunosuppression 
emerged. Murray attempted transplantation in a patient after she had received a high dose of total 
body irradiation as immunosuppression in 1958; although the surgery was successful and 
subsequent histological examination did not show any rejection, the patient died of 
thrombocytopenia following bone marrow failure induced by radiation. This resulted in a reduction 
in radiation doses and led to the first successful transplantation between non-identical twins in 
1959, between siblings in 1960 and between non-siblings in 1961. Total body radiation was shown to 
be an effective immunosuppressant; however, the radiation also produced profound bone marrow 
aplasia and subsequent high risk of infection (9). This practice was soon abandoned following the 
discovery of Azathioprine (10). 
It became possible to transplant a kidney from a deceased donor following the introduction of 
azathioprine and steroids in 1962(11), and the combination of Azathioprine and steroids became the 
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mainstream immunosuppressive regimen for almost 20 years until the introduction of cyclosporine. 
Together with azathioprine and steroids, the triple therapy immunosuppressive protocol had 
revolutionised solid organ transplantation and became the golden standard until the early 21st 
century (12). 
1.2 Maintenance immunosuppression in renal transplantation 
Overcoming an alloimmune response to an allograft following transplantation was, and still is, a 
major challenge for solid organ transplantation. Carrel first reported the inability to transplant 
allografts between animals in the 1900s in his experiment and labelled this “biological 
incompatibility” (12). Total body radiation was tried 60 years following the first animal experiment 
and successful transplantation between non-homozygotic individuals became reality. However, this 
drastic treatment is associated with high infective risk and mortality. A newer and more targeted 
treatment has been developed over the last few decades with the improved understanding of the 
role of the immune system in allograft recognition and rejection. 
The immune system identifies foreign material via the Major Histocompatibility Complex [MHC] 
antigens, and it is called the Human Leukocyte Antigen [HLA] system in humans. MHC is located in 
chromosome 31 and covers a region of about 3.6mbp. The HLA complex is divided into three 
regions: Classes I, II & III. Both Class I and II are involved in an alloimmune response, whereas Class III 
encodes components of the complement systems. Each human expresses six MHC Class I alleles and 
six to eight MHC Class II alleles, and these antigens are present on most cell surfaces and are used to 
encode donor and recipient materials. 
Any mismatch between donor and recipient HLA increase risk of rejection.  Recipient T lymphocytes 
sense donor alloantigens via antigen-presenting cells which then undergo clonal expansion and 
subsequent activation of B lymphocytes after transplantation. An activated T lymphocyte will then 
migrate to a transplanted organ, causing invasion of renal tubules and tubil itis. Inflammatory 
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cytokines produced by T cells, in turn, cause aggregation of T lymphocytes and further damage to 
allografts with apoptosis.  
Immunosuppression can be achieved by deleting lymphocytes, diverting lymphocyte traffic or 
blocking a lymphocyte response pathway (13). One ought to remember that apart from the desired 
therapeutic response to reduce the recipient response to a donor antigen, an immunosuppressant 
also causes an undesirable effect of increased risk of infection and malignancy by reducing the 
recipient response to harmful antigens.  
1.2.1 Prednisolone 
Prednisolone is a synthetic corticosteroid with predominant glucocorticoid and low 
mineralocorticoid activity. It was first isolated in 1950 and became commercially available in the 
1960s. Together with the development of azathioprine, prednisolone allowed effective 
immunosuppression and led to successful renal transplantation between non-siblings and organs 
from deceased donors. 
The mechanism of prednisolone on the immune system is complex. Prednisolone irreversibly binds 
intracellular glucocorticoid receptors, which then dimerise and interact with cellular DNA which 
either induces or inhibits gene transcription. 
The overall effects of prednisolone are anti-inflammatory and immunosuppressive. This is achieved 
by inhibition of cytokines and cell adhesive molecule synthesis.   
Although prednisolone has proven to be efficacious in renal transplantation, long-term exposure is 
associated with severe and irreversible side effects, including: Cushing’s syndrome, weight gain and 
obesity, osteoporosis, glaucoma, cataract, diabetes, depression, hypertension and avascular 
necrosis. These side effects greatly increase cardiovascular risk and mortality in the long term. 
Because of these side effects, the use of steroids in renal transplantation had been declining and 
steroid-sparing protocols became feasible after the introduction of monoclonal antibody induction. 
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1.2.2 Mycophenolate mofetil  
Mycophenolate mofetil [MMF] is a prodrug that releases mycophenolic acid, which inhibits inosine 
monophosphate dehydrogenase, a key enzyme in purine synthesis.  By preventing purine synthesis, it 
stops T and B cell proliferation following cell activation. MMF was considered as an improved version 
of azathioprine because therapeutic actions are similar in both drugs. In fact, MMF has largely 
replaced azathioprine because of the improved side-effect profiles. 
MMF is free from transplant toxicity. Its principal non-immune toxic effects are gastrointestinal and 
hematologic. There was a suggestion that CMV and viral infection are more prevalent in MMF-
treated patients, although these were thought to be dose-related (14).  
1.2.3 Calcineurin inhibitors 
Tacrolimus and its predecessor, Cyclosporine, revolutionised solid organ transplantation and became 
the mainstream of immunosuppressant.  
Cyclosporine is a prodrug which binds with cyclophilin, an intracellular protein of the immunophilin 
family, forming a complex that inhibits activation of Calcineurin and that intercepts signals from 
activated MHC receptors on T cells, and subsequent cell activation (15). The pharmacological effect 
is similar to tacrolimus: tacrolimus binds immunophilin, an FK 506-binding protein, and creates a 
complex which, in turn, inhibits Calcineurin.  
Long-term exposure of cyclosporine is associated with nephrotoxicity (16), hypertension, 
hyperlipidaemia, gingival hyperplasia, hirsutism, tremor, new onset diabetes after transplantation 
and haemolytic uraemic syndrome. 
Side effects of tacrolimus are similar to those of cyclosporine but are less frequent and less severe 
(17, 18). Long-term tacrolimus is associated with nephrotoxicity, although less severe (19, 20), and a 
higher risk of new onset diabetes after transplantation (21). 
Calcineurin inhibitors had been an important element in long-term immunosuppression following a 
renal transplant for the last 3 decades, and the use of tacrolimus is slowly rising because of the 
efficacy and improved side-effect profiles. There had been attempts to withdraw Calcineurin 
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inhibitors, mainly cyclosporine, following transplantation. A recent meta-analysis suggested that this 
did not improve allograft survival, but rather increased risk of rejection after withdrawal (22).  
Other non-CNI-based immunosuppressive therapy failed to demonstrate superior outcomes. The 
biggest study, to date, comparing tacrolimus, high- and low-dose cyclosporine, and rapamycin 
maintenance combined with daclizumab induction and prednisolone showed that patients receiving 
the tacrolimus-based regimen had the highest allograft function and the lowest rejection rate at 1 
and 3 years (23, 24). This suggested that tacrolimus should be used as the key maintenance 
immunosuppressant in renal transplantation and that a low dose should be used to reduce the 
potential long-term nephrotoxicity associated without increased risk of rejection. 
1.2.4 Rapamycin 
Rapamycin engages FKBP12 to create complexes that inhibit the intracellular mTOR protein; this, in 
turn, blocks signal 3 by preventing cytokine receptors from activating the cell cycle.  This results in 
preventing T and B cell proliferation following activation. 
The principal non-immune toxic effects of rapamycin include hyperlipidaemia, thrombocytopenia, 
and impaired wound healing, aggravation of proteinuria, mouth ulcers, skin lesions, pneumonitis, 
precipitated nephrotoxicity when used with Calcineurin inhibitors, haemolytic–uremic syndrome, 
and hypertension.  
The benefit of rapamycin is its independency from calcineurin and it was thought that it could be 
used as a replacement for tacrolimus and could avoid long-term associated side effects. It had been 
hypothesised that rapamycin has antineoplastic (25) and arterial protective effects (26), hence there 
being a big interest in rapamycin-based immunosuppressive protocols despite the side-effect profile 
and lack of evidence supporting its impact on transplant outcomes (23, 24).  
1.2.5 Induction antibodies 
Induction antibodies have been used in renal transplantation since the 1960s to prevent acute 
rejection, particularly during the early period after surgery. A steroid-sparing regimen became 
feasible with the combination of induction antibodies and more potent therapy. Different induction 
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antibodies had been demonstrated to reduce the risk of rejection in the first year and to improve 
allograft survival (27-30). Therefore, the use of induction antibodies had been rising in the last 
decade and had risen up to 81.5% of all renal transplants in the US in 2008 (31).  
Currently, only a small number of induction antibodies are used in renal transplantation: 
 Non-depleting CD25/IL2 monoclonal antibody [basiliximab, daclizumab] 
 Lymphocyte-depleting polyclonal antibody [Antithymocyte globulin] 
 Lymphocyte-depleting monoclonal antibody [Campath] 
1.3 Campath in renal transplantation 
1.3.1 History of Campath 
Campath [alemtuzumab] is a humanised rat monoclonal antibody directed against the CD52 antigen, 
which presented on all blood mononuclear cells and the male reproductive tract.  
CD52 antigen-targeted antibodies were first discovered in the 1980s by Hale et al. during the 
research on bone marrow transplantation, aiming to develop an antibody to remove donor 
lymphocytes prior to transplantation (32). CD52 antigen is one of the most abundant antigens on 
human lymphocytes. It was estimated that lymphocytes have about 450,000 CD52 molecules per 
cell, accounting for 5% of the cell surface area. Apart from the high density, CD52 is also present in 
most human lymphocyte subtypes, and in most stages of cell differentiation apart from plasma cells, 
CD52 is also present in monocytes, macrophages and eosinophil. Apart from the haematological 
compartment, CD52 antigen can also be found in the epithelial lining of the male reproductive tract 
– epididymis, vas deferens and seminal vesicles (33). Although the physiological significance of the 
CD52 antigen is still under investigation, it is observed that once the CD52 antigen is stimulated, it 
causes profound lymphopenia by cell lysis and marked cytokine releases. The effect of this 
lymphopenia was thought to be lasting for months. A previous report suggested that the B 
lymphocyte count returns to normal after 3-12 months, whereas a subset of T cells remained 
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suppressed for up to 3 years (34). It was thought that this transient lymphopenia induced by 
Campath makes this a very useful benefit in organ translation (35), which I will discuss further. 
Other short-term effects reported with Campath include depression of granulocyte or platelet count 
and elevation of liver function. The mechanisms of these effects are unclear (33). 
Although Campath agglutinates an inactive sperm in vitro, there are no reproductive complications 
reported in the literature. That might be due to the poor penetration of immunoglobulin through 
the reproductive tract and this never reached a significant concentration to cause substantial effects 
in vivo (33). 
The first Campath antibody [Campath-1M] was created from rat hybridomas in an attempt to 
produce an antibody that lyses lymphocytes in humans by fixing human complements (36). 
However, it was later noted that the efficacy of Campath-1M was poor and that it showed a 
tendency to aggregate. It was later demonstrated that the IgG subclass was the best rat isotype 
antibody in recruiting cell-mediated cytotoxicity in humans; therefore, a second class of Campath 
[IgG2b Campath 1G] was developed (37). This IgG alternative to the original Campath-1M was shown 
to be efficacious in bone marrow transplantation (38). Albeit its efficacy, Campath-1G remains a rat 
IgG antibody that might induce an anti-globulin reaction in repeat dosing. A humanised equivalent is 
then developed – Campath-1H.  Campath-1H is a human IgG1; this subclass was shown to be most 
efficacious in activating cell-mediated cytotoxicity in humans and in complementing a reaction.  
1.3.2 PROPE tolerance 
Campath induces a transient lymphopenia immediately after administration and this effect can last 
up to 3 years. Calne et al. proposed that this transient lymphopenia is important in inducing 
tolerance in a transplanted allograft (35). He proposed that with the absence of an aggressive T cell 
response to a transplanted allograft early after transplantation, it allows engagement of the immune 
system to adapt to a transplanted allograft and to generate a state of “operational” tolerance  (39). It 
was proposed that the presentation of donor MHC peptide without the supporting reaction of 
recipient T cells renders failure on the host response to the donor antigen challenge, together with 
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migration of donor antigen-presenting cells to recipients’ lymphatic systems. These reduce the 
reaction in recipient alloreactive lymphocytes in the long term; this theory was later named the 
“Window of Opportunity of Immune Engagement” (WOFIE) (40). This theory was supported in 
animal model studies done by Knectle et al. (41): his group demonstrated a prolonged allograft 
survival in primates that was treated with T cell ablation using immunotoxin and intrathymal 
injection of donor lymphocytes. 
In Calne’s original human experiment, their group administered a 10-day course of Campath 1M in 
transplant recipients with high-dose cyclosporine. However, this study showed a superior allograft 
survival with an excessive incidence of infection (42). Their follow-up experiment published 7 years 
later using Campath 1H and low-dose cyclosporine (35) demonstrated excellent clinical results with a 
marked reduction in maintenance of immunosuppressants by the conventional standard.  
These early studies certainly demonstrated an interesting property of the potential tolerance-
inducting property of Campath. 
1.3.3 Clinical studies 
The development of Campath was originally targeted to avoid a ‘graft versus host’ disease in bone 
marrow transplantation (37). And because of its powerful lymphopenic ability and potential ability in 
inducing transplant allograft tolerance, it has started being used in solid organ transplantation.  
The first published study on using Campath in solid organ transplantation was based on using 
Campath 1 (36); subsequently, a larger study was performed by Friend et al. using a 10-day course of 
Campath 1M followed by high-dose cyclosporine maintenance (42). The results showed a superior 
allograft survival in patients treated with Campath 1M, however, associated with an unacceptably 
higher risk of infection. Campath 1G (43) had also been used in treating allograft rejection.  
Compared to Campath 1M, Campath 1G and Campath 1H were substantially more efficacious and 
the first report on using Campath 1H in renal transplantation was published by Calne et al. In this 
pilot study, 13 patients were given two doses of 20mg Campath 1H followed by low-dose 
cyclosporine maintenance. This was a radical approach in maintenance of immunosuppression in the 
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days when conventional therapy consisted of high-dose cyclosporine, azathioprine and prednisolone 
maintenance. All 13 allografts were functioning during the relatively short follow-up between 6 and 
11 months. And only 1 patient experienced transplant rejection and required restarting azathioprine 
and prednisolone. These results were encouraging and further supported his theory on WOFIE and 
prope tolerance (35, 44, 45). 
A follow-up report consisted of the original 13 and an extra 18 patients with a longer mean follow-up 
of 21 months. This report demonstrated 29/31 allografts functioning at 12 months. 6 of 31 patients 
experienced rejection and all reversed with the reintroduction of azathioprine and steroids. The 
incidence was “comparable” to conventional therapy. These two studies were the founding studies 
on the use of Campath and prope tolerance. This idea of prope tolerance and ability to reduce the 
long-term immunosuppression burden was certainly attractive to clinicians.  
1.3.4 Campath as tolerance-inducing agent? 
Both studies showed recipients still being able to reject a donor kidney; despite concurrent 
immunosuppression with Cyclosporine followed by Campath, complete tolerance is not achieved. 
Kirk (46) argues that the failure of achieving tolerance was perhaps related to timing of 
administration of Campath. Campath was administered after transplantation in the Calne studies 
compared to non-human primate trials.  Furthermore, he argued that the concurrent use of 
cyclosporine also inhibits the donor immune adaptive capacity.  Li and Wells suggested that 
interaction between remaining T cells is crucial for tolerance induction in vitro and that these were 
prevented by cyclosporine in the early clinical studies (47, 48). 
In order to evaluate the effect of Campath on inducing complete tolerance further, Kirk et al. 
attempted the first study in renal transplantation using Campath induction without the use of a 
maintenance immunosuppressant (46). Seven patients received 3 to 4 doses of Campath 
intravenously at 0.3mg/kg pre-operatively and no maintenance immunosuppressant. All patients 
underwent a surveillance biopsy at day 0, day 7 to 14 and at months 1, 6, and 12, as well as when it 
was clinically indicated. This study confirmed that Campath rapidly depletes peripheral and lymph 
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node lymphocytes. All patients had excellent allograft function initially; however, 6/7 patients 
experienced rejection within the first four weeks after transplantation despite complete 
lymphopenia, and 1 patient developed recurrent focal segmental glomerular sclerosis soon after 
transplantation. Interestingly, the biopsy and RNA transcript material suggested that rejections 
observed were mediated by monocytes and macrophage lineage cells. This pilot study confirmed 
that Campath alone was not sufficient to induce transplant tolerance and this leads to a further 
study to examine whether tolerance induction is achievable by controlling the initial response with 
monocytes following Campath. In the second study, Kirk et al. used the same protocol with an 
addition of Deoxyspergualin (49); Desoxyspergualin is a polyamine-like antibiotic known to prevent 
NFB nuclear translocation in monocytes and macrophages. These then subsequently inhibit 
activation of these cells, thereby reducing antigen presentation. 5 patients were given 4 doses of 
0.3mg/kg Campath, 1 pre-operatively and 3 doses post-operatively. All patients underwent a similar 
surveillance biopsy protocol. All 5 patients had excellent allograft function for the first 2 weeks after 
transplantation; however, all patients experienced clinical rejection within 4 weeks post-
transplantation despite profound lymphocyte depletion and thrombocytopenia and neutropenia 
caused by deoxyspergualin. This study showed that Campath alone is not sufficient to induce 
complete tolerance and thus would require an adjunct immunosuppressant.   
The nature of monocyte-mediated rejection after Campath was supported by a different group and 
was observed in patients receiving a maintenance immunosuppressant (50). 
1.3.5 Campath with tacrolimus, mycophenolate mofetil and steroids maintenance 
The combination of calcineurin inhibitors, anti-proliferative agent and steroids had been the golden 
standard for transplant immunosuppressants for decades (51). The results of using Campath and 
conventional triple therapy are best described in this retrospective study by the Wisconsin group 
(52). In this study, the group investigated the efficacy of Campath induction compared to anti-CD25 
induction, Thymoglobulin, OKT3, ATG and no induction antibodies. The authors of this paper put 
patients receiving OKT3, ATG or no induction antibodies in the same group.  
22 
Dr. Ka Kit Edmond CHAN 
126 patients received 2 doses of 30mg Campath at Day 0 and Day 1 compared to 799 patients 
receiving anti-CD25 monoclonal antibodies, 160 receiving thymoglobulin and 156 others. All patients 
received a calcineurin inhibitor – either cyclosporine or tacrolimus, mycophenolate mofetil or 
steroids – for life.  
The incidence of acute rejection is significantly lower in the Campath group, particularly for those 
who experienced delayed graft function [defined as the need for dialysis within the first week of 
transplantation]. Short-term allograft survival was superior in this group compared to the other 3 
groups. 
Despite the prolonged lymphopenia, this study also showed that the times to first infection in the 
Campath group are not different from other induction agents under the conventional triple therapy 
protocol. It was unclear whether the nature and rate of infection were different from this paper. 
These single-centre retrospective results were encouraging. However, as with all retrospective 
studies, results are subject to bias on changes in practice over time.  
1.3.6 Campath with tacrolimus and mycophenolate mofetil maintenance 
Long-term steroid exposure is associated with development of diabetes after transplantation, 
increased cardiovascular risk, weight gain and osteoporosis; therefore, transplant clinicians 
endeavour to avoid the long-term use of steroids. Ciancio et al. from the University of Miami first 
reported the use of Campath induction in a steroid-sparing protocol which consisted of tacrolimus 
and mycophenolate mofetil maintenance in 2004 (53). In this retrospective study, 44 patients 
received Campath at 0.3mg/kg at day 0 and day 4, followed by a low dose of tacrolimus with a target 
level between 5 and 7ng/mL. 29/44 patients received a transplant from a deceased donor and there 
is a predominance of non-Caucasian recipients [69%]. It reported 100% patient and allograft survival 
at 1 year. Compared to the reports with Sirolimus maintenance (54, 55), patients receiving 
tacrolimus and mycophenolate mofetil maintenance have a substantially lower incidence of 
rejection: 1/40 recipients experienced rejection in the first 6 months after transplantation and 3 
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further cases were reported between 6 and 12 months. Furthermore, only 1 of 4 cases of rejection 
was antibody-mediated under this protocol.  
4/40 patients required hospitalisation during follow-up, 1 case with atypical pneumonia and one 
with infected lymphocele. No CMV or BK infection had been identified.  
The results of this study were consistent with a later and larger study comparing Campath with 
basiliximab  in a steroid-sparing regimen (56). In this single-centre study, Kaufman et al. evaluated 
the results of 123 patients receiving a single dose of 30mg Campath compared to a historic control 
group of 155 recipients receiving basiliximab induction. Both groups received a steroid-sparing 
protocol consisting of tacrolimus and mycophenolate mofetil maintenance. 1- and 3-year patient 
and allograft survival were similar between the two groups. The acute rejection rate in the Campath 
group was reported as 14.9% at 1 year and was similar to the basiliximab group. It appeared that the 
timing of rejection was somewhat different, those receiving basiliximab rejects early compared to 
the Campath group. The median day to rejection in the Campath group was 153 days compared to 
10 days in the basiliximab group. There was a suggestion that the nature of rejection in the Campath 
group appeared to be less severe – 77% Banff 1a or 1b compared to 61% in the basiliximab group. 
The overall nature and incidence of infection were very similar between the two groups. CMV 
infection occurs in 4% of patients receiving Campath compared to 5% in those receiving basiliximab. 
Varicella, herpes infection and BK nephropathy were equally uncommon between the groups. There 
was a single case of fungal pneumonitis in the Campath group. The incidence of malignancy was also 
similar between the 2 groups. Two cases of post-transplant lymphoproliferative disorder [PTLD] and 
2 other malignancies were reported in each group. 
This medium-term retrospective study demonstrated that a steroid-sparing regimen with Campath is 
feasible and is not associated with an increased risk of rejection.  
The early randomised controlled studies investigating the effect of Campath induction with a 
steroid-sparing tacrolimus and mycophenolate mofetil maintenance regimen, compared to the 
conventional triple therapy protocol with steroid maintenance and other induction, were performed 
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by the Miami group (57-59). The first study comprising 90 patients receiving a deceased donor (57, 
58) and the second study consisting of 38 patients receiving living donor transplantation (59) were 
randomised into 3 groups: Thymoglobulin induction, Campath induction and anti-CD25 induction 
[daclizumab]. Recipients in the Campath group received 2 doses of Campath at 0.3mg/kg at day 0 
and day 4, followed by a steroid-sparing maintenance protocol consisting of tacrolimus and 
mycophenolate mofetil. Patients in the Thymoglobulin and daclizumab group also received long-
term maintenance steroids along with tacrolimus and mycophenolate mofetil. Patient and allograft 
survival were similar between the three groups. Incidences and timings of rejection were similar 
between the three groups in the first 6 months and in the long term. The nature of rejection was 
also similar: there was no suggestion that antibody-mediated rejection was more prevalent. Results 
were similar between the living donor and deceased donor studies. Although the incidence of 
rejection was similar between the 3 groups, curiously, patients received Campath induction and no 
maintenance steroids appear to have a higher number of indicative transplant biopsies with 
histological features associated with chronic allograft nephropathy. These were not consistent with 
later studies (60). 
Risks of infection were similar. 8/30 deceased donor recipients and 3/13 living donor recipients in 
the Campath group required hospitalisation for infective causes, and were not different from the 
other two groups. The nature and incidence of infection were not documented in the  paper; with 
the spare use of steroids, the incidence of new onset diabetes after transplantation was lower in the 
Campath group. During the course of the study, mycophenolate mofetil was withheld in 30-50% of 
patients in the Campath group because of leucopenia.   
Although these studies were grossly underpowered, these do confirm that a steroid-sparing protocol 
is feasible with Campath induction. 
1.3.7 Campath with Calcineurin inhibitor monotherapy 
Campath induction was first used in renal transplantation in combination with low-dose cyclosporine 
monotherapy (42, 61, 62). In the first study in 1989, Friend and Calne used a 10-day course of 
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Campath 1M in combination with high-dose Cyclosporine monotherapy, showing recipients having a 
significantly lower incidence of acute cellular rejection after having received Campath 1M. However, 
the treatment is associated with a higher incidence of infection which was likely due to the high 
dosage.  
Their follow-up study using the humanised form of Campath, Campath [Campath 1H], showed a 
similar benefit in outcomes with a much lower dose of the drug (61). In this study, 31 deceased 
donor transplant recipients were given 2 doses of 20mg Campath at day 0 and day 1. This was 
followed by low-dose cyclosporine maintenance. Allograft and patient survival were reported with a 
little number of rejections in the short term. Only 4 cases of cellular rejection and 1 antibody-
mediated rejection were observed in the original study. 
A subsequent long-term follow-up study (63) confirms that the efficacy of Campath persisted. 
Watson et al. reported the 5-year follow-up report in the original cohort. 5-year patient and allograft 
survival were comparable to those receiving conventional triple therapy. The hazards of rejection 
were similar between the two groups, although there are few cases of late rejection in the group 
receiving Campath and low-dose Cyclosporine, which was not observed in the control. Risk of 
malignancy and infection were comparable to the control group. 
This pivotal pilot study demonstrated that Campath induction was safe and allows using a medium 
dose of cyclosporine monotherapy without an increased risk of complications.   
There were two randomised studies investigating the use of Campath with calcineurin inhibitor 
monotherapy. 
Vathsala et al. published a small randomised controlled study comparing 20 patients receiving 2 
doses of 20mg Campath with low-dose cyclosporine maintenance with 10 patients having no 
induction and conventional triple therapy maintenance consisting of full-dose cyclosporine, 
azathioprine and steroids in Asia (64). The result from this small trial supports findings from a 
previous cohort study: the simple regimen using Campath induction and low-dose cyclosporine is 
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feasible and comparable to conventional triple therapy, although this study is grossly underpowered 
statistically. 
The second and bigger randomised controlled study explored the effect of the same regimen but 
using tacrolimus, a newer form of calcineurin inhibitor (65). 65 patients were randomised to receive 
2 doses of 20mg Campath at day 0 and day 1, followed by a conventional dose of tacrolimus; 66 
patients were randomised to receive no induction agents with maintenance therapy of tacrolimus, 
mycophenolate mofetil and steroids. Results were encouraging: biopsy-proven rejection was lower 
in the Campath group compared to the triple therapy control group [20% vs 32%], albeit it did not 
reach statistical significance. Graft survival and allograft function were similar between the 2 groups.  
This study showed that Campath induction with tacrolimus monotherapy is at least as efficient as 
the triple therapy and that steroid maintenance is not necessary.  
1.3.8 Campath with rapamycin monotherapy maintenance 
There was concern that long-term calcineurin inhibitors cause irreversible nephrotoxicity and graft 
failure (16, 19, 66, 67). Ojo et al. examined the UNOS database and demonstrated that 16.5% of 
patients with a non-renal organ transplant have a degree of renal failure (67); they  suggested that 
this is partially contributed by the use of calcineurin inhibitors (66). In terms of a renal allograft, an 
early study published in 2004 based on a cyclosporine-based regimen suggested that at least 80% of 
renal transplant surveillance biopsies express features associated with calcineurin inhibitor toxicity 
at 10 years (16).  
Although it was thought that tacrolimus has a less long-term toxicity event compared to 
Cyclosporine (20, 68, 69), there is a trend in the transplantation circle to avoid or spare the use of 
long-term cyclosporine as well as tacrolimus. Therefore, different centres have attempted to use 
Campath with other immunosuppressants.  
The use of Campath with Sirolimus maintenance was first proposed by Knechtle et al . (55) in an 
attempt to avoid using a long-term calcineurin inhibitor and steroids. They were hoping to avoid 
long-term complications of graft fibrosis and calcineurin inhibitor toxicity (19), as well as other side 
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effects associated with long-term steroid exposure. In their pilot study, they reported results of 29 
primary renal transplant recipients undergoing living donor transplantations in their centre. The first 
24 patients received only 20mg of Campath at day 0 and day 1 after operation and rapamycin, and 
the remaining 5 patients received a modified Campath regimen of 20mg at day -1 and day 0, as well 
as a supplement dose of thymoglobulin and 2 weeks of steroids. Patient and allograft survival were 
comparable to their experience with the conventional therapy. In the first 24 patients, 6 patients 
experienced acute rejection, of which 4 cases were early antibody-mediated rejection at days 6, 11, 
17 and 147. Furthermore, 1 of these 4 antibody-mediated rejections resulted in graft loss. The 
remaining two cases of rejection were cell-mediated and also occurred early after transplantation at 
days 8 and 120. In view of the high incidence of rejection, this group modified the Campath regimen 
. Despite the addition of thymoglobulin and steroids, 2 of 5 patients receiving this modified protocol 
experienced predominantly antibody-mediated rejection early after transplantation at days 24 and 
30. All patients rejected were converted from rapamycin monotherapy to tacrolimus, 
mycophenolate mofetil and Prednisolone maintenance (70).  
Infective and malignancy complications were unclear from these reports, but there was no 
difference reported from previous experience. Albeit not being statistically significant, there is a 
trend suggesting that patients being treated with this protocol experienced a known complication 
associated with rapamycin – the rise of cholesterol and triglycerides levels resulted in 60% of 
patients starting on lipid lowering therapy, problems with lymphoceles and wound healing, and 
mouth ulcers. 
1.3.9 Campath with rapamycin and mycophenolate mofetil maintenance 
The previous report by Knechtle et al. showed that rapamycin monotherapy maintenance is not 
sufficient to prevent rejection in a renal transplant following Campath induction (55). This raised a 
question on whether the poor outcome was a result of rapamycin or simple inadequate 
immunosuppression with a single agent; this was particularly important in an effort of CNI sparing in 
renal transplantation. Flechner et al. attempted to answer this question in their pilot study (54). In 
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this pilot study, 22 patients were given 2 doses of 30mg Campath at day 0 and day 1 after 
transplantation. All patients received a steroid-sparing regimen consisting of rapamycin and 
mycophenolate mofetil maintenance. Patient survival was comparable to conventional therapy; 
however, 1-year allograft survival was substantially poorer at 86.3%. 1 patient died with adult 
respiratory distress syndrome [ARDS] and one other patient had immunosuppressants withdrawn as 
a result of ARDS. The incidence of biopsy-proven rejection was also high at 36% [8/22], with 6 of the 
8 rejection cases occurring within 90 days of transplantation.  
During the course of the study, 2 [9%] patients had ARDS, of which 1 died and 1 had 
immunosuppressants withdrawn, 2 [9%] patients had significant CMV viraemia, 4 [18%] patients had 
an oral ulcer and 2 [9%] had a peri-vaginal ulcer.  
This study reported a higher-than-expected incidence of acute rejection compared to other 
observational studies using a CNI-based regimen (52, 61, 62), thereby suggesting that CNI is crucial in 
long-term immunosuppression following Campath. 
1.3.10 Calcineurin inhibitor sparing following Campath 
Results from the clinical studies demonstrated that Campath itself does not induce transplant 
tolerance and that maintenance immunosuppression is required to avoid acute rejection despite 
lymphopenia (46, 49). We also observed that maintenance immunosuppression has a huge impact 
on a transplant outcome. The incidence of acute rejection was low in patients treated with a 
calcineurin inhibitor-based immunosuppression protocol, regardless of whether maintenance 
mycophenolate mofetil or steroids were used (52, 56, 57, 61, 63). On the contrary, the incidences of 
acute rejection in the rapamycin maintenance regimes were unacceptably high, even with the 
concurrent use of mycophenolate mofetil (54, 55). These suggest that a Calcineurin inhibitor is 
essential in an immunosuppressive regimen with Campath. 
The Pittsburgh group has attempted weaning off tacrolimus following Campath induction in hope of 
this allowing immune engagement to promote graft tolerance (71, 72) and to avoid early post-
transplantation over immunosuppression and late toxicity related to immunosuppression. 
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205 living donor transplant recipients were included in their study (73, 74); all patients received 
30mg of Campath immediately after operation, followed by a conventional dose of tacrolimus 
monotherapy. Allograft survival was 98.1% at 1 year and was comparable to their historic control. 
The incidence of acute rejection was significantly lower compared to their historic control group at 1 
year [10.7% vs 21.3%, p<0.005]. Their centre protocol aimed at starting space weaning on tacrolimus 
in stable patients at 100 days after transplantation – start by reducing tacrolimus from twice daily to 
once daily dosing, then every other day after 1 to 4 months. Further weaning was then continued 
thrice weekly, twice weekly, once weekly and was stopped. Weaning was attempted in 76% of 
patients from this cohort and only 50% of patients attempted to remain on space weaning. 26.6% of 
patients who had attempted weaning developed acute rejection, and 18.5% de novo donor-specific 
antibodies, which has a significant impact on allograft survival (75). Apart from the increased risk of 
rejection after weaning, the nature of rejection also appeared to be more severe. This tacrolimus 
weaning protocol is also associated with an excessive allograft loss to rejection. 
A second trial on stopping calcineurin inhibitors was attempted by the Wisconsin group; their group 
previously presented a successful result using Campath induction with maintenance therapy with 
Calcineurin inhibitors, mycophenolate mofetil and steroids (52). In this randomised controlled study, 
40 stable patients were randomised to either continue or stop Calcineurin inhibitors 2 to 16 months 
after transplantation, concurrent with mycophenolate mofetil and steroid maintenance. Only 19 of 
20 patients underwent calcineurin inhibitor withdrawal, of which 20% required anti-rejection 
treatment after withdrawal and 3 were biopsy-proven. There were no new cases of rejection 
observed in the control group. 3/8 surveillance biopsies in the withdrawal group showed features 
with acute alloimmune activities, whereas no control group did. 
These 2 studies both suggested that tacrolimus withdrawal in clinically stable patients is associated 
with an increased risk of rejection afterwards. Considering that tacrolimus is significantly less toxic 
compared to its predecessor (20, 68, 69), the risk of tacrolimus withdrawal following Campath 
certainly outweighs its benefits.  
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1.3.11 Lymphocyte repopulation following Campath 
Results from the clinical studies demonstrated that Campath is a powerful lymphopenic agent and 
that repopulation of lymphocytes varies depending on the subsets (46, 49, 52, 54, 62, 76). Campath 
itself does not induce transplant tolerance, and maintenance immunosuppression is required to 
avoid acute rejection despite lymphopenia (46, 49). We also observed maintenance 
immunosuppression having a huge impact on transplant outcomes. The incidence of acute rejection 
was low in patients treated with a calcineurin inhibitor-based immunosuppression protocol, 
regardless of whether maintenance mycophenolate mofetil or steroids were used (52, 56, 57, 61, 
63). On the contrary, the incidence of acute rejection in the rapamycin maintenance regimes was 
unacceptably high, even with the concurrent use of mycophenolate mofetil (54, 55).  
The difference in efficacies between different immunosuppression maintenance may be due to the 
functional nature of a residual lymphocyte following depletion. Pearl et al. underwent a study to 
investigate the phenotype and functioning characteristics of residual lymphocytes following 
lymphodepletion of Campath (77). Blood samples were drawn and analysed using flow cytometry 
prior to depletion and weekly for 4 weeks in 5 patients during the original tolerance-induction study 
(49); samples from patients who received rabbit anti-thymocyte globulin or daclizumab were acted 
as controls. This study showed almost complete lymphodepletion with naive T cells and regulatory T 
cells after Campath, but with a single phenotype (CD3+ CD4+ CD45RA- CD62L CCR7-). This depletion-
resistant subset was thought to be a memory-effect T cell. These cells expand quickly following 
depletion and were uniquely prevalent during rejection. Interestingly, these memory T cells were 
also resistant to steroids, rapamycin and deoxysepergualin in vitro, but were uniquely sensitive to 
calcineurin inhibitors. These data might explain the reasons why Campath is not pro-tolerant and 
why calcineurin inhibitors are crucial for transplant immunosuppression maintenance following 
Campath induction. 
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1.3.12 Other indications of Campath 
Campath was originally prepared and first utilised in allogeneic transplantation to prevent graft 
versus host through in vitro purging of T-cell lymphocytes from bone marrow prior to reinfusion (37, 
78). However, its ability to induce profound lymphodepletion has allowed it to be used in many 
auto-immune diseases, including rheumatoid arthritis (79-81), multiple sclerosis (82-85), ocular 
inflammatory disease (86), graft versus host disease (87, 88), and haematological malignancies, e.g. 
non-Hodgkin lymphoma (89, 90) and leukaemia (91-93), besides organ transplantation.  
1.3.13 Complications with Campath 
Infection 
It was thought that the powerful lymphodepleting ability of Campath might result in high risk of 
infection (42). Previous reports have suggested poor patient survival being associated with its use in 
patients with multiplying relapsed vasculitis exposed to Campath 1-H during the 1990s (94), and with 
reports of fatal fungal infections in kidney/pancreas transplant recipients exposed to multiple doses 
(95-97).  
There was a concern of a slightly higher incidence of CMV infection in the earlier report using 
Campath (65). Subsequent clinical studies did not show a significantly different incidence and timing 
of CMV disease or other infections following Campath induction (52, 54-57, 98) in the short term. A 
long-term follow-up study with Campath is sparse in the literature; the 5-year, long-term follow-up 
pioneer study in Calne’s group did not show a substantial difference in the risk of infection in the 
Campath group (63), albeit it had a small number of patients. Moreover, the effect of Campath on 
the risk of infection appears to be dose-related in both transplantation and rheumatological 
literatures, which used up to 400mg of Campath per treatment (79, 96, 99). The incidence of 
infection was higher in patients given a high dose of Campath 1M in the pioneer study in the 1980s 
(42). This is supported by a recent study presented by Nath et al. (96). They evaluated the effect of 
Campath on fungal infection, showing those who received Campath as maintenance therapy in their 
pancreas transplant programme having a fold rise in the incidence of systemic fungal infection [3.6% 
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vs 9.2%], and systemic fungal infection in these patients was associated with high mortality – 3/8 
[38%] patients died during on-going treatment for their fungal infection. The incidence of fungal 
infection appears to be low in cases when Campath doses are low and are used as induction only 
(97, 98). 
A further report from Pittsburgh suggested that patients who received Campath as a supplement 
with concurrent treatment of rejection are associated with a 3.5-fold increase in the risk of 
opportunistic infection (99). 
These data strongly suggest that Campath 1-H should not be used in repeated, multiple-dosing 
regimens or in individuals already carrying a heavy burden of immunosuppression. However, an 
extensive body of reports, both cohort studies and randomised prospective trials, is now available to 
show that when used at total cumulative doses of between 30 and 60 mg, delivered intravenously 
(IV) or subcutaneously as induction therapy at the time of renal transplantation, Campath 1-H is a 
safe and effective therapy. 
Autoimmune disease 
Apart from the infective risk, higher risk of autoimmune disease following repeat dose s of Campath 
had been reported in the multiple sclerosis literatures (100). Patients with multiple sclerosis were 
treated with a substantially higher dose of Campath compared to transplant recipients, ranging from 
12-30mg daily for 5 consecutive days followed by an annual treatment consisting of 3 days of 12mg 
daily treatment. 22.2% of patients in this cohort developed autoimmune disease following Campath, 
often at 12-18 months after treatment. Graves’ disease was the commonest autoimmune disease 
[31/52 cases], and other haematological, renal and dermatological autoimmune diseases were also 
observed. However, the author did not elicit a dose-related effect in MS. 
Autoimmune disease following Campath in solid organ transplantation is rarely reported. There was 
only one case reported in the literature. An open letter by Kirk et al. (101) reported 1 patient 
developing Graves’ disease 4 years after transplantation, during which she received 4 doses of 
Campath at 1.2mg/kg which is substantially higher than protocols in other units.  
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1.4 Problems with long-term immunosuppression 
Long-term maintenance immunosuppression is crucial to prevent acute rejection and to maintain 
long-term allograft survival. However, chronic immunosuppression not only reduces the immune 
response of recipients to allografts, but also reduces a recipient’s immune reaction to infection as 
well as the ability of immune surveillance which prevents growth and development of malignancies. 
It was also suggested that long-term immunosuppression reduces DNA repair at a molecular level 
and further increases risk in developing malignancies (102). 
A recent report that analysed data from the UNOS registry suggested a cumulative incidence of 
malignancy up to 7.5% at 3 years, of which skin cancer was the most prevalent (103). This report also 
showed that transplant recipients have an increased risk in most types of malignancy. The incidences 
of the most common solid malignancies, e.g. lung, prostate, breast and cervical cancer, were only 
modestly increased. However, there is a marked increase in risk with skin cancer and lymphoma. It 
was estimated that the rates of skin cancer and lymphoma in transplant recipients were 90 and 37 
times higher, respectively, compared to the general population after being adjusted for age. 
Furthermore, these findings were consistent throughout other registry data from Australia, New 
Zealand, Denmark and Norway. It was an interesting finding that long-term immunosuppression has 
a selective effect on skin cancer and lymphoma, which were both found to be linked to a viral 
pathology with human papilloma virus (104) and Epstein-Barr virus respectively (105). 
This report also investigated the risk factors of developing malignancy following transplantation. 
Non-Caucasoids have a significantly reduced risk in developing any form of malignancy. In particular, 
Orientals and South Asians have an 89% reduced risk of skin cancer compared to Caucasians. A 
similar result was found in the Afro-American populations, of whom skin cancer risk was reduced by 
94%.  
Immunosuppression also has a substantial impact on the risk of malignancies: recipients on a 
tacrolimus-based immunosuppressant regimen have a 35% reduced risk of non-melanoma skin 
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malignancy, whereas those who received azathioprine maintenance increase the risk by 17%. 
Although there was a theoretical suggestion that rapamycin-based immunosuppression reduces the 
incidence of malignancies (25), data from this large registry study failed to support this (103). 
The risk of skin malignancy is also 17% lower in recipients receiving induction antibodies; this might 
be confounded by the reduction in Azathioprine use following induction therapy. There was no 
suggestion of increased risk of other solid organ malignancies, compared to a previous report which 
was based on a large proportion of patients receiving anti-Thymoglobulin as induction (106). 
As far as this data is concerned, patient survival certainly improves after transplantation (4). 
Furthermore, the risk of developing common solid organ malignancies was not higher compared to 
those remaining on a waiting list (103).   
Besides the risk of malignancy, it has long been established that immunosuppression increases risk 
of infection (107, 108), that the pattern and nature of infection change over time after 
transplantation (108), and that they differ with immunotherapy used (109, 110).  
Conventional teaching suggested that infections within the first 4 weeks following transplantation 
are mainly donor- or recipient-related, particularly bacteraemia as a result of wound infection, or 
related to anaesthetics and equipment used in invasive monitoring.  
The risk of opportunistic infections, either from residual infections or reactivations of latent 
infections, was the highest in the first 12 months after transplantation. It was thought that patients 
were most heavily immunosuppressed during this period because of initial induction therapy as well 
as resulting escalation of immunosuppression following treatment of rejection, during which the 
rate was highest in the first year. Herpes virus, cytomegalovirus, hepatitis, tuberculosis and 
pneumocystis carinii pneumonia are common historically. As the excess immunosuppressive effects 
have worn off after the first 12 months, community-acquired infection becomes the commonest 
cause in transplant recipients (107, 108). The nature of infection has changed with the introduction 
of induction antibodies, which allows spare use of corticosteroids, as well as introduction of viral and 
antifungal prophylaxis after transplantation (109). 
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There is little in the literature describing the precise nature and rate of infection in recipients 
following transplantation.  
Patients should not be dissuaded from transplantation because of malignancy and infection risk; 
instead, clinicians should endeavour to reduce these risks by limiting long-term immunosuppressive 
load and developing a vigilant surveillance programme. 
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2  Aim 
The purpose of this thesis was to describe the experience of using Campath induction and tacrolimus 
monotherapy in renal transplantation in the Imperial College Kidney and Transplant Centre, 
Hammersmith Hospital.  
This thesis consisted of different studies to examine various clinical aspects of the use of 
immunosuppression regime. 
1] Our early experience with the regime based on a the short-term pilot study, the results were 
reported in Chapter 4 and a more detailed examination of long term results and causes of graft loss 
were reported in Chapter 6 and chapter 8 
2] As a result of the encouraging experience with the pilot study, I developed a randomised 
controlled study to examine my hypothesis that the efficacy of this regime was non inferior to the 
conventional regime. Results of this RCT were described in Chapter 5 
3] The ideal dosage of Campath used as induction was unclear, I set out to examine if the  dosage of 
Campath should be adjusted for subjects weight in a retrospective cohort study and the results were 
described in Chapter 7 
4] Apart from examine the efficacy of this regime, I also investigated the risk profile associated with 
this immunosuppression regimen. The risk of long term allograft pathology, haematological effects 
m infection, malignancy and metabolic effects were examined in Chapter 9,10 & 11 respectively 
5] Campath is a powerful lymphodepletion agent, it was suggested that the rate of repopulation 
following Campath might be related to the occurrence of allograft rejection. I developed a 
mathematical model to examine this hypothesis and reported the results in Chapter 10. 
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3 Patients and Methods 
3.1 Patients 
The study data included in this thesis were based on patients receiving a kidney from a living donor 
or deceased donor from November 2002 in the Imperial College Kidney and Transplant Centre. 
Number of subjects varied between analysis in different chapters due to difference in timeline and 
design of the study. Patients who received a simultaneous kidney and pancreas transplant, as well as 
those undergoing desensitisation for blood group incompatibility and flow crossmatch positive 
transplant recipients, were excluded. 
The key study group patients transplanted between received the minimalistic Campath induction 
with a tacrolimus monotherapy maintenance protocol. In some studies, the cohort of patients who 
received our historic immunosuppression regime based on daclizumab induction – the tacrolimus 
and mycophenolate mofetil maintenance protocol were acted as the control group. 
All participants were followed up in the transplant clinics in the Imperial College Kidney and 
Transplant Institute. 
3.2 Methods 
This studies used in this thesis were self-funded and were reviewed and approved by the 
institutional review board.  
3.2.1 Interventions 
3.2.1.1 Campath group 
Immunosuppression was started with Methylprednisolone at 500 mg and a loading dose of 
tacrolimus [0.5mg/kg] prior to surgery. The following operation – 30 mg of Campath [MabCampath, 
Roche] – was administered intravenously with hydrocortisone at 100mg and chlorphenamine at 
10mg as premedication to prevent a cytokine reaction caused by Campath. Twice-daily tacrolimus 
was started orally at day 0 post-transplantation with a 12-hour trough target of 5-8mg/mL.  
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The patients also received our sparing protocol, consisting of hydrocortisone at 100mg intravenously 
or prednisone at 30mg orally twice daily between day 0 and day 3, then reduced to 30mg daily 
between days 4 and 6, and ultimately stopped. 
3.2.1.2 daclizumab group 
Immunosuppression was started with Methylprednisolone at 500 mg and a loading dose of 
tacrolimus [0.75mg/kg] and mycophenolate mofetil at 750mg prior to surgery. Following the 
operation, daclizumab [Zenapax, Roche] at 2mg/kg was administered intravenously. Twice-daily 
tacrolimus was started orally at day 0 post-transplantation with a 12-hour trough target of 8-
12mg/ml, with twice-daily mycophenolate mofetil at 500mg and a target level of 1.2-2.5g/l. 
All patients received our steroids sparing protocol, consisting of hydrocortisone at 100mg 
intravenously or prednisone at 30mg orally twice daily between day 0 and day 3, then reduced to 
30mg daily between days 4 and 6, and ultimately stopped. 
All patients with this protocol received a second dose of daclizumab at 2mg/kg on day 14 after 
transplantation. 
The tacrolimus target was higher in the first year with this group, in which the 12-hour trough target 
was 8-12ng/ml in the first year, and reduced to 5-8 ng/ml after 1 year. 
3.2.1.3 Antibiotics prophylaxis 
Patients from both groups received Valganciclovir at 450mg daily for 3 months as cytomegalovirus 
infection prophylaxis regardless of donor or recipient cytomegalovirus status, as well as Co-
Trimoxazole as Pneumocystis Carinii Pneumonia prophylaxis for 6 months. 
Patients who had had a previous history of, or in close contact with others with tuberculosis and 
patients with a high risk of reactivation of latent tuberculosis were given lifelong tuberculosis 
prophylaxis in the form of Isoniazid at 150mg daily and pyridoxine at 50mg weekly to reduce the risk 
of neuropathy associated with treatment. 
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Campath induction was not used in patients with hepatitis because of safety concerns in the 
literature(112). All patients with hepatitis were given Lamivudine prophylaxis following daclizumab 
induction. 
3.2.1.4 Rejection 
Allograft rejection was diagnosed by a transplant biopsy and was treated with the steroids. 
Methylprednisolone at 500mg per day for 3 days followed with oral prednisolone at 30mg daily and 
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4 Pilot study results in Campath and tacrolimus monotherapy protocol 
4.1 Introduction  
Campath is a monoclonal antibody that targets CD52 receptors which are present on most 
circulating lymphocytes, and activation of CD52 receptors results in profound temporary 
lymphopenia.  
Campath was first used in renal transplantation as an induction agent in combination with low-dose 
cyclosporine monotherapy (42, 61, 62) in 1989. Friend and Calne used a 10-day course of Campath 
1M in combination with high-dose Cyclosporine monotherapy, showing recipients who received 
Campath 1M to have a significantly lower incidence of acute cellular rejection. However, the 
treatment was associated with a higher incidence of infection which was likely due to the high 
dosage.  
Their follow-up study using the humanised form of Campath, Campath-1H, showed a similar benefit 
in outcomes with a much lower dose of the drug (61). Allograft and patient survival were reported 
with a little number of rejections in the short term. The subsequent long-term follow-up study (63) 
reported by Watson et al. confirms the efficacy of Campath. 5-year patient and allograft survival 
were comparable to those received in conventional triple therapy. The hazards of rejection were 
similar between the two groups, although there are several cases of late rejection in the group 
receiving Campath and low-dose Cyclosporine, which was not observed in the control. This pivotal 
pilot study demonstrated that Campath induction was safe and allows using a medium dose of 
cyclosporine monotherapy without an increased risk of complications.   
Apart from cyclosporine monotherapy, Campath had been used in renal transplantation in 
combination with other maintenance immunosuppressant (52,54,57-58) . Short results from these 
studies were encouraging, showing a similar allograft survival and function and low rate of rejection, 
except when Campath was used along with rapamycin. It was proposed that the difference in 
rejection rate between different protocols were related to the differential effect of lymphodepletion 
with Campath(77). This depletion-resistant subset was thought to be a memory-effect T cell that 
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expands quickly following depletion and were resistant to steroids, rapamycin and deoxysepergualin 
in vitro, but were uniquely sensitive to calcineurin inhibitors.  These data supports the crucial role of 
calcineurin inhibitor maintenance following Campath induction. 
There is a trend in the transplantation circle to avoid or spare the use of long-term cyclosporine as 
well as tacrolimus, albeit it had been shown that calcineurin inhibitors were crucial for long-term 
transplant success. There was concern that long-term calcineurin inhibitors cause irreversible 
nephrotoxicity and graft failure (16, 19, 66, 67). Ojo et al. examined the UNOS database, 
demonstrating that 16.5% of patients with a non-renal organ transplant have a degree of renal 
failure (67) and suggesting that this was partially contributed by the use of calcineurin inhibitors 
(66). In terms of renal allografts, an early study published in 2004 based on a cyclosporine-based 
regimen suggested that at least 80% of renal transplant surveillance biopsies express features 
associated with calcineurin inhibitor toxicity at 10 years (16). However, it was thought that 
tacrolimus has a less long-term toxicity event compared to Cyclosporine (20, 68, 69). 
Therefore, the Imperial College Kidney and Transplant Centre set out to investigate the feasibility of 
successful transplantation with lower-dose maintenance of tacrolimus. Thus, our unit developed the 
regimen of Campath induction with medium-dose tacrolimus in 2004, with the precedence of Calne 
et al. The difference with this regimen from previous protocols was not only a different induction 
agent, but also that it avoided the use of long-term mycophenolate mofetil and steroids. Further 
immunosuppression would only add in the face of allograft rejection. We anticipated that this 
minimalistic approach to maintenance immunosuppressants would translate into a reduction of 
long-term complications. 
I discussed the short-term result from this cohort in this chapter, which led to development of our 
randomised controlled study (111). 
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4.2 Patients and methods  
4.2.1 Patients  
The study group consisted of 59 patients transplanted between August 2004 and November 2005 
who received the minimalistic Campath induction with a tacrolimus monotherapy maintenance 
protocol. Our historic cohort of 101 patients who transplanted from November 2002 received the 
daclizumab induction – the tacrolimus and mycophenolate mofetil maintenance protocol acted as 
the control group. 
All participants were followed up in the transplant clinics in the Imperial College Kidney and 
Transplant Institute. 
Demographics 
Table 4-1 Demographics 
  
Campath     
number [%]  
daclizumab 
number [%]  
Gender F 25 [42.4%] 49 [48.5%] 
 
M 34 [57.6%] 52 [51.5%] 
Ethnici ty Afro-Caribbean 6 [10.2%] 10 [9.9%] 
 
South Asian 16 [27.1%] 21 [20.8%] 
 
Caucasian 35 [59.3%] 67 [66.3%] 
 
Others 2 [3.4%] 3 [3.0%] 
Fi rs t transplant Y 55 [93.2%] 94 [93.1%] 
 
N 4 [6.8%] 7 [7.3%] 
Donor type Deceased 27 [45.8%] 55 [54.5%] 
 
Living 32 [54.2%] 46 [45.5%] 
Cold ischaemic time Hours 17.9 + 13.5 15.6 + 13.2 
Recipient age Years 45.1 + 13.1 45.1 + 12.4 
Donor age Years 47.6 + 14.4 46.5 + 14.2 
HLA mismatch 
 
3.2 + 1.8 3.2 + 1.7 
Follow-up Months 70.5 + 24.1 82.6 + 30.2 
 
Detailed demographics were listed in Table 4-1. 57.6% of patients transplanted in the Campath 
group were male and were comparable to the historic control of 51.5%. 37.2% of the cohort in this 
study were non-Caucasoid; this reflects the underlying ethnic composition in the catchment area of 
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the Imperial College Kidney and Transplant Centre. Proportions of non-Caucasoid transplanted in the 
two groups were similar. 10.2%, 27.1% and 3.4% of patients transplanted in the Campath group 
were Afro-Caribbean, South Asian and from other ethnic backgrounds, compared to 9.3%, 20.8% and 
3.0% in the daclizumab group, respectively. Over 93% of patients transplanted in both groups had no 
previous solid organ transplantation. The proportion of living donor transplantation recipients was 
slightly higher in the Campath-treated group [54.2% in Campath group vs 45.5% in the daclizumab 
group]; this was likely reflecting a change of practice over the follow-up period as living donor 
transplantation, where feasible, has become a more favourable treatment for patients with end-
stage renal failure. In the remaining patients who received a renal transplant from a deceased 
donor, the mean cold ischaemic time in the Campath group was 17.9 hours and was similar to the 
daclizumab-treated group at 15.6 hours. The average recipient and donor ages were indifferent 
between groups. The average recipient age was 45.1 years in both groups, and the average donor 
age was 47.6 years in the Campath group and 46.5 years in the daclizumab group. On average, both 
Campath and daclizumab groups have a 3.2 Human Leucocytes Antigen [HLA] mismatch between 
recipient and donor.  
57/59 [96.6%] patients in the Campath group and 97/101 [96.0%] patients in the daclizumab group 
were under active follow-up in the transplant unit to date or until graft loss. 1 patient was 
transferred back to the local nephrology centre for follow-up at 13 months, and the remaining 
patients were transferred to other centres between 2 and 5 years after transplantation. Of the 
remaining 96% of patients under active review, the average follow-up in the Campath group was 
70.5 months and was significantly lower than the historic daclizumab cohort of 82.6 months. 
4.3 Statistics  
The purpose of this study was to examine the short- and long-term outcomes in the original cohort 
of patients treated with the minimalistic immunosuppressive protocol. 
4.3.1 Primary endpoint: 
 Patient survival 
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4.3.2 Secondary endpoints: 
 Patient survival with functioning graft 
 Allograft survival after being censored for patient death with function 
 Allograft function at 3, 6 and 12 months after transplantation 
 Rejection-free survival  
 Calcineurin inhibitor toxicity 
 Transplant glomerulopathy 
 Treatment survival 
4.3.3 Outcome definition 
Allograft failure was defined as the requirement of dialysis; the date of failure was the date of 
dialysis commencing. 
Allograft function was assessed using serum creatinine and MDRD eGFR. 
Allograft rejections, calcineurin inhibitor toxicity and transplant glomerulopathy were all biopsy-
proven and classified by the Banff 2007 criteria. 
4.3.4 Statistics analysis plan 
This study was examined as the intention to treat analysis.  
The Logrank method was used in comparison in survivals between the 2 groups, under an 
assumption that the underlying risk of failure and difference in hazards between groups were 
constant. The Weibull parametric model was used in cases where this assumption was violated and 
where the underlying risk of failure changes with time. The Cox semi-parametric model was used if 
the assumption of constant difference in hazards was violated. 
The Kaplan Meier method was used to estimate cumulative survival over time. Patient survival, 
allograft survival and freedom from rejection, CNI toxicity and transplant glomerulopathy were 
examined using the same method. 
Censoring for loss of follow-up or death with a functioning graft was assumed to be non-informative. 
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A mixed-effect model was used to estimate the difference in function at the baseline and difference 
in trajectory between groups on allograft function, as well as accounting for repeat measurements 
from the same patients over time. The point estimate on numeric outcomes on allograft function 
were tested using a Student’s t test.  
All statistical tests were performed as a two-sided test and were deemed to be statistically 
significant if the p value was <0.05. 
Statistic tests were performed using Stata 12.0 (StataCorp, Texas). 
4.4 Results 
4.4.1 Patient survival 
 
Figure 4-1 Twelve-month patient survival in pilot study  
Figure 4-1 shows the twelve-month patient survival in this cohort. No patient loss was observed in 
the Campath group; therefore, there was cumulative patient survival of 100% at 12 months. There 
were three patient deaths in the daclizumab cohort. The first patient died with bone marrow failure 
and sepsis 3 months after transplantation. The second patient died at home unexpectedly at 4 
months after transplantation; the cause of death was thought to be cardiac-related. The third 
patient died with overwhelming fungal sepsis 6 months after transplantation. As a result, cumulative 
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There was no statistical significance on patient survival between the groups [p=0.1927, Logrank]. 
4.4.2 Allograft survival 
 
Figure 4-2 Twelve-month patient survival with functioning graft in pilot study 
 
Figure 4-3 Twelve-month censored allograft survival in pilot study 
Figure 4-2 and Figure 4-3 (above) show 12-month patient survival with a functioning graft and 
allograft survival after censoring with death with a functioning graft. There was no patient death in 
the first 12 months in the Campath group [Section 4.4.1]. 3 grafts were lost in total in the Campath 
group. One graft was lost due to technical failure. The second graft was lost soon after 
transplantation due to renal vein thrombosis in a recipient with a background of lupus nephritis and 
presence of pro-coagulant. The third graft was lost due to severe thrombotic microangiopathy at 2 
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was a result of antibody-mediated rejection because a later investigation confirms that this patient 
did not suffer from a familial form of haemolytic uraemic syndrome. Therefore, cumulative allograft 
survival was 94.9% at 3, 6 and 12 months in the Campath group, respectively. 
The three graft losses were a result of patient death in the daclizumab group [Section 4.4.1]. 
Another 3 grafts were lost in this cohort. The first graft was lost as a result of transplant renal artery 
thrombosis soon after surgery in a patient with significant pro-coagulant. The second graft was lost 
as a result of chronic antibody-mediated rejection at 8 months; the third graft was lost at 10 months 
after transplantation with late presented graft pyelonephritis associated with the ileal conduit. 
Cumulative patient survivals with a functioning graft in this group were 99.0%, 97.0% and 94.1% at 3, 
6 and 12 months, respectively. Cumulative allograft survivals after being censored for patient death 
with a functioning graft were 99.0%, 99.0% and 97.0% at 3, 6 and 12 months, respectively.  
There were no statistical significant differences between the two groups in patient survival with 
functioning graft [p=0.8452, Logrank test] and allograft survivals after being censored for patient 
death with a functioning graft [p=0.4968, Logrank test]. 
Rejection 
 
Figure 4-4 Twelve-month rejection-free survival in pilot study  
Figure 4-4 (above) demonstrates a Kaplan Meier plot on cumulative freedom from rejection 
between the 2 groups in the first 12 months. There was a suggestion that risk of rejection was lower 
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risk of rejection reduces over time in this 12-month period [p<0.001, Weilbull model] and that it 
violated the baseline assumption of constant baseline risk with the Logrank model; therefore, an 
adjusted model was used. After being adjusted for changes of baseline risk over time, the model 
suggested that patients in the daclizumab group have a 3.2-fold increased risk of rejection; however, 
it did not reach statistical significant at 5% level [HR 3.2, 95% CI 0.92, 10.92; p=0.069]. 
3/59 [5.1%] patients in the Campath group experienced an episode of rejection in the first 12 
months. 1 patient had severe antibody-mediated rejection at 2 months after transplantation which 
failed to respond to escalation of immunosuppression and resulted in graft loss. The remaining 2 
rejections were cell-mediated rejection at 7 and 8.5 months, of which the latter was thought to be a 
result of non-compliance with immunosuppression. 
15/101 [14.9%] patients experienced an episode of rejection in the first 12 months in the daclizumab 
group. 2 cases of pure antibody-mediated rejection were reported within the first month after 
transplantation. 11 cases of cellular rejection were reported in the control group, with an average 
time to rejection of 2.3 months. The remaining 2 cases of rejection were mixed antibody and cellular 
rejection developed within the first months of transplantation, of which one case developed chronic 
antibody-mediated rejection and resulted in graft loss at 8 months. 
4.4.3 Allograft function 
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Figure 4-5 (above) demonstrates allograft function, measured by using MDRD eGFR, between the 
two groups. Allograft function was similar between the two groups at 1, 3, 6 and 12 months after 
transplantation.  
MDRD eGFR was 45.8+18.1, 48.7+15.6, 50.0+14.8 and 52.1 + 14.3 ml/min/1.73m2 at 1, 3, 6 and 12 
months in the Campath group, respectively, and it was 44.1+21.3, 47.3+16.2, 47.4+15.6 and 
48.9+15.5 ml/min/1.73m2 in the daclizumab group at the same timeline. 
The longitudinal model showed that there was no significant difference between the groups in 
overall allograft functions [Average difference in function: -1.6 ml/min/1.73m2, 95%CI -7.2, 4.0; 
p=0.574]. Moreover, the rates of changes in allograft function were not different between the two 
groups [Difference in rate of function changes per month: -0.17 ml/min/1.73m2/month, 95%CI -
0.63.0.28; p=0.451]. 
4.4.4 Calcineurin inhibitor toxicity 
 
Figure 4-6 Twelve-month CNI toxicity-free survival in pilot study  
Chronic calcineurin inhibitor toxicity was rare in the early phase after transplantation and this was 
illustrated clearly in Figure 4-6. CNI toxicity in this cohort was diagnosed on an allograft biopsy from 
clinical grounds during the investigation of allograft dysfunction. 2 patients were diagnosed with CNI 
toxicity in the first twelve months, 1 from the Campath-treated group at 5 months and 1 patient 























101 100 97 97 96 95 94DACLIZUMAB
59 57 56 55 55 55 55CAMPATH
Number at risk





CNI toxicity free survival
50 
Dr. Ka Kit Edmond CHAN 
Cumulative CNI toxicity-free survivals were 98.2% and 99.0% at 12 months in the Campath and 
daclizumab group respectively. There was no statistical significance in the difference between the 
groups [p=0.6885, Logrank test]. 
4.4.5 Transplant Glomerulopathy 
 
Figure 4-7 Twelve-month transplant glomerulopathy-free survival in pilot study  
The incidence of transplant glomerulopathy was low in the first 12 months following transplantation. 
There were 2 cases of transplant glomerulopathy in the daclizumab group. The first case developed 
acute transplant glomerulopathy 2 weeks after transplantation; allograft function stabilised after 
optimising of immunosuppression and has remained functioning to date. The second case developed 
transplant glomerulopathy 3 months following treatment of antibody-mediated rejection. Allograft 
functions continue to deteriorate gradually despite escalation of immunosuppression. Moreover, the 
allograft failed at 38.4 months. 
Cumulative transplant glomerulopathy-free survival was 100% and 98.0% at 12 months in the 
Campath and daclizumab-treated groups respectively. There was no statistically significant 
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4.4.6 Treatment survival 
 
Figure 4-8 Twelve-month treatment survival in pilot study  
Treatment survival was defined as a patient maintained on the treatment protocol. 54/59 [91.5%] 
patients in the Campath group remained in tacrolimus monotherapy in the first year. mycophenolate 
mofetil and steroids were added to 3 patients who experienced rejection. mycophenolate mofetil 
was added to 2 patients to facilitate further reduction in tacrolimus doses. Both patients received 
kidneys from elderly non-heart-beating donors, and subsequent transplant biopsies persistently 
demonstrated substantial scarring. 
Conversely, 86/101 [85.2%] patients in the daclizumab group remained steroid-free at 1 year. All 15 
patients received steroids at parts of the treatment of rejection. 
Cumulative treatment survival in the Campath group was 98.2%, 98.2% and 91.1% at 3, 6 and 12 
months, respectively, compared to 88.0%, 87.0% and 84.9% at the same timeline in the daclizumab 
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4.4.7 New Onset Diabetes after Transplantation 
 
Figure 4-9 Twelve-month NODAT-free survival in pilot study  
The incidence of new onset diabetes after transplantation [NODAT], defined as the de novo need for 
oral hypoglycaemics or insulin, was low at 12 months in both groups. 47 patients in the Campath 
group were not diabetic before transplantation, but 2 [4.3%] developed diabetes in the first 12 
months. 2 of 72 [2.8%] patients in the daclizumab group who were non-diabetic prior to 
transplantation developed NODAT at 10 and 11 months after transplantation. 
Cumulative NODAT-free survival in the Campath group was 95.7% at 3, 6 and 12 months, 
respectively, compared to 100%, 100% and 97.0% at the same timeline in the daclizumab group. 
There was no statistically significant difference between the 2 groups [p=0.6709, Logrank]. 
4.5 Summary 
In this chapter, I reported the results of our pilot study, using Campath induction with tacrolimus 
monotherapy compared to our historic patient cohort receiving daclizumab induction, tacrolimus 
and MMF maintenance in 2004.  
My study showed 1-year cumulative patient and graft survival were similar between the two groups. 
There were 3 graft losses and no patient deaths in the Campath group, compared to 3 graft losses 
and 3 patient deaths in the daclizumab group. The cumulative patient survivals with a function graft 
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More importantly, the risk of rejection was substantially lower in the Campath-treated group despite 
the avoidance of MMF maintenance. It was estimated that patients in the daclizumab group 
experienced a 3.2-fold increased risk of rejection, albeit it did not reach statistical significance. The 
natures of rejections were similar between the two groups. 
There were no differences in allograft function between the two groups or the trajectories of 
function over time. 
One of the objectives of this pilot study was to establish whether it is feasible to reduce the 
tacrolimus dosage to lower the incidence of Calcineurin inhibitor toxicity. Our data showed that 
incidences of CNI toxicity were low with both tacrolimus protocols, and there was no significance 
between the two protocols at 12 months. 
NODAT is associated with an increased cardiovascular risk in transplant recipients and results in 
lower graft survival, and tacrolimus was thought to be associated with an increased risk of NODAT. 
Our data showed that incidences of NODAT were similar between the two groups at 12 months 
despite a lower-dose tacrolimus in the Campath protocol benefitting with a lower incidence of 
NODAT.   
91.1% of patients in the Campath group remained on tacrolimus monotherapy at 1 year.  
Our pilot results were encouraging and demonstrated similar patient and allograft survival at 1 year 
with a trend of lower allograft rejection in the Campath-treated group. Therefore, we proceeded to 
a formal randomised controlled study and were discussed in the next chapter. 
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5  CamTac trial 
5.1 Introduction  
The combination of induction therapy and the use of tacrolimus-based regimens offer the promise 
of steroid-free maintenance regimens (113, 114), without an increased risk of rejection or graft 
failure, which were associated with steroid withdrawal from Cyclosporine [CsA] based regimens 
(115), or the associated the calcineurin-inhibitor toxicity related to aggressively dosed -based 
regimens (16, 116).  
It has been suggested a substantial proportion of recipients are receiving more long-term 
immunosuppression than they require maintaining good, rejection-free, renal transplant function 
(117). Furthermore, long term immunosuppression was associated with an increased risk of 
developing malignancy (118), infection (107) and patients’ death (119). Therefore, transplant 
physicians are considering  regimens combining potent induction therapies with decreased intensity 
of long-term maintenance therapy. 
Prospective randomised trials have demonstrated equivalent efficacy and safety of regimens using 
Campath induction without long-term steroids compared to classical CsA-based triple therapy (64), 
to tacrolimus/mycophenolate mofetil (MMF)/steroid triple therapy without induction (65), to 
induction with interleukin-2 receptor (IL-2R) MoAb or anti-thymocyte globulin with tacrolimus and 
MMF used in all three limbs (58), and in a small cohort comparing CsA with rapamycin monotherapy 
after Campath (121). Two large trials have compared induction with Campath with anti-thymocyte 
globulin or basiliximab followed by tacrolimus and MMF in both groups, with or without early 
steroid withdrawal, and both showed equivalent patient and graft survival with less rejection in the 
Campath arm (122, 123). The Pittsburgh group has taken the use of Campath further, reporting that 
the simple combination of Campath with low-dose tacrolimus maintenance monotherapy without 
steroids or MMF produces good outcomes, particularly in living donor transplantation (74), and this 
regimen has been shown to be as efficient as tacrolimus-based triple therapy without induction (65). 
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In our centre, the short-term experience using Campath induction and tacrolimus therapy without 
steroids or MMF maintenance was encouraging [Chapter 3], and there was a lack of formal 
randomised controlled studies to compare a conventional daclizumab induction/conventional-dose 
tacrolimus/MMF with this simple regimen. Therefore, we developed this randomised controlled 
study to examine the efficacy and safety of this regimen compare to our standard protocol. 
In this chapter, I discussed our experience and results of this randomised controlled study.  
5.2 Patients and methods  
5.2.1 Patients  
All patients receiving only a kidney transplant from a living donor or heart-beating deceased donor 
were invited to participate in this study. Recruitment was initiated in October 2005, and completed 
in April 2008 
A total of 123 patients were randomised. The two arms were well balanced with no major 
differences in terms of live versus deceased donor transplantation, recipient gender, age, primary 
renal diagnosis, ethnicity, and first versus subsequent transplantation. The proportion of pre-
sensitised patients was slightly higher in the daclizumab group [Table 5-1] 
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Recipient age [yrs.] 47.3+13.4 47.0+10.6 
Donor age 44.3+13.2 48.4+12.0 
Donor type 
 Living donor 52 [63%] 25 [61%] 
Deceased donor 30 [37%] 16 [39%] 
HLA MM 3.3+1.7 3.4+1.9 
Gender 
  Female 28 [34.1%] 14 [34.1%] 
Male 54 [65.9%] 27 [65.9%] 
Ethnicity 
  Afro-Caribbean 10 [12.2%] 7 [17.1%] 
Asian 27 [32.9%] 10 [24.4%] 
White 41 [50%] 21 [51.2%] 
Others 4 [4.9%] 3 [7.3%] 
Primary disease 
  Glomerulonephritis 20 [24.4%] 9 [22%] 
Diabetes 18 [22%] 6 [14.6%] 
Polycystic kidney disease 10 [12.2%] 5 [12.2%] 
Hypertension 6 [7.3%] 4 [9.8%] 
Reflux nephropathy 5 [6.1%] 4 [9.8%] 
Interstitial nephritis 1 [1.2%] 2 [4.9%] 
Other 5 [6.1%] 0 [0%] 
Unknown 17 [20.7%] 11 [26.8%] 
First transplant 78 [95.1%] 36 [87.8%] 
Pretransplant sensitisation status 
 PRA 50% 4 [4.8%] 8 [19.5%] 
PRA 85% 1 [1.2%] 3 [7.3%] 
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5.2.2 Methods 
This study was a self-funded, institutional review board-approved and registered [Clinicaltrial.gov 
NCT00246129], single-centre prospective randomized comparison of Campath and low-dose 
tacrolimus monotherapy compared with daclizumab, tacrolimus and mycophenolate mofetil. 
5.2.2.1 Trial design 
This was a randomised controlled study aiming to look at the effect of a new treatment protocol, 
consisting of Campath induction with tacrolimus monotherapy maintenance, compared to the 
control protocol, consisting of daclizumab induction with tacrolimus and mycophenolate mofetil 
maintenance therapy.  
This study was planned for non-inferiority in the treatment group in patient survival with a 
functioning graft at 1 year, compared to the control group. It was estimated that 1-year patient 
survival with a functioning graft in the control group would be 95% from the pilot study. The 
allocation ratio was 2:1 in Campath-to-daclizumab protocols. The reason for this allocation ratio was 
based on financial issues. The daclizumab protocol was substantially more expensive compared to 
the Campath protocol. The 2:1 ratio allocation would allow maximising the number of patients 
recruited for the funding available. This study was stratified for the type of donors because of the 
difference in graft outcomes between deceased and living donor transplantations. There were no 
changes to the trial design after the trial commenced. 
5.2.2.2 Interventions 
Trial group: 
 Campath (MabCampath, Genzyme) at 30mg IV post-operatively. 
 Tacrolimus [0.1mg/kg; target level 5-8 ng/ml] from Day 0. 
 Methylprednisolone at 500mg IV pre-operatively. 
 Prednisolone at 30mg bd Day 0-3, 30mg od Day 4-6, then stopped. 
Control group: 
 Daclizumab (Zenapax, Roche) at 2mg/kg at Day 0 and Day 14. 
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 Tacrolimus [0.15mg/kg; target level 8-12 ng/ml in first year, reduced to 5-8 ng/ml after 1 
year] from Day 0.  
 Mycophenolate mofetil [500mg twice daily; target level: 1.2-2.5 g/l]. 
 Methylprednisolone at 500mg IV pre-operatively. 
 Prednisolone at 30mg bd Day 0-3, 30mg od Day 4-6, then stopped. 
Allograft rejection was diagnosed by a transplant biopsy and was treated with steroids. 
Methylprednisolone at 500mg per day for 3 days, oral prednisolone at 30mg daily and was tapered 




 Patient survival with functioning graft at 1 year 
Secondary endpoints: 
 Patient survival at 1 year 
 Allograft survival at 1 year after being censored for patient death with function 
 Allograft function at 3, 6 and 12 months after transplantation 
 Rejection-free survival at 1 year 
 Allograft failure defined as the requirement of dialysis; the date of failure was the date 
dialysis commenced. 
 Allograft function was assessed using serum creatinine and MDRD eGFR. 
Allograft rejections were all biopsy-proven. 
There were no amendments to study endpoints after the trial commenced. 
5.2.2.4 Sample size 
The sample size was calculated to reflect a non-inferiority of 10% in patient survival with a 
functioning graft at 1 year, with an estimated 1-year survival of 95% in the control group by 
independent statistics advice for the unit. It is estimated that the trial would require 80 subjects in 
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the treatment group and 40 subjects in the control group, based on a 2:1 randomisation. The power 
calculation was reviewed and approved by COREC prior to the study. 
Interim analysis on allograft survival and function were undertaken after 50% of trial  recipients had 
reached the primary endpoint. Peto rules were used in the trial-stopping boundary (p<0.001), as well 
as if there were clinical concerns with new treatments. Results on interim analysis were reviewed by 
an external reviewer from the Royal Free Hospital Renal Unit and blindly by the transplant research 
group. 
5.2.2.5 Randomisation 
Randomisation was performed with the method of random permuted block with a random block size 
between 6 and 9, with a randomisation ratio of treatment and control group of 2:1. 
5.2.2.6 Concealment 
Treatment allocation was concealed in an opaque envelope and prepared by staff members in the 
Leslie Brent Laboratory, who were independent to the study. In order to reduce bias, treatment 
allocation was pre-printed prior to study started and stored securely. The investigator was blinded to 
block sizes, and 20 sequential treatment allocations were used at one time. Different folders for 
deceased and living donors were used for stratification. Patient recruitments continued until both 
arms reached the minimum number required in the study design. 
5.2.2.7 Implementation 
Information sheets regarding the trial were given to patients in the last living donor clinic review 
prior to transplantation, in the living donor recipients. Due to the impossibility of predicting the offer 
of deceased donor organs, information sheets were only given to patients receiving a deceased 
donor transplant a few hours prior to the transplantation. 
The randomisation sequence for 150 participants was generated prior to the start of the study by 
staff members in Leslie Brent Laboratory.  
5.2.2.8 Consent 
Consent for participation and treatment allocation were assigned by a junior investigator 
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[myself] or by duty transplant clinicians prior to transplantation.  
5.2.2.9 Blinding 
This was an open-label study involving different immunosuppression maintenance drugs, where 
drug levels required to be monitored carefully by clinicians, hence blinding was inappropriate. 
5.3 Statistics  
This study was examined as the intention to treat analysis; all patients had their induction therapy 
assigned by randomisation. Maintenance treatment might have changed as a result of complications 
and was classified as treatment failure. However, they remained in the randomised group, since the 
immunosuppressive effect of the initial treatment persists for a long period after transplantation.  
The Logrank method will be used for comparison between patient, graft and rejection-free survival 
between the 2 groups. The Kaplan Meier method was used to estimate cumulative survival over 
time, and variance of cumulative survival was estimated using the Greenwood formula. 
Censoring for loss of follow-up or death with a functioning graft was assumed to be non-informative. 
Numeric outcomes on allograft function at 6 months, 1, 2 and 3 years will be tested using a 
Student’s t test, as pre-determined in the study design. Due to the limited study number, no sub-
group analysis was planned. 
For the purpose of this project, a mixed-effect model was used to examine the difference in function 
over time between the 2 arms as well as the effect of rejection on graft function. 
Statistic tests were performed using Stata 12.0 (StataCorp, Texas). 
5.4 Results 
Trial recruitment was initiated in October 2005 and completed April 2008, 123 patients underwent 
randomisation. The two arms were well balanced with no major differences in terms of live versus 
deceased donor transplantation, recipient gender, age, primary renal diagnosis, ethnicity, and first 
versus subsequent transplantation.  
There were a higher portion of subjects in the daclizumab arm were sensitised against human 
leukocyte antigens defined as subject with calculated PRA more than 50%. Subject was sensitised in 
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the context of a previous transplant in two of four patients in the Campath arm and four of eight 
patients in the daclizumab arm. On single-antigen bead analysis, three of the sensitised patients in 
each arm had detectable donor-specific antibodies. This did not have a detectable effect on rejection 
or graft survival because none of the sensitised patients (calculated PRA >50%) in either arm 
suffered acute rejection during the first 2 years, and only one sensitised patient (in the Campath 
arm) suffered graft failure (due to progressive fibrosis in a scarred graft which functioned poorly 
from implantation). 
5.4.1 Primary outcomes 
5.4.1.1 Patient survival with functioning graft 
The primary outcome of this trial was cumulative patient survival with a functioning graft; we were 
interested in cumulative survival/hazard in participants who either died or sustained graft loss, 
defined previously as the requirement of commencing dialysis. 12-month cumulative patients with a 
functional graft are best demonstrated in Figure 5-1 below. 
1-year cumulative survival was 97.5% and 95.1% in the Campath and daclizumab groups. There were 
2 grafts lost in each group in the first 12 months. In the Campath group, there was one graft with 
primary non-function, and a graft from elderly extended criteria was lost at 7 months after 
transplantation following recovery from prolonged delayed graft function. A repeat transplant 
biopsy on this allograft showed persistent tubulofibrosis with no evidence of rejection. There were 2 
graft losses in the daclizumab group, there was one primary non-function and one patient died with 
severe CMV disease at 5 months which developed soon after completing the course of prophylaxis. 
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Figure 5-1 CamTac trial: Patient survival with functioning graft 
Examination on primary outcome 
This study was powered for a non-inferiority design with a 10% margin in patient survival with a 
functioning graft at 1 year in the Campath group. Analysis was based on FDA recommendation of a 
non-inferiority study using a fixed-margin approach. 
1-year cumulative survival in the Campath group = 97.5% 
1-year cumulative survival in the daclizumab group = 94.9% 
Difference = Survival in Campath group – Survival in daclizumab group 
      = 97.5% - 94.9% 
      = 2.6% 
Using the Greenwood formula, estimated standard error = 2.21% [Stata output]. 
Upper 95% CI of difference = 2.6 + 1.96 x 2.21%  
         = 6.9% 
Lower 95% CI of difference = 2.6 - 1.96 x 2.21% 
          = -1.7% 
Using the fixed-margin approach, estimated differences in the survival rate between the two groups 
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and thus there was no evidence to suggest inferior survival in the Campath group at a 5% 
significance level. 
5.4.2 Secondary endpoints 
5.4.2.1 Patient survival  
 
Figure 5-2 CamTac trial: Patient survival 
Figure 5-2 (above) shows the Kaplan Meier plot of patient survival in this study. Cumulative 12-
month patient survival was 100% and 97.5% in the Campath and daclizumab group [Logrank 
p=0.1547]. One patient in the daclizumab arm died of hemophagocytosis at 4.4 months associated 
with disseminated cytomegalovirus (CMV) disease after the cessation of CMV prophylaxis after a 
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5.4.2.2 Allograft survival after being censored for patient death with function 
 
Figure 5-3 CamTac trial: Allograft survival [Censored for death with function]  
Cumulative allograft survival after being censored for death with function was 97.6% in both groups 
at 1 year [Logrank test, p=0.9864].  
At 1 year, two grafts were lost in the Campath group, and one was lost in the daclizumab group, with 
one of the Campath group graft losses being related to donor organ quality with significant 
interstitial fibrosis and tubular atrophy on early biopsies for poor initial graft function progressing to 
graft failure without any evidence of rejection on multiple biopsies, despite the recipient being 
sensitised. [The sister organ was randomised to the daclizumab group and provided significantly 
impaired function in a pre-emptively transplanted recipient with significant residual native renal 
function.] The second graft loss in the Campath group was a result of a primary non-function 
allograft from an extended criteria donor. 
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5.4.2.3 Allograft function at 3, 6 and 12 months after transplantation  
 
Figure 5-4 CamTac: Allograft function 
Graft function did not differ significantly between the two groups [Figure 5-4], despite lower 
tacrolimus trough levels as per protocol in the Campath than daclizumab groups. Proteinuria 
[measured as spot urine protein/creatinine ratio P/Cr] did not differ at 6 or 12 months between the 
two groups [Campath arm 34.2/28.9 mg/mmol, daclizumab arm 31.4/59.7mg/mmol]. 
 
5.4.2.4 Rejection-free survival at 1 year 
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Although the results appeared to have a trend of a lower cumulative risk of rejection in the Campath 
group, the difference did not reach statistical significance at a 5% level [HR 2.2, 95%CI 0.76,  6.2; 
p=0.148]. 1-year rejection-free survival was 91.2% in the Campath group compared to 82.3% in the 
daclizumab group [Logrank test, p=0.1378]. 
Seven patients in the Campath arm suffered 12 rejection episodes in the first year, and seven 
patients in the daclizumab arm suffered 11 episodes. Although rejection was more frequent in the 
daclizumab arm, the difference did not reach statistical significance. One patient in each arm 
suffered acute antibody-mediated rejection [both in the presence of concomitant acute cellular 
rejection]. Both of these responded to treatment with a plasma exchange with 2g/kg human pooled 
intravenous immunoglobulin. Two patients in the Campath arm suffered repeated rejection 
episodes, responsive to steroids initially, but were treated as being steroid-resistant with 
intravenous immunoglobulin after the second recurrence, eventually leading to graft loss  after 1 
year.  
5.4.2.5 Treatment survival 
 
Figure 5-6 CamTac: Treatment survival 
Analysis of the treatment survival on a per-protocol (which is heavily influenced by rejection-free 
survival because rejection episodes are the most important reason for failure of per-protocol 
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functioning graft at 1 year in Campath arm patients remaining steroid-free on tacrolimus 
monotherapy at 1 year was 75.6%, and in the daclizumab arm, the comparable proportion of 
patients remaining steroid-free on tacrolimus/MMF therapy was 74.6%, p=0.1378 by log-rank test). 
5.5 Summary 
This Campath/tacrolimus monotherapy regimen has been shown to have good outcomes compared 
with an induction-free regimen using tacrolimus, MMF and steroids, with similar graft and patient 
survival, and a lower rejection rate at 6 months although not significantly so at 1 year.  
We have now shown that this regimen produces equivalent, excellent graft and patient survival at 1 
year compared with a more directly comparable regimen without long-term steroid exposure but 
with daclizumab induction therapy and MMF maintenance. 
In common with most trials of Campath induction, we demonstrated a low incidence of acute 
rejection in the first 6 months associated with the use of Campath. Unlike some of the reported 
studies, our cohort did not suffer a significant level of “catch-up” acute rejection episodes beyond 6 
months although the difference in rejection rates between the two arms did not reach statistical 
significance at 6 or 12 months. We did not observe the increased risk of CMV disease or antibody-
mediated rejection that has been speculated to be associated with the use of Campath induction 
therapy. 
Our trial was conservatively powered to detect a non-inferiority in efficacy, defined as a 10% non-
inferiority margin in survival with a functioning graft at 1 year, so we were not able to exclude the 
possibility of smaller differences, and the single-centre nature of the study may limit its applicability 
although the similarity of our outcomes to those reported with similar regimens in other centres 
suggests that these good short-term results do not simply reflect local practice. 
In the absence of stratification for sensitised or regrafted recipients, our study populations were not 
balanced for sensitisation against human leukocyte antigens, but this did not impact on the outcome 
measures reported here. 
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This RCT confirmed the short-term efficacy of Campath induction and tacrolimus monotherapy 
regimen and I will discuss the medium term outcomes of this regime in the next chapter, and the risk 
associated with this regimen in Chapter 11. 
Note: 
Part of the data from this chapter has been used in previously in my MSc Medical Statistics thesis 
titled “3 year results of a randomized controlled trial of Campath and low dose tacrolimus 
monotherapy compared with daclizumab, tacrolimus and mycophenolate mofetil and best measures 
to model long term renal transplant function” (124) with London School of Hygiene and Tropical 
Medicine, University of London. Complete data was published as a research paper “Kidney 
transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy-
-an open label, randomized trial “ in 2011 (111) 
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6 Medium-term outcome with Campath induction and tacrolimus monotherapy 
6.1 Introduction  
Short-term data from the literature and our study showing the results of using this minimalistic 
regimen with Campath induction and tacrolimus monotherapy maintenance were encouraging, 
showing similar allograft and patient survival at 1 year with a suggestion of a lower risk of rejection 
in the Campath group. However, there is a lack of long-term data regarding safety and efficacy of 
Campath induction, especially in combination with tacrolimus monotherapy. 
There was only one three-year report by the Pittsburgh group found in the literature describing their 
experience with a similar regimen, but with tacrolimus weaning. Their group had attempted 
tacrolimus weaning following Campath induction at 100 days following transplantation, in hope of 
this allowing immune engagement to promote graft tolerance (71, 72) and avoiding early post-
transplant immunosuppression and late toxicity as a result. Their study showed that weaning 
tacrolimus was associated with an increased risk and severity of rejection, as well as graft loss. This 
study confirmed the importance of long-term tacrolimus maintenance following Campath, although 
it did not address the question of late tacrolimus-related complications. Furthermore, there was 
concern that Campath induction only prevents rejection after early transplantation by inducing 
lymphopenia and that it may associate with an excess risk of late rejection (125), resulting in poorer 
long-term outcomes. 
Our centre has the advantage that we actively follow up our patients after transplantation in our 
unit and this produces comprehensive data on long-term follow-up in our patients; in this chapter, I 
am going to examine the medium-term results on the group of patients who received our minimalist 
regimen. I will concentrate on examining the incidence and risk of late rejection as well as potential 
complications associated with long-term tacrolimus exposure. 
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6.2 Patients and methods  
6.2.1 Patients  
All patients receiving only a kidney transplant from a living donor or deceased donor between 
November 2002 and December 2006 were included in this retrospective cohort study, to provide a 
minimum of 5-year follow-up in all patients. 
The study group consists of 146 patients who are receiving minimalistic Campath induction with a 
tacrolimus monotherapy maintenance protocol. A cohort of 148 patients who transplanted from 
November 2002 received the daclizumab induction; the tacrolimus and mycophenolate mofetil 
maintenance protocol acted as the control group. 
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Demographics 
Table 6-1 Demographics 
  




Gender F 58 [39.7%] 65 [43.9%] 
 
M 88 [60.3%] 83 [56.1%] 
Ethnicity Afro-Caribbean 20 [13.7%] 19 [12.8%] 
 
South Asian 42 [28.7%] 32 [21.6%] 
 
Caucasian 79 [54.1%] 91 [61.5%] 
 
Others 5 [3.4%] 6 [4.1%] 
First transplant Y 129 [88.4%] 133 [89.9%] 
 
N 17 [11.6%] 15 [10.1%] 
Donor type Deceased 63 [41.2%] 73 [49.3%] 
 
Living 83 [56.9%] 75 [50.7%] 
Cold ischaemic time Hours 20.4 + 11.9 16.9 + 12.8 
Recipient age Years 45.9 + 13.0 45.3 + 12.2 
Donor age Years 46.3 + 13.8 46.5 + 14.2 
HLA mismatch 
 
3.35 + 1.70 3.16 + 1.67 
Follow-up Months 71.7 + 8.6 86.7 + 16.4 
 
Detailed demographics are listed in Table 6-1.  
88/146 [60.3%] patients transplanted in the Campath group are male, and this was comparable to 
the control group of 56.1%. 42.2% of the cohort in this study is non-Caucasoid; this reflects the 
underlying ethnic diversity in the catchment area of the Imperial College Kidney and Transplant 
Centre. Proportions of non-Caucasoid transplanted in the two groups were similar. 13.7%, 28.7% and 
3.4% of patients transplanted in the Campath group were Afro-Caribbean, South Asian and from 
other ethnic backgrounds, compared to 12.8%, 21.6% and 4.1% in the daclizumab group, 
respectively. 13.1% of transplants in this group are repeat grafts. The proportion of living donor 
transplantation recipients was higher in the Campath group [56.9% vs 50.7% in the daclizumab 
group]; this is likely reflecting a change of practice over the follow-up period as living donor 
transplantation, where feasible, has become a more favourable treatment for patients with end-
stage renal failure. In the remaining patients who received a renal transplant from a deceased 
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donor, cold ischaemic time in the Campath group was 20.6 hours and was slightly higher, compared 
to the daclizumab-treated group at 16.9 hours. Average recipient and donor ages were indifferent 
between groups. Average recipient age was 45.8 and 45.3 years in the Campath and daclizumab 
group respectively; average donor age was 46.3 years in the Campath group and 46.5 years in the 
daclizumab group. On average, Campath has a 3.4 Human Leucocytes Antigen [HLA] mismatch 
between recipient and donor, compared to 3.2 in the daclizumab group. 
140/146 [95.9%] patients in the Campath group and 141/148 [93.3%] patients in the daclizumab 
group have been under active follow-up in the Imperial College Kidney and Transplant Centre to date 
or until patient or graft loss. 
6.3 Statistics  
The purpose of this study is to examine the medium-term outcomes in the early cohort of patients 
treated with the minimalistic immunosuppressive protocol. 
6.3.1 Primary endpoint: 
 Patient survival 
6.3.2 Secondary endpoints: 
 Patient survival with functioning graft 
 Allograft survival after being censored for patient death with function 
 Allograft function at 3, 6 and 12 months and annually after transplantation 
 Rejection-free survival  
 Calcineurin inhibitor toxicity 
 Transplant glomerulopathy 
 Treatment survival 
6.3.3 Outcome definition 
Allograft failure was defined as the requirement of dialysis; the date of failure was the date dialysis 
commenced. 
Allograft function was assessed using serum creatinine and MDRD eGFR. 
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Allograft rejections, calcineurin inhibitor toxicity and transplant glomerulopathy were all biopsy-
proven and classified by the Banff 2007 criteria. 
6.3.4 Statistics analysis plan 
This study was examined as the intention to treat analysis.  
The Logrank method was used in comparison, in survival, between the 2 groups, under an 
assumption that the underlying risk to failure and difference in hazard were constant. The Weibull 
parametric model was used in cases where this assumption is violated and where the underlying risk 
of failure changes with time. The Cox semi-parametric model was used if the assumption of constant 
difference in hazard was violated. 
The Kaplan Meier method was used to estimate cumulative survival over time. Patient survival, 
allograft survival and freedom from rejection, CNI toxicity and transplant glomerulopathy were 
examined using the same method. 
Censoring for loss of follow-up or death with a functioning graft was assumed to be non-informative. 
A mixed-effect model was used to estimate the difference in function at the baseline and difference 
in trajectory between groups on allograft function, as well as accounting for repeat measurements 
from the same patient over time. The point estimate on numeric outcomes on allograft function at 6 
months, 1, 2, 3, 4 and 5 years will be tested using a Student’s t test.  
All statistical tests were performed as a two-sided test and were deemed to be statistically 
significant if the p value was <0.05. 
Statistics tests were performed using Stata 12.1 (StataCorp, Texas). 
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6.4 Results 
6.4.1 Patient survival 
 
Figure 6-1 Five-year cumulative patient survival 
Figure 6-1 (above) shows the cumulative patient survival between the two groups.  
There were 9 deaths in the Campath group during the 5-year follow-up. Malignancy accounted for 
4/9 deaths. There was a metastatic gastric carcinoma at 25.4 months, one patient died from 
metastatic pancreas carcinoma at 40.8 months, one patient died from angiosacroma at 36.9 months 
and one patient died from recurrent renal cell carcinoma at 56.4 months. There were 2 cardiac 
deaths at 14.1 and 44 months, 1 patient died as a result of pneumonia complicated with 
encapsulating sclerosing peritonitis at 17.4 months, 1 patient was found dead at home at 52.4 
months (the cause of death was presumed to be cardiac-related) and 1 patient died from 
complications with idiopathic thrombocytopenic purpura at 59.7 months. The results at 1-, 3- and 5-
year cumulative survival were 100%, 97.7% and 93.1% in the Campath group, respectively. 
Medium-term patient survival was similar in the daclizumab group, and cumulative patient survival 
was 97.3%, 95.2% and 94.4% at 1, 3 and 5 years, respectively. There were 8 deaths recorded in the 
daclizumab group. 4 deaths were sepsis-related. 1 patient died from hemophagocytosis at 4.4 
months, which was associated with disseminated cytomegalovirus (CMV) disease after the cessation 
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Dr. Ka Kit Edmond CHAN 
months. 1 died from encapsulating sclerosing peritonitis at 17.4 months and one patient was found 
dead at home at 3.9 months. There was no statistically significant difference in survival between the 
groups [p=0.7703, Logrank].  
6.4.2 Allograft survival 
 
Figure 6-2 Five-year cumulative patient survival with functioning graft  
 
Figure 6-3 Five-year cumulative censored graft survival 
Figure 6-2 and Figure 6-3 (above) show long-term patient survival with functioning graft and allograft 
survival after censoring with death with a functioning graft.  
There were 25 graft losses in the Campath group during the 5-year follow-up. 9 grafts were lost as a 
result of patient death. One graft was lost due to renal vein thrombosis in a patient with positive 
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Dr. Ka Kit Edmond CHAN 
operation haemorrhage, and one graft from an elderly donor with long cold ischaemia had never 
fully functioned – repeat biopsies showed scarring and absence of rejection. Rejection accounts for 
11 cases of graft loss: 2/11 were due to transplant glomerulopathy, 4 were due to rejection 
resistance to treatment and 5 grafts were lost due to a rejection result of non-compliance.  
Cumulative patient survivals with a function graft in the Campath group were 96.6%, 93.0% and 
82.4% at 1, 3 and 5 years, respectively. Cumulative allograft survivals after being censored for 
patient death with a functioning graft were 96.6%, 93.0% and 88.5% at 1, 3 and 5 years, respectively.  
17 graft losses were reported in the daclizumab group. Eight graft losses were a result of patient 
death in the daclizumab group. 6 grafts were lost as a result of rejection, one loss was due to 
transplant glomerulopathy, 1 was due to resistance rejection and 4 were related to non-compliance. 
One graft was lost as a result of transplant renal artery thrombosis soon after surgery in a patient 
with significant pro-coagulant. One graft was lost at 10 months after transplantation with late 
presented graft pyelonephritis associated with the ileal conduit and one graft was lost due to 
transplant renal artery stenosis. 
Cumulative patient survivals with a function graft in this group were 94.6%, 90.5% and 87.7% at 1, 3 
and 5 years, respectively. Cumulative allograft survivals after being censored for patient death with a 
functioning graft were 97.3%, 95.1% and 92.9% at 1, 3 and 5 years, respectively.  
There were no statistically significant differences between the two groups in patient survival with 
functioning graft [p=0.2553, Logrank test] and allograft survivals after being censored for patient 
death with a functioning graft [p=0.2200, Logrank test]. 
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6.4.3 Rejection 
 
Figure 6-4 Five-year rejection-free survival 
Cumulative rejection-free survival in the Campath group was 94.4%, 88.6%, 79.1% and 76.8% at 6 
months, 1, 3 and 5 years after transplantation, respectively. 33 patients experienced rejection in this 
group, of which 25/33 [75.8%] were cell-mediated and the remaining 24% were antibody-mediated 
rejection. 
Proportions of patients experiencing rejection were similar in the daclizumab group. 0.5-, 1-, 3- and 
5-year cumulative rejection-free survival in this group was 88.4%, 85.6%, 81.1% and 78.7%, 
respectively. 23/31 rejections observed were cell-mediated and the remaining 25.8% were antibody-
mediated rejection. 
As demonstrated in Figure 6-4 above, the risk of rejection is highest in the first 12 months after 
transplantation. Therefore, assessment on difference of rejection between groups ought to be 
adjusted for time. The time-adjusted model did not show the Campath group experiencing a 
significant difference in rejection risk [HR 1.05; 95% CI 0.64, 1.73; p=0.837, Weibull regression 
model]. 
Furthermore, there was little evidence to support a difference in the risk of late rejection in the 
Campath group. After correcting for risk of rejection in the first year, adjusted 5-year cumulative 
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Dr. Ka Kit Edmond CHAN 
risk model did not suggest an increased risk of late rejection [HR 1.77, 95%CI 0.78, 4.01; p=0.169, 
Cox model]. 
6.4.4 Allograft function 
 
Figure 6-5 Long-term allograft function [MDRD eGFR] 
Figure 6-5 (above) shows allograft function in the two groups over 5 years. MDRD eGFR in the 
Campath group was 51.7+15.0, 53.7+14.7, 52.7+15.7 and 52.8+17.6 ml/min/1.73m2 at 6 months, 1, 
3 and 5 years after transplantation, respectively. Allograft function in the daclizumab group at a 
similar time point was 48.9+16.7, 50.5+16.7, 49.9+16.7 and 49.3+16.9 ml/min/1.73m2. There were 
no statistically significant differences in function at all time points. 
A mixed-effect model was used to estimate the trend of function over time and to examine whether 
there would be a difference in trends of function after transplantation. The model confirmed that 
there was no overall statistically significant difference in function between groups [Difference -
3.2ml/min/1.73m2, 95%CI -6.8, 0.4; p=0.080]. Data did not suggest any significant changes in 
function over time in either group. The model estimates non-significant changes of eGFR of -
0.002ml/min/1.73m2 per month [95%CI -0.05, 0.05, p=0.925] in the Campath group and 0.002 
ml/min/1.73m2 per month [95%CI -0.05, 0.05, p=0.929] in the daclizumab group. Thus, there was no 
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6.4.5 Calcineuin inhibitor toxicity 
 
Figure 6-6 Five-year Calcineurin inhibitor toxicity-free survival 
CNI toxicity-free survival between the two groups in the long term is shown in Figure 6-6 above. CNI 
toxicity remained rare in both groups. Although it was hoped that a lower, initial dose of tacrolimus 
in the Campath group might translate into a lower incidence of CNI toxicity in the long term, albeit 
the incidence of CNI toxicity remains low, the data did not demonstrate a significant difference 
between the groups [p=0.9002, Logrank]. 
Cumulative CNI toxicity-free survival in the Campath group was 94.3%, 92.0% and 91.2% at 1, 3 and 
5 years, respectively, compared to 96.6%, 94.4% and 90.4% in the daclizumab group. 
6.4.6 Transplant Glomerulopathy 
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Dr. Ka Kit Edmond CHAN 
Transplant glomerulopathy was diagnosed on a transplant biopsy. In total, 18 cases of transplant 
glomerulopathy were diagnosed in the Campath group, of which 8 cases had been diagnosed with 
rejection prior to biopsy evidence of transplant glomerulopathy. 11 cases of transplant 
glomerulopathy were diagnosed in the daclizumab group, and 5/11 cases had previous rejection.  
Overall allograft survival was poor after diagnosed transplant glomerulopathy despite escalation of 
treatment. 3 [16.7%] of 18 cases of TG in the Campath group subsequently lost their graft, whereas 4 
[36.4%] cases in the daclizumab-treated graft failed. 
Overall cumulative freedom from TG in the Campath group was 96.4%, 91.2% and 86.3%, 
respectively, and was 97.2%, 94.2% and 91.9% in the daclizumab group over 1, 3 and 5 years. There 
was no evidence of significant difference between groups [Figure 6-7; p=0.1546, Logrank]. 
6.4.7 Treatment survival 
 
Figure 6-8 Five-year treatment survival 
Treatment survival was defined as patients remaining on tacrolimus monotherapy in the Campath 
group and being steroid-free in the daclizumab group. 
Data suggested that 83.6%, 72.6% and 65.8% of patients in the Campath group remained on 
tacrolimus monotherapy at 1, 3 and 5 years after transplantation, respectively.  
Rejection was the commonest reason for treatment failure; 33 [70.2%] patients in the Campath 
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Dr. Ka Kit Edmond CHAN 
of transplant glomerulopathy, and 3 [6.4%] treatment failures were a result of cases of CNI toxicity, 
in which MMF was added to facilitate a large reduction in tacrolimus.  5 [10.6%] cases had MMF 
added because of biopsy features of significant ischemia and interstitial fibrosis, and it was decided 
that the tacrolimus burden be reduced to improve allograft function. 1 [2.1%] case had MMF started 
for recurrent glomerulonephritis. 
6.4.8 New Onset Diabetes after Transplantation [NODAT] 
 
Figure 6-9 Five-year NODAT-free survival 
The incidence of new onset diabetes after transplantation [NODAT], defined as the de novo need for 
oral hypoglycaemics or insulin, was shown in Figure 6-9 above. 119 patients in the Campath group 
were not diabetic before transplantation compared to 109 in the daclizumab group. Cumulative 
hazards of NODAT were comparable between the two groups [p=0.6366, Logrank]. 
Cumulative NODAT-free survival in the Campath was 97.4%, 92.8% and 90.8% at 1, 3 and 5 years, 
respectively, compared to 93.3%, 90.3% and 89.2% in the daclizumab group.  
6.5 Summary 
Short-term results using this minimalistic regimen with Campath induction and tacrolimus 
monotherapy maintenance were encouraging, showing similar allograft and patient survival at 1 
year with a suggestion of a lower risk of rejection in the Campath group. I demonstrated this data in 
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Dr. Ka Kit Edmond CHAN 
literature also supports the use of Campath as an induction agent in renal transplantation  (30); 
however, outcomes from these reports are limited to short-term results. There was a lack of 
medium or long-term data regarding safety and efficacy of Campath induction, especially in 
combination with tacrolimus monotherapy. Therefore, I studied the medium-term outcome in 
patients who reached at least 5-year follow-up in our centre to assess the safety and efficacy of 
Campath induction in the medium-long term. 
My data showed 1-, 3- and 5-year cumulative survival of 100%, 97.7% and 93.1% in the Campath 
group, respectively, and the results were similar to the daclizumab group, wherein cumulative 
patient survival was 97.3%, 95.2% and 94.4% at 1, 3 and 5 years. 
Cumulative patient survivals with a functioning graft in the Campath group were 96.6%, 93.0% and 
82.4% at 1, 3 and 5 years, respectively, and were 96.6%, 93.0% and 88.5% at 1, 3 and 5 years after 
being censored for patient death. There was no statistically significant difference compared to the 
daclizumab cohort: the cumulative patient survivals with a functioning graft in the daclizumab 
cohort were 94.6%, 90.5% and 87.7% at 1, 3 and 5 years, respectively, with cumulative censored 
allograft survivals of 97.3%, 95.1% and 92.9% at 1, 3 and 5 years. The commonest cause of graft loss 
in the Campath group was rejection, accounting for 11 cases in total, and the causes of graft loss in 
the whole Campath cohort will be discussed in detail in Chapter 8. 
The risk of rejection was lower in the first 6 months in the Campath group [5.6% vs 11.6%] , and 
cumulative risk of rejection converges between the two groups by 12 months [11.4% vs 14.4%]. 
There was no evidence suggesting a higher risk of late rejection in the Campath group. The nature of 
rejection was also similar: antibody-mediated rejection accounted for 24% of cases of rejection in 
the Campath group and 25.8% in the daclizumab cohort. There was also no evidence of significant 
difference in the risk of developing transplant glomerulopathy between groups. Overall cumulative 
freedom from transplant glomerulopathy in the Campath group was 96.4%, 91.2% and 86.3% and 
was 97.2%, 94.2% and 91.9% in the daclizumab group over 1, 3 and 5 years, respectively.  
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Estimated GFR was stable in both groups over time. It was estimated that eGFR of 53.7+14.7 and 
52.8+17.6 ml/min/1.73m2 at 1 and 5 years in the Campath group would be slightly higher compared 
to the daclizumab group – 50.5+16.7 and 49.3+16.9 ml/min/1.73m2 – although it did not 
demonstrate a statistically significant difference. 
We hoped that the lower-dose tacrolimus exposure in the first year in the Campath group might 
translate into a substantial reduction in the already-low incidence of CNI toxicity. The incidence of 
Calcineurin inhibitor toxicity remains low in both groups in the long term in our unit [8.8% vs 9.6% at 
5 years]; this is likely a result of meticulous monitoring and careful dose adjustment.  
Finally, in the medium term, the risk of new onset diabetes after transplantation remained low with 
the spare use of steroids: my data showed that 90.8% and 89.2% of non-diabetic patients remained 
NODAT-free at 5 years.  
This term study demonstrated that this minimalistic regimen with Campath induction and medium-
dose tacrolimus is efficacious with a similar medium-term outcome compared to a conventional 
daclizumab regimen with dual maintenance. Furthermore, 65.8% of patients in the Campath group 
remained on tacrolimus monotherapy at 5 years after transplantation. 
 I will be describing the risk of infection and malignancy associated with this regimen in chapter 11.3 
and chapter 11.4.  
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7 Weight-adjusted dose-finding study 
7.1 Introduction  
The use of Campath induction is becoming more popular, especially with those recipients who were 
immunologically sensitised (126). However, the optimal dosage of Campath used was not well 
studied (52). The current dosage of Campath varies between centres and these were described in 
detail later in this chapter.  
It was also unclear as to whether the dosage should be adjusted for bodyweight of the recipients for 
optimal risk and immunosuppressive benefits. There were little data investigating the effect of 
dosage of Campath on the duration of lymphopenia and whether this temporal lymphopenia was 
associated with any significant risk to recipients. The impact of duration of lymphophenia and its 
impact on infective risk were studied in chapter 10 and chapter 11.3. 
Calne’s team administered a total dose of 40mg of Campath to 31 deceased donor renal transplant 
recipients who had had no previous transplant, at 20mg each for two consecutive days immediately 
after transplantation together with a cyclosporine monotherapy maintenance regimen [Target range 
100-150ng/ml] in his early study (35, 127) in 1999. Both short and long term outcomes were 
encouraging. 
The interest in using Campath in renal transplantation grew following Kirk et al. who published their 
findings in an attempt to use Campath to induce transplant tolerance in 2003 (46). Kirk’s group 
attempted to induce transplant tolerance in seven patients using 3 to 4 doses of 0.3mg/kg Campath 
in transplantation without the use of any maintenance immunosuppressant; this was a substantially 
higher dose compared to previous reports. All patients experienced rejection within the first 3-4 
weeks after rejection despite T cell depletion, and all rejections were reversed by reintroducing a 
maintenance immunosuppressant. Although this study failed to demonstrate a significant 
tolerogenic capacity with Campath, it did confirm that high-dose Campath does not prevent renal 
allograft rejection.  
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The Kirk study also laid the foundation that long-term maintenance in renal transplantation is 
necessary after Campath induction, and further study examined the effect of combining Campath 
with different immunosuppressants. 
Knechtle et al. reported their experience of using Campath induction and Sirolimus induction in 2003 
(52, 55). Knechtle’s group treated 126 patients with a total of 40mg Campath induction in two 
divided doses over 2 days after operation and followed up with Sirolimus monotherapy 
maintenance. The dose of Campath was not corrected with weight; The short data from this study 
suggested that a similar efficacy compared to the historic control cohort. Although the absolute 
incidence was not reported explicitly, this report suggested that patients receiving 40mg of Campath 
have a similar risk of infection compared to other induction agents. Moreover, there were no data 
suggesting any difference in the risk of malignancy in the short term. This regimen is feasible for 
renal transplantation, despite concerns with the Sirolimus-resistant characteristics of residual 
lymphocytes after 40mg of Campath (77). 
To date, there have been 7 randomised controlled studies investigating the use of Campath in renal 
transplantation. Each study used different dosages of Campath as well as different types of 
immunosuppressant maintenance. 
A small, early randomised controlled study by Ciancio et al. published in 2007 (57) compared 30 
patients receiving Campath induction with 30 patients receiving thymoglobulin and 30 receiving 
daclizumab induction. All patients received tacrolimus, mycophenolate mofetil and steroid 
maintenance. Patients in the Campath group received 0.6mg/kg of Campath in total in two divided 
doses; this is equivalent to approximately 40mg in a standard 70kg patient. The majority of patients 
recruited in this study are Caucasian, Hispanics and Afro-Americans. Clinical outcomes were similar 
between the three groups.  
Vathsala et al. presented their results from Singapore which consisted of mainly oriental patients 
(64): 20 patients were given 40mg of Campath and cyclosporine monotherapy compared to 10 
patients receiving conventional triple therapy – cyclosporine, azathioprine and prednisolone 
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maintenance. Intuitively, one would imagine the body habitus in oriental persons to be significantly 
smaller compared to the Western population. This suggested that this group of patients was 
exposed to a much higher dose of Campath compared to previous studies. The rate of rejection was 
similar to previous Western population studies, albeit this study is grossly underpowered. 
A similar but larger study published by Margreiter et al. (65), using a similar steroid maintenance 
regimen that compared 65 patients receiving 40mg of Campath and tacrolimus monotherapy to 66 
patients receiving conventional triple therapy, consisted of no monoclonal antibody induction and 
maintenance immunosuppressants with tacrolimus, mycophenolate mofetil and steroids. Short-term 
1-year patient and allograft survival were similar between the groups. There was a suggestion that 
the incidence of rejection is lower in the Campath-treated group, likely because of the addition of 
induction therapy at transplantation.  
Our group presented a lower dose of 30mg of Campath which is feasible and safe in renal 
transplantation (111). In our study, we compared a 30mg induction of Campath and tacrolimus 
monotherapy to daclizumab induction and tacrolimus with mycophenolate mofetil maintenance.  
Our study demonstrated that this lower dose of Campath delivers a similar outcome to conventional 
therapy and that a higher dose of Campath was not necessary. 
The INTAC study group have presented the largest study to date, using 30mg of Campath in renal 
transplantation (123). 501 patients were included in this multicentre study; patients were 
randomised to receive either 30mg of Campath, basiliximab  or rabbit antithymocyte globulin [rATG] 
depending on immunological risk. This study showed that Campath induction is significantly better in 
preventing rejection in 6, 12 and 36 months after transplantation in those with low immunological 
risk.  
Results from these randomised controlled studies demonstrated that there is no consensus on what 
dosage of Campath should be given. It ranges from a body weight-adjusted dosage of up to 
1.2mg/kg to a standard dosing of 30 to 60mg in total. There are no clear differences in transplant 
outcomes between these studies.  
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Infection is a major concern because of the strong lymphopenic power associated with Campath. 
In transplantation literature, the emphases are often on efficacy outcomes and it is only recently 
that adverse events associated with immunosuppression started to be reported more explicitly. So 
far, the infection profile reported from the early cohort reports and randomised controlled study 
was encouraging. The 5-year report from the Calne team (63) suggested a slightly higher risk of CMV 
disease and herpes zoster infection in the Campath-treated group. There were no notable 
differences in other infections between groups. Recipient weights were not reported in this study 
and it was unclear as to whether these recipients carried a higher infection risk. Reports from 
Knechtle et al. did not detect a difference in infection risk with 40mg of Campath (52). 
An early study by Ciancio et al. demonstrated that the incidence of severe infection requiring 
hospitalisation is similar in patients receiving 0.6mg/kg of Campath to those receiving daclizumab 
and Thymoglobulin. Their group reported that 27% of patients receiving Campath had at least one 
hospital admission with infective complications after transplantation, and data did not suggest an 
increased risk of infection with Campath. Despite the lymphopenia, viral infections were uncommon 
(57). This study is underpowered and did not describe the nature and incidence of infection in the 
groups.  
In the Vathsala study (64), it mainly consisted of oriental persons receiving a large dose of Campath 
per body weight. The report suggested that 40% of Campath-treated patients experienced at least 1 
moderate or severe infection, although the nature or severity of the infection was not described in 
detail. Data did not suggest an increased risk of viral infection.  
The Margreiter study (65) presented some interesting data regarding infection. Despite the lower 
proportion of recipients with negative CMV status in the Campath group [34% vs 42%] and CMV 
prophylaxis to high-risk recipients, 18 cases of CMV infection were reported in the Campath group 
and were significantly higher compared to 8 cases in the control group [Rate Ratio 2.28]. Although 
the infection in the Campath group is less severe and there was no tissue-invasive CMV disease in 
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the Campath group, whereas 3/8 cases in the control group were invasive cases. Incidences of 
bacterial and fungal infection were similar between the two groups. 
All these studies were based on a high dose of 40mg of Campath induction, showing transplant 
outcomes were satisfactory. 
The effect of Campath in addition to concurrent immunosuppressants is best demonstrated by this 
large study reported from Pittsburgh aiming to address the incidence of opportunistic infection with 
Campath (99). The group reported an incidence of infection in 547 patients receiving Campath; this 
group consists of 65% of patients receiving Campath for organ transplant induction, and as 
maintenance or rescue therapy in the remaining group. Data suggested that patients receiving 
Campath on repeat dosing as recue therapy have a crude 3.5-fold increase in the risk of infection 
compared to those receiving Campath as induction agents. Although the data presented in this study 
did not measure the absolute changes in the rate of infection, it does highlight that patients who 
were already heavily immunosuppressed, particularly with concurrent use of steroids, were more 
likely to have an increased risk of infection. 
The effect of repeat Campath dosing and infection in transplantation was best demonstrated by the 
report published by the Minnesota group, who previously used Campath as maintenance in their 
pancreas transplant programme wherein some patients received up to 30mg per month. Their group 
reported their experience with fungal infection with repeat Campath in 2005 (96). 121 pancreas 
transplant recipients were included in their study, 56 as part of transplant induction and 65 as part 
of conversion from calcineurin inhibitors. 6.6% developed an invasive fungal infection and the 
incidence of fungal infection was substantial ly higher in those receiving Campath as conversion 
therapy [9.2% vs 3.6%]. 3 patients died during ongoing treatment of their fungal infection. This 
raised the alarm that Campath doses should be limited to avoid the unacceptable risk of fatal fungal 
infection associated with higher total dosage. 
Currently, most centres use either a single dose or two 30mg doses. Friend et al. argue that current 
30mg doses were chosen mainly because Campath was made in 30mg vials. Therefore, it was more 
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convenient to use 30mg dosing (128). A recent study published by Margreiter et al. attempted to 
answer this question (129). In this small randomised study, 66 patients received two 20mg doses of 
Campath compared to 65 patients receiving 30mg of Campath. Patient and graft survival at 1 year 
after transplantation were similar between the groups, and the incidence of allograft rejection at 1 
year was higher in the group receiving less Campath [20% vs 6%]; there was no difference in the 
incidence of infection between groups. This study is the first attempt to address the issue regarding 
dosage and complications with Campath; results did not suggest a marked difference in 
immunosuppressant-related complications. However, this study was substantially underpowered 
and the difference in Campath dosages is perhaps too little to judge the effect. 
The aim of this study was to examine the risk and benefit of high and low doses of Campath in renal 
transplantation. We were fortunate enough that our centre covers a wide area of North West 
London with a large ethnic diversity, in which patients’ sizes vary. In this chapter, we examined 
whether those receiving a lower dosage of Campath induction per body weight was associated with 
higher risk of rejection and allograft failure because of inadequate immunosuppression, as well as 
aiming to address the question of whether the immunosuppressant-related complications are 
related to a higher dose of Campath. 
7.2 Patients and methods  
7.2.1 Patients  
This is a retrospective study based on data collected on subjects transplanted using the Campath 
Regime between Nov 2005 and May 2011 for the Imperial College Kidney and Transplant Centre 
transplant registry. The use of data was authorised by the Imperial College Kidney and Transplant 
Centre’s transplant research group. Patient data were anonymised to secure patient confidentiality. 
Demographics 
608 patients were included in this study, and the mean weight was 76.1+17.3 kg. In order to study 
the effect of weight-adjusted Campath dosing, per bodyweight exposure was calculated by dividing 
the standard dosage of 30mg by a patient’s body weight. It estimated that the median Campath 
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exposure was 0.40 mg/kg, and the cohort was divided into quartiles to maximise its statistical power 
[<0.35mg/kg, 0.35-0.40mg/kg, 0.40-0.48mg/kg and >0.48mg/kg]. Details of demographics are as 
follows. 
Table 7-1 Demographics – Weight-adjusted dose-finding study  
  Below 
0.35mg/kg 
0.35 to 0.40 
mg/kg 




Gender Female 35 [21.3%] 37 [27.0%] 63 [38.2%] 80 [56.3%] 
 
Male 129 [78.7%] 100 [73.0%] 102 [61.8%] 62 [43.7%] 
Ethnici ty AFRO-CARIBBEAN 12 [7.3%] 21 [15.3%] 16 [9.7%] 12 [8.5%] 
 
ASIAN 37 [22.6%] 45 [32.9%] 59 [35.8%] 67 [47.2%] 
 
CAUCASIAN 108 [65.9%] 60 [43.8%] 80 [48.5%] 50 [35.2%] 
 
OTHER 7 [4.3%] 11 [8.0%] 10 [6.1%] 13 [9.2%] 
Primary transplant Yes 152 [92.7%] 126 [92.0%] 146 [88.5%] 127 [89.4%] 
 
No 12 [7.3%] 11 [8.0%] 19 [11.5%] 15 [10.6%] 
Donor type Deceased 82 [50.0%] 64 [46.7%] 91 [55.2%] 87 [61.3%] 
 
Living 82 [50.0%] 73 [53.3%] 74 [44.9%] 55 [38.7%] 
Pre-Tx DSAb No 148 [90.2%] 120 [87.6%] 160 [97.0%] 130 [91.6%] 
 
Yes 16 [9.8%] 17 [12.4%] 5 [3.0%] 12 [8.5%] 
CIT Hours 24.4 + 8.3 22.9 + 7.3 22.8 + 7.0 23.7 + 8.1 
Age Years 48.4 + 11.8 49.7 + 14.1 49.9 + 14.6 45.1 + 15.7 
Donor age Years 47.1 + 13.5 47.3 + 15.0 47.5 + 15.6 46.4 + 15.7 
HLA MM 
 
3.6 + 1.8 3.5 + 1.8 3.4 + 1.8 3.5 + 1.8 
Mean follow-up Months 29.1 + 17.1 32.4 + 18.1 33.5 + 19.1 32.6 + 17.8 
  
Female patients are smaller in general and have contributed to a larger proportion in the group 
exposed to the biggest dose of Campath. Thus, the proportion of female patients falls as the 
Campath exposure falls and as patient weight increases. 
In the lowest Campath-exposed group, there was a large portion of Caucasoid [65.9%], and vice 
versa, in the larger exposure group.  
There were no substantial differences in the number of previous transplants and pre-transplant 
donor-specific antibody statuses between the 4 groups. 
Furthermore, duration of cold ischaemic time, donor and recipient age, HLA mismatch and duration 
of follow-up were similar between the four groups. 
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7.2.2 Methods 
The purpose of this analysis is to examine the relative benefit and risk on those who received a 
higher or lower dose of Campath by weight in our cohort. 
Campath dosages per body weight were calculated by dividing the Campath dosage received [30mg] 
by a patient’s dialysis dry weight or by the lowest recorded weight in the first 3 months after 
transplantation if information regarding dry weight was not available. 
This cohort was divided into 4 groups following the interquartile ranges according to the Campath 
dosage received per body weight [<0.35mg/kg, 0.35-0.40mg/kg, 0.40-0.48mg/kg and >0.48mg/kg].  
The primary outcome of this study is patient survival at 1, 3 and 5 years. 
The secondary outcomes of this study include: 
 Allograft survival at 1, 3 and 5 years 
 Nature and incidence of acute rejection at 1 year 
 Nature and incidence of late rejection after 1 year 
 Allograft function at 1, 3, and 5 years 
 Effect of lymphocyte repopulation between groups 
 Incidence of infection between groups  
Allograft failure is defined as the need of a patient requiring returning to long-term dialysis. 
All rejections were based on histological diagnosis, and biopsies were performed on clinical grounds 
and were examined independently by a histolopathologist at the Imperial College and Kidney 
Transplant Centre.  
Allograft functions were assessed using serum creatinine and MDRD eGFR. Data on follow-up 
creatinine were collected from the data collected via routine biochemistry blood work performed in 
regular clinical follow-up. 
Data on lymphocyte profiles were collected from routine blood work performed in regular clinical 
follow-up. 
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Infections were diagnosed based on microbiological diagnosis. Positive urine, bronchiolar lavage, 
drain fluid, ascites and blood cultures constituted significant episodes of bacterial infection. 
Cytomegalovirus PCR positivity [>1000 copies/ml] and biopsy-proven BK virus nephropathy  
[intranuclear inclusion bodies with positive staining for SV40] were considered to be significant 
markers of viral infections. 
7.3 Statistics  
All statistical analyses were performed using Stata 12 [StataCorp, Texas]. 
Patient, allograft and rejection-free survival were presented using the Kaplan Meier plot. Impact on 
survival from different variables was analysed using the Cox proportional hazard model or the 
Weibull parametric model to adjust for time scales if appropriate. Censoring was assumed to be non-
informative. 
Allograft function and lymphocyte data were analysed using a mixed-effect model to account for the 
nature of repeat measurements over time, as well as allowing analysis on the effects of various 
factors on trajectories over time. Continuous variables were log-transformed into normal distributed 
data to improve adherence to model assumptions if needed. 
Incidences of infection were presented as the incidence per 100 patient years. The Poisson model 
was used to analyse rate and rate ratio; alternatively, a negative binomial model is used when the 
underlying assumption of equal mean and variance with the Poisson model is violated. 
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7.4 Results 
7.4.1 Patient survival 
 
Figure 7-1 Patient survival between 4 dosage groups  
Figure 7-1 (above) demonstrates overall patient survival between 4 groups. 1-, 3- and 5-year patient 
survivals in the 0.35mg/kg group below were 98.1%, 95.6% and 86.2%; 100%, 100% and 98.1% in the 
0.35-0.40mg/kg group; 98.1%, 95.2% and 93.6% in the 0.40-0.48mg/kg group; and 99.3%, 95.4% and 
83.4% in the 0.48mg/kg group above. There was no statistically significant difference in patient 
survival between the 4 groups [p=0.2192, Logrank]. 
22 patients died during follow-up within this cohort, and there was no significant difference in 
cumulative risk of death between the 4 groups, as discussed earlier. Cardiac death is the commonest 
cause of death in this cohort despite the proactive pre-transplant cardiac screening programme in 
the Imperial College Kidney and Transplant Centre; it accounts for 5/22 deaths. Unsurprisingly, a 
large proportion of cardiac deaths [4/5] were found in the patient group with the largest patients 
[those receiving <0.35mg/kg of Campath]. There were 3 patients that died as a result of complication 
of malignancy, 3 died with infectious causes and 3 died with complications of encapsulation 
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7.4.2 Allograft survival 
 
Figure 7-2 Censored allograft survival between 4 dosage groups  
 
Figure 7-3 Patient survival with functioning graft between 4 dosage groups 
Figure 7-2 and Figure 7-3 demonstrate the allograft survival after being censored for death with 
function and patient survival with a functioning graft over 5 years. 1-, 3- and 5-year patient survivals 
in the 0.35mg/kg group below were 85.1%, 90.7% and 86.9%; 97.7%, 91.8% and 89.9% in the 0.35-
0.40mg/kg group; 94.8%, 90.6% and 82.3% in the 0.40-0.48mg/kg group; and 98.6%, 94.8% and 
91.7% in the 0.48mg/kg group above. There was no statistically significant difference in patient 
survival between the 4 groups [p=0.2859, Logrank]. 
Patient death is the commonest cause of graft loss, accounting for 22/67 graft losses in this cohort. 
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cause of graft loss following a patient’s death. 21 grafts were lost as a result of rejection, of which 3 
were due to patient non-compliance with long-term immunosuppressive therapy. The proportion of 
graft losses as a result of rejection was between 3.5% and 4.5% between the 4 groups. There were 3 
graft losses due to transplant glomerulopathy, one in each group apart from the 0.48mg/kg group 
above. 5 grafts were lost following withdrawing immunosuppression in cases with overwhelming 
infection. 2 grafts were lost because of recurrent disease; both cases were due to recurrent focal 




Figure 7-4 Rejection-free between 4 dosage groups 
Figure 7-4 (above) shows rejection-free survival between the four groups in the long term. Although 
5-year cumulative rejection-free survivals were similar in the 4 groups, it was 73.7%, 76.0%, 77.0% 
and 75.2%, respectively. The difference in rejection is best observed in the first 12 months post-
transplantation: rejection risk appeared to be highest in those receiving less than 0.35mg/kg of 
Campath induction [28.7% vs 19.9%, 19.5% and 19.9% in the 0.35-0.40mg/kg, 0.40-0.48mg/kg and 
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This is best demonstrated in Figure 7-5 below. It is estimated that those receiving less than 
0.35mg/kg of Campath on induction have a 49.8% increase in the risk of rejection within the 12 
months after transplantation [HR1.50, 95%CI 1.02, 2.20; p=0.038]. 
 
Figure 7-5 12-month rejection-free survival at 0.35mg/kg 
There was no evidence suggesting an increased risk of late rejection after 1 year in any group [24 
months post-transplantation vs 12-24 months post-transplantation: HR 0.30, 95%CI 0.11, 0.83; 
p=0.02, Exponential survival model with Lexis expansion] or a difference in the risk of late rejection 
between 4 groups [p=0.2617, Logrank]. 
Nature of rejections was similar between all weight groups, albeit those receiving less Campath 
experienced higher risk and earlier rejection, as demonstrated above. Table 7-2 (below) shows the 
nature of rejection between the groups. The actuarial rate of rejection was significantly higher in 
patients receiving less than 0.35mg/kg of Campath. The risk of rejection was increased in both 
antibody-mediated or T cell-mediated rejections. Antibody-mediated rejection accounted for 16 
[40.0%] cases of acute rejection in those receiving less than 0.35mg/kg of Campath, and was similar 
to the patients receiving above 0.35mg/kg of Campath [37.7%].  
Table 7-2 Nature of acute rejection 
Group Cellular AMR No rejection 
<0.35mg/kg 24 [14.6%] 16 [9.8%] 124 [75.6%] 
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7.4.4 Allograft function 
 
Figure 7-6 Long-term allograft function between 4 dosage groups  
Figure 7-6 (above) shows allograft function between the four groups over 5 years of follow-up. 
Detailed allograft function is listed in Table 7-3 below. At first glance, allograft function in the 
0.35mg/kg column appeared to be lowest in the first 6 months after transplantation; however, this 
result might be physiological as a result of higher creatinine with increased body mass. 
Table 7-3 Allograft function between 4 groups [MDRD eGFR ml/min/1.73m2, mean +SD] 
Month  <0.35mg/kg 0.35-0.40mg/kg 0.40-0.48 mg/kg >0.48mg/kg 
6 51.0 + 16.68 52.9 + 18.08 56.3 + 17.85 57.7 + 18.93 
12 51.7 + 16.31 54.9 + 18.34 55.6 + 16.51 57.8 + 19.54 
24 49.8 + 16.15 54.4 + 16.34 54.2 + 16.82 59.1 + 18.02 
36 48.7 + 17.93 52.5 + 16.86 53.2 + 17.44 55.6 + 18.65 
48 47.2 + 16.11 56.2 + 20.86 52.3 + 17.37 52.1 + 20.47 
60 67.0 + 11.89 62.4 + 16.07 52.0 + 19.40 40.5 + 5.88 
 
Also, we ought to be aware that the estimation of average allograft function in this group is subject 
to a substantial influence of random variations caused by effects of correlations between repeat 
measurements from the same patients as well as a smaller number of subjects with a time lapse. 
Therefore, a mixed-effect model was used to estimate the difference in initial allograft function and 
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Table 7-4 Effect of Campath dosage on allograft function [Mixed-effect model]  
  eGFR 95%CI p 
Baseline function <0.35mg/kg 51.24 48.28, 54.20  
ml/min/1.73m2 at month 0 0.35-0.40mg/kg1 2.81 -1.55, 7.17 0.207 
 0.40-0.48 mg/kg1 5.86 1.69, 10.02 0.006 
 >0.48mg/kg1 9.26 4.83, 13.69 0.000 
Changes in eGFR per month 0.35mg/kg -0.06 -0.16, 0.04 0.218 
ml/min/1.73m2 per month 0.35-0.40mg/kg1 0.02 -0.12, 0.16 0.764 
 0.40-0.48 mg/kg1 -0.01 -0.15, 0.12 0.828 
 >0.48mg/kg1 -0.11 -0.26, 0.03 0.113 
 
The mixed model suggested that patients who received higher dosages of Campath have a 
significantly higher eGFR, as predicted, resulting from a lower creatinine and body mass. More 
importantly, there was no evidence suggesting deterioration in function over time. The model 
estimated a non-statistically significant change of -0.06ml/min.1.72m2 of eGFR per month [95%CI -
0.16, 0.04; p=0.218] in patients receiving 0.35mg/kg of Campath. There was no evidence suggesting 
that patients who received higher doses of Campath had different trajectories compared to the 
0.35mg/kg group. 
7.4.5 Transplant Glomerulopathy 
 
Figure 7-7 Transplant Glomerulopathy-free survival 
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Figure 7-7 (above) shows transplant glomerulopathy-free survival between the four groups. All 
transplant glomerulopathy was diagnosed with an allograft biopsy in cases with graft dysfunction. 
Transplant glomerulopathy-free survival was 94%, 87%, 90.6% and 93.9% in the below 0.35mg/kg, 
0.35-0.40mg/kg, 0.40-0.48mg/kg and above 0.48mg/kg groups, respectively. There was no evidence 
suggesting a difference in the risk of developing transplant glomerulopathy between groups 
[p=0.425, Logrank]. 
7.4.6 Infection risk 
All infections were diagnosed based on microbiological evidence. Positive urine, bronchiolar lavage, 
drain fluid, ascites and blood cultures constituted significant episodes of bacterial infection. 
Cytomegalovirus PCR positivity [>1000 copies/ml] and biopsy-proven BK virus nephropathy  
[intranuclear inclusion bodies with positive staining for SV40] were considered to be significant 
markers of viral infections. 
Incidence of infection  
The rate of infection over time is best presented in Figure 7-8 below, and is expressed as the 
incidence per 100 patient years. It is estimated that the rate of overall infection was 169.4+425.3 per 
100 patient years in the first 6 months and that the rate was a reduced 49.7+164.5, 42.7+193.9 and 
38.4+146.0 per 100 patient years at 6-12, 12-24 and 24-36 months after transplantation, 
respectively. The rate of infection in the first 6 months after transplantation was statistically 
significantly higher after adjusting for effects of repeat measurement using the Mixed-Effect Poisson 
Model. It was estimated that the rate of infection was 63% lower after the first 6 months [ rate ratio 
0.37 95%CI 0.30, 0.47; p<0.001], 71% lower between 12 and 24 months [rate ratio 0.29 95%CI 0.23, 
0.36; p<0.001] and 75% lower 24-36 months after transplantation [rate ratio 0.25 95%CI 0.19, 0.15; 
p<0.001].  
Infection rates were also differing between groups. Total infection was increased in the <0.35 mg/kg 
group in the first 6 months after transplantation, albeit it did not reach statistical significance; it was 
estimated that this group has a 31% increase in risk on overall infection compared to the 0.40-
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0.48mg/kg group [95%CI 0.86, 1.99; p=0.201]. This was mainly due to an excess wound and surgical 
infection, which I will describe later in this report. As demonstrated in Figure 7-8, patients who 
received the highest dose of Campath >0.48mg/kg also appeared to have the highest risk of 
infection. Moreover, the increased infection risk appeared to have persisted after 6 months. 
Compared to the group who received an average dose of Campath, the group exposed to the highest 
dose of Campath have a 2.6-fold increased risk of infection [95%CI 1.35, 4.88; Neg binomial model 
p=0.004] during 6 months following the initial high-risk period, a 29% increased risk [95%CI 0.78, 
2.13; Neg binomial model p=0.327] the second year after transplantation and a 2.6-fold increased 
risk of overall infection even 2 years after transplantation [95%CI 1.1,  5.9; Neg binomial model 
p=0.028]. 
 
Figure 7-8 Total infection rate between 4 groups  
Nature of infection 
As a result of the changes in infection risk over time, the pattern and nature of infection between 4 
groups were stratified into 4 timelines for analysis. As discussed earlier, patients receiving less than 
0.35mg/kg of Campath have the highest risk of infection in the first 6 months; this was attributed to 
an increased rate of surgical infection. It was estimated that the incidence of surgical-related 
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those receiving the average dosage [Table 7-6]. This increased risk of surgical infection is likely due 
to the large body habitus associated with the higher body weight. 
Infection risk was highest in patients receiving above 0.48mg/kg of Campath throughout all 
timelines, particularly urinary tract infection and bacteraemia [Table 7-5]. There was a substantially 
higher proportion of females in this group who had a higher risk of urinary tract infection and who 
would confound the observed event rates; therefore, a multivariate approach was used to adjust the 
effect of gender difference. The adjusted analysis suggested that patients receiving a high dose of 
Campath have a 1.8-, 2.02-, 2.1- and 2.7-fold increased risk of urinary tract infection at 6, 12, 24 and 
36 months, respectively, after transplantation after being adjusted for the gender effect. The 
incidence of bacteraemia was 12.5-fold higher in this group at 12 months after transplantation, 
compared to those receiving an average dose of Campath [Table 7-6]. 
Data from this study suggested that the difference in infection risk was limited to bacterial infection; 
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Table 7-5 Rate of infection between weight groups [Incidence /100 patient years]  
  Below 0.35mg/kg 0.35 to 0.40mg/kg 0.40 to 0.48mg/kg Above 0.48mg/kg 
UTI 6 months 66.9+10.57 48.8+9.58 51.3+8.94 113.6+14.4 
 6-12 months 13.0+4.91 20.8+6.58 30.0+7.08 55.0+10.39 
 12-24 months 4.2+2.40 10.4+3.93 21.1+4.83 47.7+8.18 
 24-36 months 7.8+4.48 12.1+5.41 11.6+4.40 41.5+9.80 
Surgical 6 months 53.5+9.46 24.4+6.77 28.0+6.60 18.3+5.79 
BK 6 months -  7.5+3.76 - 5.5+3.17 
 6-12 months 1.9+1.86 2.1+2.08 - - 
 12-24 months - 1.5+1.49 - 1.4+1.40 
 24-36 months - - - 2.3+2.31 
Fungal 6 months - - 3.1+2.20 - 
 6-12 months - - 1.7+1.67 - 
 12-24 months - - 1.1+1.11 1.4+1.40 
 24-36 months - - 1.7+1.66 2.3+2.31 
CMV 6 months 3.3+2.36 3.8+2.66 4.7+2.70 1.8+1.83 
 6-12 months 7.4+3.72 2.1+2.08 1.7+1.67 2.0+1.96 
 12-24 months - - - - 
 24-36 months - - - 2.3+2.31 
Bacteraemia 6 months 16.7+5.29 16.9+5.63 28.0+6.60 25.6+6.85 
 6-12 months 1.9+1.86 2.1+2.08 6.7+3.33 23.6+6.80 
 12-24 months - - 12.2+3.68 7.0+3.14 
 24-36 months 13.0+5.79 9.7+4.84 - - 
Other 6 months 11.7+4.42 13.1+4.97 6.2+3.11 12.8+4.84 
 6-12 months 3.7+2.62 6.2+3.61 6.7+3.34 11.8+4.81 
 12-24 months 13.9+4.38 4.5+2.57 13.3+3.84 5.6+2.81 
 24-36 months 18.1+6.85 4.8+3.42 3.3+2.35 4.6+3.27 
Total 6 months 152.1+15.95 114.6+14.67 121.4+13.75 177.7+18.1 
 6-12 months 27.9+7.19 33.3+8.33 46.7+8.82 92.3+13.46 
 12-24 months 18.0+5.00 16.3+4.93 47.7+7.27 63.1+9.41 
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Table 7-6 Time-stratified infection rate ratio between groups [Adjusted for gender]  
  Below 0.35mg/ kg 0.35 to 0.40mg/kg 0.40 to 0.48mg/kg 
[Reference] 
Above 0.48mg/kg 
UTI 6 months 1.37 [0.78,2.40; p=0.278] 0.93 [0.52,1.66; p=0.801] 1 1.78 [1.03,3.09; p=0.038] 
 6-12 months 0.67 [0.24,1.83; p=0.431] 1.34 [0.59,3.06; p=0.489] 1 2.02 [0.91,4.48; p=0.082] 
 12-24 months 0.20 [0.06,0.69; p=0.011] 0.53 [0.21,1.32; p=0.174] 1 2.11 [1.13,3.97; p=0.020] 
 24-36 months 0.77 [0.19,3.22; p=0.723] 1.27 [0.37,4.36; p=0.705] 1 2.73 [1.04,7.14; p=0.041] 
Surgic al  6 months 2.13 [1.06,4.27; p=0.033] 1.08 [0.51,2.31; p=0.840] 1 0.66 [0.27,1.60; p=0.361] 
BK 6 months - - 1 0.87 [0.18,4.28; p=0.860] 
 6-12 months 0.86 [0.05,13.93; p=0.914] - 1 - 
 12-24 months - - 1 - 
 24-36 months - - 1 - 
Fungal  6 months 0.78 [0.00,Inf; p=1.000] - 1 4.65 [0.00,Inf; p=0.999] 
 6-12 months 0.83 [0.00,Inf; p=1.000] - 1 6.26 [0.00,Inf; p=0.999] 
 12-24 months - - 1  
 24-36 months - - 1  
CMV 6 months 0.88 [0.12,6.34; p=0.895] 1.09 [0.17,6.74; p=0.929] 1 0.38 [0.03,4.46; p=0.440] 
 6-12 months 3.51 [0.39,31.97; p=0.265] 0.95 [0.06,15.54; p=0.973] 1 1.31 [0.08,22.28; p=0.851] 
 12-24 months - - 1 - 
 24-36 months - - 1 - 
Bacteraemia 6 months 0.94 [0.37,2.41; p=0.903] 1.62 [0.70,3.78; p=0.262] 1 1.50 [0.61,3.69; p=0.375] 
 6-12 months 0.89 [0.06,14.44; p=0.936] 3.50 [0.38,31.95; p=0.267] 1 12.52 [1.56,100.25; p=0.017] 
 12-24 months - - 1 0.52 [0.17,1.59; p=0.253] 
 24-36 months - - 1 0.73 [0.00,Inf; p=1.000] 
Other 6 months 0.89 [0.30,2.63; p=0.831] 0.44 [0.12,1.54; p=0.197] 1 0.83 [0.27,2.52; p=0.745] 
 6-12 months 0.59 [0.10,3.58; p=0.562] 1.23 [0.27,5.64; p=0.793] 1 2.43 [0.57,10.38; p=0.230] 
 12-24 months 0.86 [0.35,2.10; p=0.738] 0.31 [0.08,1.15; p=0.080] 1 0.46 [0.14,1.50; p=0.199] 
 24-36 months 4.20 [0.82,21.46; p=0.084] 1.23 [0.17,9.16; p=0.839] 1 1.42 [0.19,10.61; p=0.730] 
Total  6 months 1.31 [0.86,1.99; p=0.201] 0.99 [0.65,1.51; p=0.964] 1 1.34 [0.88,2.05; p=0.178] 
 6-12 months 0.85 [0.40,1.82; p=0.683] 1.41 [0.72,2.75; p=0.317] 1 2.57 [1.35,4.88; p=0.004] 
 12-24 months 0.35 [0.18,0.69; p=0.003] 0.35 [0.17,0.72; p=0.004] 1 1.29 [0.78,2.13; p=0.327] 
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7.5 Summary 
The use of Campath is becoming more popular as an induction agent in transplantation; however, 
the dosage of Campath used in an immunosuppressive protocol varies depending on the transplant 
centre protocol. Results from these randomised controlled studies have demonstrated that there is 
no consensus on what dosage of Campath should be given. It ranges from a body weight-adjusted 
dosage of up to 1.2mg/kg to a standard dosing of 30 to 60mg in total (42, 46, 57-59, 64, 65, 111, 130, 
131). There are no clear differences in transplant outcomes between these studies.  
We observed that the risk of systemic fungal and mycobacterial infections was high in patients who 
received high and repeated doses of Campath as maintenance therapy (97). Therefore, an optimal 
dosage of Campath induction should be sought to balance the infective risk associated with Campath 
whilst providing maximum immunosuppressive benefits.  
There were no data in the literature defining the optimal dosage of Campath, and the purpose of 
this retrospective study is to examine the effect of a body weight-adjusted dosage of Campath on 
transplant outcomes. 
608 patients were included in this study and were divided into 4 groups based on the quartile of 
Campath exposure per weight [<0.35mg/kg, 0.35-0.40mg/kg, 0.40-0.48mg/kg and >0.48mg/kg]. 
1-, 3- and 5-year patient survival was similar between the 4 groups. There were 22 deaths in this 
cohort and cardiovascular death remained the commonest cause of death despite our proactive 
approach to cardiac screening. Unsurprisingly, 80% of cardiac deaths were found in the group with 
the largest patients [<0.35mg/kg group]. There were 3 cases of sepsis-related death and these were 
distributed evenly between groups. 
My data showed that allograft survival was similar between the 4 groups and that the results were 
not different after being censored for death with function. Rejection was the commonest cause of 
graft loss. The proportion of graft loss as a result of rejection was between 3.5% and 4.5% between 
the 4 groups. 
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The incidence of rejection was low in the Campath-treated group, which was consistent with our 
experience with the randomised controlled study [Chapter 5]. However, I noted that there was an 
approximate 49.8% increase in the risk of rejection in the first 12 months with larger patients who 
had received less than 0.35mg/kg of Campath. There was no evidence to suggest a difference in the 
risk of late rejection between groups, albeit uncommon.  
The natures of rejection were similar between all weight groups, and the risk of rejection was 
increased in both antibody-mediated or T cell-mediated rejections. 
My mathematical model on allograft function using MDRD eGFR suggested that patients who 
received a higher dosage of Campath have a significantly higher eGFR, as predicted, resulting from a 
lower creatinine and body mass. There was no evidence suggesting deterioration in function over 
time. There was no evidence suggesting that patients who received different doses of Campath have 
different trajectories compared to the 0.35mg/kg group. 
I used the incidence of infections as a marker of immunosuppressive risk in this cohort. All infections 
were diagnosed based on microbiological evidence. It is estimated that the rate of overall infection 
was 169.4+425.3 per 100 patient months in the first 6 months and that the rate was a reduced 
49.7+164.5, 42.7+193.9 and 38.4+146.0 per 100 patient years at 6-12, 12-24 and 24-36 months after 
transplantation.  
Total infection was increased in the <0.35 mg/kg group in the first 6 months after transplantation, 
albeit it did not reach statistical significance. It was estimated that this group have a 31% increase in 
risk on overall infection compared to the 0.40-0.48mg/kg group and that this was mainly due to an 
excess wound and surgical infections. 
Patients who received the highest dose of Campath >0.48mg/kg also appeared to have the highest 
risk of infection. Compared to the group who received an average dose of Campath, this group 
exposed to the highest dose of Campath have a 2.6-fold increased risk of infection in the first 6 
months and this increased infective risk persisted after 2 years. Urinary tract infection and 
bacteraemia were most common in this group compared to patients exposed to less Campath. The 
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gender-adjusted analysis suggested that patients receiving a high dose of Campath have a 1.8-, 2.02-
, 2.1- and 2.7-fold increased risk of urinary tract infection at 6, 12, 24 and 36 months, respectively, 
after transplantation after being adjusted for the effect of the higher proportion of females. The 
incidence of bacteraemia was 12.5-fold higher in this group at 12 months after transplantation, 
compared to those receiving an average dose of Campath. 
My study is the first of its kind in the literature, which has aimed to examine the ideal body weight-
adjusted Campath dosage to provide maximum immunosuppressive benefits with the least infective 
risk. I showed that patients who were exposed to a high dose – above 0.48mg/kg – did not result in a 
lower risk of rejection, whereas those receiving less than 0.35mg/kg of Campath experienced a 48% 
increased risk of rejection. Furthermore, the higher weight-adjusted Campath dosage is associated 
with an increased risk of urinary tract infection and bacteraemia. The effects of this increased risk of 
infection appeared to persist for years after transplantation. 
As a result of this study, we changed our immunosuppressive protocol to a weight-adjusted 
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8 Causes of graft loss 
8.1 Introduction 
Short-term renal allograft survival has improved over the last decades, but it is yet to translate into 
improvement in long-term survival (132).  
Howard et al. have examined the causes of graft loss in their centre over the last three decades, 
showing allograft rejection as the commonest cause of graft loss despite the proportion of graft loss 
due to rejection falling from 66% in the 1970s to 45% in the 1990s with the improvement in 
immunosuppression (119). 
Patient death with a functioning graft persisted to be an important cause of long-term graft loss 
(119, 133). Howard et al. reported that a patient’s death accounted for an increased incidence of 
allograft failure; this is likely due to the changes in transplant recipient population and that more 
patients with complex medical histories have been transplanted over the last three decades. 
Cardiovascular disease is the commonest cause of transplant death, accounting for approximately 
36% of cases. Infection was the second commonest cause of death and this accounted for 17.6% of 
death recorded in the UNOS registry. Albeit less common, malignancy after long-term 
immunosuppressant exposure is associated with 9.2% of total mortality. 
Long-term allograft dysfunction due to medication toxicity is another important cause of graft loss 
and long-term allograft dysfunction. It was reported that a high incidence of tubular fibrosis followed 
10 years of cyclosporine exposure (16). The effect of long-term tacrolimus exposure on renal 
transplantation has remained unclear, although it is believed that tacrolimus is less toxic compared 
to cyclosporine (17). 
Other factors such as recurrent glomerular disease (134) and transplant glomerulapathy (135) are 
both important causes of graft failure in the long term. 
The number of patients receiving Campath induction in renal transplantation has been rising in the 
last decade following the report by Kirk et al. (46). Furthermore, there are plenty of clinical trials and 
cohort studies describing effects of Campath induction in the short term (52-57, 62, 65, 73, 136), but 
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a few are describing the long-term effects and causes of allograft loss following this powerful 
induction.  
The purpose of this chapter is to examine the cause of graft loss and death in our centre and to 
examine whether and how much this differs from published literature in patients receiving this 
simple immunosuppressive regimen. 
8.2 Methods 
This is a retrospective study based on data collected on subjects transplanted between Aug 2004 
and May 2011 for the Imperial College Kidney and Transplant Centre transplant registry. The use of 
data was authorised by the Imperial College Kidney and Transplant Centre transplant research 
group. Patient data were anonymised to guarantee patient confidentiality. 
All patients receiving induction therapy consisted of 30mg of Campath intravenously and long-term 
tacrolimus monotherapy maintenance.  
Demographics 
Table 8-1 Demographics 
  N [%], Mean ± SD 
Gender  Female 261 [35.2%] 
 
Male 481 [64.8%] 
Ethnicity Afro-Caribbean 75 [10.1%] 
 
Asian 242 [32.6%] 
 
Caucasian 370 [49.9%] 
 
Others 55 [7.4%] 
First transplant Yes 682 [91.9%] 
 
No 60 [8.1%] 
Donor type Deceased 389 [52.4%] 
 
Living 353 [47.6%] 
Cold ischaemic time [hrs.] 21.9±9.0 
Age at transplant [yrs.] 47.8±14.3 
Donor age [yrs.] 47.2±15.0 
HLA mismatch 3.5±1.8 
Follow-up [months] 37.2±23.1 
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Table 8-1 (above) shows the detailed demographics on the patient cohort included in this study. The 
majority of patients transplanted in our centre are male. 50% of patients transplanted in our unit are 
non-Caucasoid; this reflects the ethnicity mix of our catchment population. Furthermore, the 
majority of patients received the renal allograft as their first transplant. 52.4% of renal allografts 
were from deceased donors with an average cold ischaemic time of 21.9 hours. The mean HLA 
mismatches were 3.5. 98.1% of patients were under active follow-up in our centre until allograft loss 
or death. Mean follow-up was 37.2 months, with median and longest follow-up of 33.6 and 92 
months, respectively. 
All patients who had only undergone kidney transplantation without a prior desensitisation 
procedure were included in this report. 
Primary outcomes of this study include: 
 Allograft survival in 1, 3, 5 and 7 years 
 Causes of graft loss 
Allograft failure is defined as the need of a patient requiring returning to long-term dialysis or death. 
All causes of graft loss were confirmed following reviewing clinical notes. 
8.3 Statistics 
All statistical analyses were performed using Stata 12 [StataCorp, Texas]. 
Allograft survivals were presented using the Kaplan Meier plot, and cumulative survival was 
presented to adjust for loss of follow-up and variation in transplant vintage. 
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8.4 Results 
8.4.1 Overall allograft survival 
 
Figure 8-1 Overall patient survival 
 
Figure 8-2 Overall graft survival [Censored for death with function]  
Figure 8-1 and Figure 8-2 (above) show the cumulative patient survival with functioning graft and 
censored allograft survival in the whole cohort. There were 97 graft losses in total, of which 33/97 
[34.0%] were a result of a recipient’s death. 
The estimated cumulative patient survivals with a functioning graft were 94.8%, 87.7%, 80.4% and 
79.3% at 1, 3, 5 and 7 years following transplantation, respectively.  
Moreover, cumulative allograft survivals were 96.0%, 91.6%, 87.1% and 86.4% at 1, 3, 5 and 7 years 
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8.4.2 Causes of graft loss 
Table 8-2 (below) lists details of causes of allograft loss in our unit.  
Patient death with a functioning graft remained the commonest cause of allograft failure under this 
simple minimalistic regimen: patient deaths account for 34% of total graft losses, which is equivalent 
to 4.4% of the study cohort. 13/33 deaths were due to overwhelming sepsis, and 8 graft losses were 
due to cardiac deaths. 5 patients died as a result of underlying malignancies, of which 3/5 cases 
originated from the gastrointestinal system, 1 was recurrent renal cell carcinoma and 1 case was 
metastatic angiosacroma originating from a haemodialysis fistula. 2 patients died as a result of 
complications associated with encapsulating peritoneal sclerosis [EPS] related to previous peritoneal 
dialysis. 1 patient died following a haemorrhagic stroke, 1 patient died following dissection of a 
thoracic aneurysm and 1 patient with significant vascular disease died from an ischaemic bowel. 
Causes of death in 2 patients were unclear. 
Despite the powerful immunosuppressive effects of Campath, rejection remains an important cause 
of long-term graft losses. 31.9% of graft losses were caused by rejection; this is equivalent to 4.2% of 
the cohort. There were 12 cases of cellular rejection leading to graft losses despite the 
reintroduction of oral prednisolone and mycophenolate mofetil. 8 grafts were lost following 
diagnosis and treatment of antibody-mediated rejection; all 8 cases were treated with intravenous 
immunoglobulin and plasma exchange parallel to the reintroduction of steroids and mycophenolate 
mofetil. 3 allografts were lost soon after diagnosis of transplant glomerulopathy. 
8 allografts were lost as a result of non-compliance and 7 allografts were lost following the medical 
decision to stop immunosuppression in the face of life-threatening sepsis. 
6 allografts from extended-criteria deceased donors failed soon after transplantation despite 
producing initial marginal function post-transplantation. Repeat histological examination did not 
show evidence of acute rejection in these cases.  
Technical failure and primary non-function accounted for 6 and 2 cases of graft losses respectively. 
There were 2 cases of severe transplant renal artery stenosis and resulting graft loss.  
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The incidence of calcineurin inhibitor toxicity in our group was reportedly low with the low dose of 
maintenance tacrolimus (16), and there was only 1 [0.1%] case of CNI toxicity-related graft loss in 
the cohort.  
2 graft losses were following renal artery and venous thrombosis and 1 graft underwent graft 
nephrectomy because of an intractable ureteric leak. 
Table 8-2 Causes of graft loss 
Cause  n [%] 
Death 33 [34.0%] 
Sepsis 13 [13.4%] 
Cardiac 8 [8.2%] 
Malignancy 5 [5.2%] 
EPS 2 [2.1%] 
Unknown 2 [2.1%] 
CVA 1 [1.0%] 
Dissection of thoracic aneurysm 1 [1.0%] 
Ischaemic bowel 1 [1.0%] 
Rejection 31 [31.9%] 
Acute cellular rejection  12 [12.4%] 
Non-compliance 8 [8.2%] 
Antibody-mediated rejection 8 [8.2%] 
Immunosuppressant withdrawal 7 [7.2%] 
Transplant Glomerulopathy  3 [3.1%] 
Donor factors 6 [6.2%] 
Technical failure 6 [6.2%] 
Primary non-function 2 [2.1%] 
Pyelonephritis 2 [2.1%] 
Recurrent disease 2 [2.1%] 
TRAS 2 [2.1%] 
Cardiac failure 1 [1.0%] 
CNI toxicity 1 [1.0%] 
Renal vein thrombosis 1 [1.0%] 
Arterial thrombosis 1 [1.0%] 
Unknown 1 [1.0%] 
Ureteric leak 1 [1.0%] 
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8.5 Summary 
Published reports from the literature have showed a significant improvement in short-term allograft 
survival over the last three decades, but it has yet to translate into long-term survival improvement.  
Although there is a large quantity of literature showing a favourable short-term use of Campath 
induction, the use of Campath induction has shown to improve short-term allograft survival in a 
meta-analysis (29). The long-term outcome of using Campath and its associated causes of graft loss 
was not well documented.  
In the chapter, I examined the overall graft and patient survival in our unit and explored the causes 
of graft failure under this simple regimen. 
My study showed that the estimated cumulative patient survivals with a functioning graft were 
94.8%, 87.7%, 80.4% and 79.3% at 1, 3, 5 and 7 years following transplantation, respectively. And 
cumulative allograft survivals were 96.0%, 91.6%, 87.1% and 86.4% at 1, 3, 5 and 7 years, 
respectively, after censoring for patients having died with a functioning graft. 
Patient death with a functioning graft remained the commonest cause of graft loss in our unit, 
accounting for 34% of graft losses. Sepsis was the commonest cause of patient death in our unit, 
corresponding to 13/742 [1.8%] patients in this study cohort. On the contrary to previous UNOS 
reports, cardiovascular death only accounted for a moderate portion of total patient deaths [8/33, 
24.2%]. The reduction of cardiovascular death is likely because of a proactive cardiac screening prior 
to transplantation in our transplant recipients, and this is reported in detail in the thesis submitted 
by my colleague, Dr. Nichola Kumar, from Imperial College.  
Although our data in the RCT showed that acute rejection was lower in the Campath-treated group 
at 1 year and little evidence suggested an increased risk of late rejection in the long term, rejection 
remained an important cause of graft losses. 12/31 cases were cellular rejection, 8/31 were 
antibody-mediated rejection and 3/31 cases were lost as a result of transplant glomerulopathy.  
Despite this simple monotherapy regimen, 8 grafts were lost as a result of rejection caused by 
medication non-compliance.  
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9 Long-term allograft pathology 
9.1 Introduction 
Data in the literature suggested a lack of improvement in long-term allograft survival despite a 
substantial improvement in short-term results in terms of survival and lower rejection risk (132). It 
was reported that patient death and rejection were the main causes of long-term graft loss (119, 
133) and this is consistent with our experience [Chapter 8]. 
Long-term allograft dysfunction due to medication toxicity is another important cause of graft loss 
and long-term allograft dysfunction. It was reported that a high incidence of tubular fibrosis followed 
10 years of cyclosporine exposure (16). Other factors such as recurrent glomerular disease (134) and 
transplant glomerulopathy (135) are both important causes of graft failure in the long term. 
Calcineurin inhibitor toxicity  
It is well established that calcineurin inhibitors are crucial in long-term allograft survival, but they are 
associated with a significant risk of nephrotoxicity after long exposure with either cyclosporine or 
tacrolimus. CNI toxicity can manifest in acute settings with a transient fall in allograft function due to 
an excess dosage or, more commonly, in a chronic setting following a long exposure to CNI over 
years.  
A previous report looking at 888 surveillance biopsies on 99 patients over 10 years by the Nankivell 
group suggested that 100% patients who were treated with cyclosporine will manifest at least one of 
the elements of CNI toxicity in their allograft histology. And 53.9% of patients will have some 
features of CNI toxicity on a protocol biopsy after 1 year (137). 
It is unclear whether tacrolimus is associated with a similar risk of long-term allograft toxicity to 
cyclosporine. A large US transplant registry report examined almost 70,000 non-renal solid organ 
transplants and showed that liver transplant patients treated with tacrolimus have a lower risk of 
developing CNI toxicity and have a better renal function in the long term (67). A smaller study in 
renal transplant recipients showed data supporting a better CNI toxicity profile with tacrolimus 
(138).  
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The effect of long-term tacrolimus exposure on renal transplants has remained unclear, although it is 
believed that tacrolimus is less toxic compared to cyclosporine (17). We were hoping that by further 
reducing the maintenance dosage of tacrolimus following Campath induction, it might translate into 
a reduced incidence of CNI toxicity. 
Transplant Glomerulopathy 
Transplant glomerulopathy [TG] in a renal allograft was first described in 1970 by Hood (139) and 
has been a major cause of graft loss and dysfunction in the long term. TG is a histological diagnosis 
based on features described by the Banff Working Group (140), defined as duplication of glomerular 
basement membranes in 10%, or more, of glomerular capillary loops in glomerulus. It is thought that 
development of TG is associated with the presence of anti -HLA antibodies and results from chronic 
rejection (141). 
Previous reports estimated that TG is rare during the first year after transplantation; however, the 
incidence of transplant glomerulopathy could rise to as high as 20% in 5 years in a steroid- and 
cyclosporine-treated era (116, 135). Furthermore, development of TG is associated with worse 
clinical outcomes despite augmentation of immunosuppressants (142).  
The incidence and nature of TG is unclear following a powerful lymphopenic Campath induction and 
tacrolimus monotherapy. I will try to address the incidence of TG in our programme. 
Recurrent glomerular disease 
Recurrent glomerular disease is a well-recognised complication in renal transplantation (134, 143-
146) and it is thought that recurrent glomerular disease is the third commonest cause of graft loss in 
the first 10 years following a patient death with functioning graft and allograft rejection (134). The 
author estimated that the risk of graft loss from recurrence increased with the years of follow-up, 
from 0.6% in the first year to 8.4% in the tenth year.  
A recent review paper by Choy et al. examined the risk of recurrent disease in renal transplant 
recipients, suggesting that 80-100% with Type 2 membranoproliferative glomerulopathy experience 
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recurrent disease in the first 5 years, and 15-30% experience allograft loss in renal recipients with 
Type II MPGN as a result of recurrent disease (143). 
Focal segmental glomerulosclerosis [FSGS] is an important cause of end-stage disease in our centre 
and other units. Recurrence of FSGS after transplantation was thought to be rapid and common 
(143, 146). It was estimated that 20-50% of patients with underlying primary FSGS would experience 
recurrent disease following transplantation (143) and that 13-20% of patients with primary FSGS will 
experience graft loss as a result of recurrent disease in the long term. 
IgA nephropathy is the commonest glomerular disease leading to end-stage renal failure. Recurrent 
IgA nephropathy is reported in 13-46% of patients, and 2-16% of cases of allograft loss result in the 
long term.  
Lupus nephritis, ANCA-associated glomerulonephritis and anti-GBM disease are other common 
causes of recurrent glomerular disease after transplantation. It is estimated that up to 2-9% of 
recipients with lupus nephritis and up to 17% of patients with ANCA vasculitis experience recurrent 
disease after transplantation.  
The aim of this chapter is to examine the pattern of long-term allograft pathology in the whole of 
Campath-treated cohort transplants between Aug 2004 and May 2011, to investigate whether our 
medium-dose tacrolimus monotherapy maintenance translates to a further reduction in CNI toxicity 
as well as a lower risk of TG with a low risk of acute rejection early after transplantation. Moreover, I 
am going to report the incidence of recurrent glomerular disease in this group of patients after this 
lymphocyte-depleting treatment. 
9.2 Methods 
This is a retrospective study based on data collected on subjects transplanted between Aug 2004 
and May 2011 for the Imperial College Kidney and Transplant Centre transplant registry. The use of 
data was authorised by the Imperial College Kidney and Transplant Centre transplant research 
group. Patient data were anonymised to guarantee patient confidentiality. 
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All patients receiving induction therapy consisted of 30mg of Campath intravenously and long-term 
tacrolimus monotherapy maintenance.. 
Demographics 
Table 9-1 Demographics: Long-term allograft pathology 
  N [%], Mean ± SD 
Gender  Female 261 [35.2%] 
 
Male 481 [64.8%] 
Ethnicity Afro-Caribbean 75 [10.1%] 
 
Asian 242 [32.6%] 
 
Caucasian 370 [49.9%] 
 
Others 55 [7.4%] 
First transplant Yes 682 [91.9%] 
 
No 60 [8.1%] 
Donor type Deceased 389 [52.4%] 
 
Living 353 [47.6%] 
Cold ischaemic time [hrs.] 21.9±9.0 
Age at transplant [yrs.] 47.8±14.3 
Donor age [yrs.] 47.2±15.0 
HLA mismatch 3.5±1.8 
Follow-up [months] 37.2±23.1 
 
Table 9-1 (above) shows the detailed demographics on the patient cohort included in this study. The 
majority of patients transplanted in our centre are male. 50% of patients transplanted in our unit are 
non-Caucasoid; this reflects the ethnicity mix of our catchment population. Furthermore, the 
majority of patients received the renal allograft as their first transplant. 52.4% of renal allografts 
were from deceased donors with an average cold ischaemic time of 21.9 hours. The mean HLA 
mismatches were 3.5 in 98.1% of patients under active follow-up in our centre until allograft loss or 
death. Mean follow-up was 37.2 months, with median and longest follow-up of 33.6 and 92 months 
respectively. 
The purpose of this analysis is to examine the cause of graft loss in our Campath-treated cohort since 
we started using this minimalistic regimen. 
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All patients who had only undergone kidney transplantation without a prior desensitisation 
procedure were included in this report. 
Primary outcomes of this study include: 
 Incidence and timing of development of CNI toxicity 
 Incidence and timing of development of transplant glomerulopathy 
 Incidence and timing of development of recurrent disease 
Diagnosis of these long-term allograft pathologies is based on histological examination on indicative 
biopsies performed when there is a clinical need. 
9.3 Statistics  
All statistical analyses were performed using Stata 12 [StataCorp, Texas]. 
Times to event survivals were presented using the Kaplan Meier plot, and cumulative survivals were 
presented to adjust for loss of follow-up and difference in transplant vintage. Censoring was 
assumed to be non-informative. 
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9.4 Results 
9.4.1 Calcineurin inhibitor toxicity 
Incidence 
 
Figure 9-1 CNI toxicity-free survival 
Figure 9-1 (above) shows the cumulative survival of calcineurin inhibitor toxicity in this study cohort. 
In total, 21 patients were diagnosed with CNI toxicity on clinical indicative biopsies, of which 3/21 
cases were diagnosed following dose increase after allograft rejection. 
1-, 3-, 5- and 7-year cumulative incidences of CNI toxicity were 2.3%, 3.0%, 3.7% and 3.7%, 
respectively.  
There was only one case of graft loss as a result of CNI toxicity and this accounted for 1% of graft loss 
in our large cohort [Chapter 8]. 
These results were encouraging and markedly different from previous literature based on a 
Cyclosporine regimen. Furthermore, this study provides insightful data that supports our regimen 
with low-dose tacrolimus being associated with a minimal risk of CNI toxicity in the long term. 
9.4.2 Transplant Glomerulopathy 
Transplant glomerulopathy is diagnosed on histological features associated with thickening and 
duplication of glomerular basement membranes in the absence of active immune reactivity or 
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mediated response, either in the form of donor-specific antibodies or acute or chronic antibody-
mediated rejection (140).  
Incidence 
Transplant glomerulopathy is uncommon in our experience using this minimalistic regimen. Figure 
9-2 (below) shows the cumulative transplant glomerulopathy-free survival in our cohort. All TG cases 
were diagnosed on indicative biopsies in cases of transplant allograft dysfunction or increasing 
proteinuria. Results include all biopsies which demonstrated features of transplant glomerulopathy 
diagnosed by histopathologists.  
Our results showed cumulative TG-free survival of 96.8%, 94.4% and 91.1% at 1, 3 and 5 years, 
respectively, substantially lower than published data. 
 
 
Figure 9-2 Transplant Glomerulopathy  
There were 3 graft losses as a result of transplant glomerulopathy despite optimisation of 
immunosuppressants; TG accounts for 3% of graft losses in our cohort [Chapter 8]. 
9.4.3 Recurrent disease 
In this study, I examined the incidence of recurrent disease in patients who were thought to have a 
glomerular disease causing end-stage renal failure and who underwent renal transplantation in the 
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transplantation were included in this analysis. Recurrent glomerular disease was diagnosed based on 
indicative transplant biopsies at the time of allograft dysfunction or other clinical indications.  
181 [24.7%] patients were thought to have a glomerular disease prior to renal transplantation. 9/181 
[4.97%] cases of recurrent glomerular disease were observed. The incidence of glomerular disease in 
this cohort and risk of recurrence are detailed in Table 9-2. 
IgA nephropathy is the commonest glomerular disease that leads to renal transplantation in our 
unit. 4/62 [6.5%] patients experienced recurrent disease within 7-year follow-up at 8, 11, 23 and 37 
months post-transplantation. 2/10 [20%] patients with membranous glomerulopathy recurred at 22 
and 42 months following transplantation. Recurrent MCGN is the second commonest cause of 
recurrent disease in this cohort; 1 [8.3%] patient developed recurrent MCGN at 13 months. 1 patient 
developed recurrent Anti GBM disease at 24 months.  
Of all patients with underlying FSGS, 1 [2.3%] developed recurrent disease at 1 month following 
transplantation and disease progression was aggressive despite plasmapheresis and increased 
immunosuppressive therapy. Thus, it resulted in graft loss at 16 months. 
Table 9-2 Recurrent Glomerular disease 
 No recurrent disease Recurrent disease 
Anti GBM disease 7 [87.5%] 1 [12.5%] 
Amyloid 1 [100.0%] 0 [0.0%] 
Chronic Glomerulonephritis 15 [100.0%] 0 [0.0%] 
FSGS 42 [97.7%] 1 [2.3%] 
IgA Nephropathy 58 [93.5%] 4 [6.5%] 
Lupus Nephritis 18 [100.0%] 0 [0.0%] 
MCGN 11 [91.7%] 1 [8.3%] 
Membranous Glomerulopathy 8 [80.0%] 2 [20.0%] 
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Figure 9-3 Glomerular disease recurrence-free survival (below) depicts the cumulative recurrence 
disease-free survival. The median time to recurrence was 22 months. Cumulative survivals were 
98.2%, 94.9% and 97.8% at 1, 3 and 5 years, respectively. 
 
Figure 9-3 Glomerular disease recurrence-free survival 
 
9.5 Summary 
Long-term allograft dysfunction due to medication toxicity, recurrent glomerular disease (134) and 
transplant glomerulopathy (135) are important causes of graft failure in the long term. In this 
chapter, I examined the incidence of CNI toxicity, transplant glomerulopathy and recurrent 
glomerular disease in our cohort following Campath induction. 
Nankivell et al. reported results from 888 surveillance biopsies on 99 patients over 10 years, 
suggesting that 100% of patients who were treated with cyclosporine will manifest at least one of 
the elements of CNI toxicity in their allograft histology at 10 years, and 53.9% of patients will have 
some features of CNI toxicity on a protocol biopsy after 1 year (137). This is very different from our 
experience: our results are certainly very similar to previous reports suggesting that tacrolimus is 
less toxic compared to cyclosporine (17). Only 21/742 [2.8%] patients in this study experienced 
allograft dysfunction caused by CNI toxicity, of which 3/21 cases were diagnosed after the tacrolimus 
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was 2.3%, 3.0%, 3.7% and 3.7%, respectively. There was only one case of graft loss as a result of CNI 
toxicity and it accounted for 1% of graft loss in our large cohort. My data showed that the incidence 
of CNI toxicity was substantially lower compared to previous reports using this minimalistic medium-
dose tacrolimus regimen. 
Development of transplant glomerulopathy is associated with worse clinical outcomes despite 
augmentation of immunosuppressants (142). Previous reports have estimated that the incidence of 
transplant glomerulopathy has been as high as 20% in 5 years in a steroid- and cyclosporine-treated 
era (116, 135). The incidence of transplant glomerulopathy is low in our centre. My results showed 
cumulative TG-free survival of 96.8%, 94.4% and 91.1% at 1, 3 and 5 years, respectively, substantially 
lower than published data. There were 3 graft losses as a result of transplant glomerulopathy 
despite optimisation of immunosuppressants; TG accounts for 3% of graft loss in our cohort [Chapter 
8]. 
Recurrent glomerular disease is a well-recognised complication in renal transplants (134, 143-146) 
and it is thought that recurrent glomerular disease is the third commonest cause of graft loss in the 
first 10 years following patient death with functioning graft and allograft rejection (134). 
Furthermore, it is estimated that the risk of graft loss from recurrence increased with the years of 
follow-up from 0.6% in the first year to 8.4% in the tenth year, and the risk of recurrent disease 
varies depending on the underlying primary disease.  
In this study, I identified 181 [24.7%] patients who were thought to have a glomerular disease prior 
to renal transplantation, of which 9/181 [4.97%] cases of recurrent glomerular disease were 
observed. The median time to recurrence was 22 months. Cumulative survivals were 98.2%, 94.9% 
and 97.8% at 1, 3 and 5 years, respectively. Patients with membranous glomerulopathy have the 
highest risk of recurrent disease, whereas none of the patients who were thought to have underlying 
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10 Haematological profile 
10.1 Introduction 
Results from the clinical studies demonstrated that Campath is a powerful lymphopeni c agent and 
repopulation of lymphocytes varies depending on the subsets (46, 49, 52, 54, 62, 76). Campath itself 
does not induce transplant tolerance, and maintenance immunosuppression is required to avoid 
acute rejection despite lymphopenia (46, 49). We also observed that the choice of maintenance 
immunosuppression has a huge impact on a transplant outcome. The incidence of acute rejection 
was low in patients treated with a calcineurin inhibitor-based immunosuppression protocol 
following Campath, regardless of whether maintenance mycophenolate mofetil or steroids were 
used (52, 56, 57, 61, 63). On the contrary, the incidences of acute rejection in the rapamycin 
maintenance regimes were unacceptably high, even with the concurrent use of mycophenolate 
mofetil (54, 55). The difference in efficacies between different types of immunosuppression 
maintenance may be due to the functional nature of a residual lymphocyte following depletion.  
Pearl et al. underwent a study to investigate the phenotype and functioning characteristics of 
residual lymphocytes following lymphodepletion of Campath (77). Blood samples were drawn and 
analysed using flow cytometry prior to depletion and this was done weekly for 4 weeks in 5 patients 
during the original tolerance induction study (49); samples from patients who received rabbit anti-
thymocyte globulin or daclizumab acted as controls. This study showed almost complete 
lymphodepletion with naive T cells and regulatory T cells after Campath, but with a single phenotype 
(CD3+ CD4+ CD45RA- CD62L CCR7-). This depletion-resistant subset was thought to be a memory-
effect T cell. These cells expand quickly following depletion and were prevalent during rejection.  
Interestingly, these memory T cells were also resistant to steroids, rapamycin and deoxysepergualin 
in vitro, but were uniquely sensitive to calcineurin inhibitors. These data might explain the reason 
why Campath is not pro-tolerant and why calcineurin inhibitors are crucial for transplant 
immunosuppression maintenance following Campath induction. 
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The effects of the recovery of lymphocytes and risk of infection following Campath are not clear; 
there is no literature describing whether lymphocyte repopulation is associated with an increased 
risk of rejection. University of Minnesota adopted a trial of using repeat doses of Campath following 
lymphocyte repopulation to avoid rejection; with little success, the trial was terminated early for 
safety reasons.   
Furthermore, there were concerns that high-dose Campath is associated with an increased incidence 
of autoimmune disease as well as autoimmune haemolytic anaemia (100, 101, 147). The incidence 
of haematological disease is not well described in the literature, and together with my colleague, Dr. 
Rawya Charif, we examined the trend of the haematological profile in patients treated with this 
simple immunosuppressive regimen. 
I examined the relationship between rejection and residual lymphocyte/monocyte counts, 
investigating whether the lymphocyte compartment in patients who experienced acute rejection in 
the first 12 months recovers at a different rate. 
I collaborated with Dr. Charif in this study design, we collected data together and I performed the 
necessary statistical analysis and developed the mathematical models used to analyse the 
relationship between the lymphocyte profile and risk of rejection.  
10.2 Methods 
The purpose of this study was to examine the changes of the haematological profile following 
Campath induction in our transplant patient cohort. 
Primary objectives of this study were: 
1. Investigate the pattern of the haematological profile and its recovery following Campath 
2. Investigate whether there was an association between the rate of lymphocyte repopulation 
and risk of rejection 
96,695 results reported from a routine haemological laboratory on 483 patients transplanted 
between 1st November 2005 and 1st April 2010 were used in this analysis.  
Lymphopenia and neutropenia were defined as lymphocyte counts being below 1 x109/L. 
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Thrombocytopenia was defined as total platelet counts being below 50 x109/L. 
All rejections were diagnosed on allograft biopsies and were performed on clinical indications. All 
lymphocyte data before rejection were included in the rejection model as lymphocyte counts might 
be affected by the addition of immunosuppressants and might influence the accuracy of the model. 
10.3 Statistics  
All statistical analyses were performed using Stata 12 [StataCorp, Texas]. 
Haematological profiles were analysed using a mixed-effect model to account for the nature of 
repeat measurements over time, as well as allowing analysis of the effects of various factors on 
trajectories. Continuous variables were log-transformed into normal distributed data to improve 
adherence to model assumptions if needed. 
10.4 Results 
 
Figure 10-1 Long-term total white blood cell counts following Campath induction 
Figure 10-1 (above) shows the average total white blood cell [WBC] profile in our cohort over time. 
There was a transient rise in the total WBC count immediately after transplantation, which was likely 
due to the steroids administered during the induction phase. Following the first week, the total 
white blood cell started to fall and appears lower than pre-transplant levels, which was likely caused 
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recover after 6 months and reached the pre-transplant level at 12 months, following lymphocyte 
repopulation.  
Lymphocyte, Neutrophils, Monocytes and Basinophils were described in more detail in this chapter. 
10.4.1 Lymphocyte 
 
Figure 10-2 Long-term lymphocyte counts following Campath induction 
Campath is a power agent-inducing transient lymphopenia following transplantation; the effect of 
Campath on lymphocytes is best demonstrated in Figure 10-2 above. The recipient lymphocyte 
compartment depleted instantly following administration and the lymphocyte remained suppressed 
in the first 12 months after transplantation. Lymphocyte counts dropped from 1.67+0.75 x109/ml on 
average prior to transplantation to 0.19+0.17 x109/ml in the first week following administration.  
99.8% of patients remain significantly lymphopenic in the first month [95%CI: 98.3,  100%], and as 
demonstrated in the figure above, lymphocytes started to repopulate after 3 months. Average 
lymphocyte counts were 0.55+0.32 at 3 months and continued to improve, whereby reaching an 
average of 1.03+0.55 at 12 months after transplantation. 
Although the average lymphocyte counts appeared to have reached the lower limit of reference, 
there was a concern that the duration of lymphopenia varies between patients following treatment. 
Using a survival model to adjust for difference in timelines, I demonstrated that the proportion of 
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months [Table 10-1]. By 2 years, 75.6% of patients in this cohort had recovered their lymphocyte 
compartment. Interestingly, my data show a very small proportion [1.4%] of the cohort remaining 
lymphopenic at 5 years. I demonstrated in an earlier chapter that there was no association between 
lymphopenia and infection risk.  
Table 10-1 Percentage of patients with lymphopenia following Campath induction 
Months from transplantation Percentage patient with lymphocyte <1 x 109 
0 99.8% [98.3%, 100.0%] 
3 96.8% [94.5%, 98.1%] 
6 76.5% [72.1%, 80.4%] 
12 52.3% [47.3%, 57.0%] 
24 24.6% [20.5%, 28.9%] 
36 7.5% [5.1%, 10.5%] 
48 1.4% [0.5%, 3.4%] 




Figure 10-3 Long-term neutrophil following Campath induction 
There was a transient neutrophilia following administration of induction steroids in the first week 
following transplantation [Figure 10-3]. The overall neutrophil profile appeared to be stable over 
time.  
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3/8 cases developed neutropenia after reintroduction of mycophenolate mofetil following treatment 
of allograft rejection.  
2/8 cases developed neutropenia during prophylactic treatment of PCP with co–trimoxazole, and 
neutrophil counts recovered following treatment change to nebulise pentamidine. 
 
Figure 10-4 Neutrophil profiles in patients with reported persistent neutropenia  
10.4.3 Monocytes 
 
Figure 10-5 Long-term monocyte counts following Campath induction 
It had been previously demonstrated that Campath has a different degree of effects on lymphocyte 
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the residual monocyte populations are resistant to a list of conventional immunosuppression  types 
apart from calcineurin inhibitors (77). 
My study confirmed previous findings that monocytes depleted immediately following Campath and 
their level remained suppressed for the first 4 weeks after transplantation [Figure 10-5]. Monocytes 
repopulated substantially faster compared to the lymphocyte compartment. Monocyte counts in 
45% of cohort patients reached a normal level within the first 6 months and 65% of patients’ routine 
blood tests demonstrated normalised monocyte levels by 1 year. 
10.4.4 Platelets and haemoglobin 
 
Figure 10-6 Long-term platelet counts following Campath induction 
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Figure 10-6 and Figure 10-7 (above) showed the long-term trend of platelet counts and haemoglobin 
of this cohort. With courtesy to data from Dr. Rawya Charif, we observed 11 cases of haematological 
autoimmune disorder. 7 cases of idiopathic thrombocytopenic purpura [ITP] alone, 1 case of 
autoimmune haemolytic anaemia [AHA] and 3 patients experienced both ITP and AHA.  
The majority of patients presented with a sudden onset of anaemia and/or thrombocytopenia. All 
patients received a combination of intravenous immunoglobulin, steroids and rituximab. 1 patient 
underwent splenectomy. 3 patients required Romiplostim. 2 patients died [1 sepsis, 1 myocardial 
infarction], and 1 graft was lost following the withdrawal of immunosuppression in the context of 
sepsis. 7 of the 9 surviving patients achieved complete remission with a normal platelet count and 
haemoglobin. The remaining 2 patients with ITP are in partial remission, with a platelet count 
>50x109/L, having been treated for less than 3 months. 
10.5 Rejection and lymphocyte repopulation 
 
Figure 10-8 Lymphocyte repopulation profiles between rejecters and non-rejecters 
Figure 10-8a (above) showed the lymphocyte proliferation profiles in patients who experienced 
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individuals subsequently experienced rejection repopulating their circulatory lymphocyte at a 
different rate compared to those who did not reject. In order to study this question, the 
mathematical model used must be adjusted for repeat measurement in an individual so as to 
examine the underlying trend over all groups. Therefore, I fitted a mixed-effect model to examine 
the trajectory of lymphocyte proliferation between the two groups of patients over time. 
Furthermore, lymphocyte counts measured in routine blood work are highly skewed and the model 
was fitted in a natural log scale as a result. As a result of the estimation, the model is fitted in Figure 
10-8b and is displayed in the table below. 
Repopulation of lymphocytes in Campath-treated patients follows a cubic mathematical function 
manner. Therefore, there was an early, sharp rise in lymphocyte counts following time 0 and the 
rate of repopulation changes over time and reached the plateau at the end of the observation. In 
this case, we observed the fastest rise in lymphocyte counts in the first 20 weeks following Campath 
and reached the plateau stage at around 30 weeks after transplantation. 
It was estimated that residual lymphocyte counts in the rejecter group of 0.110 x109/ml compare to 
0.117 x109/ml in those who did not experience rejection subsequently. The difference between the 
two groups did not reach statistical significance [Relative difference 0.94, 95%CI 0.85, 1.03; p=0.197 
Mixed-effect model]. The model also estimated the average difference in the rate of lymphocyte 
repopulation between the rejecter and non-rejecter of 0.03% per week and this did not reach 
statistically significant difference [Mean 0.03%, 95%CI -0.34%, 0.40%; p=0.875]. 
Table 10-2 Mixed-effect model showing differences in lymphocyte repopulations  
Factor  Mean  95% CI p value 
Time Week 16.79% [16.33, 17.25]  <0.001 
 
Week2 -0.38% [-0.40, -0.36] <0.001 
 
Week3 0.00% [0.00, 0.00] <0.001 
Difference in rate of repopulation  0.03% [-0.34, 0.40]  0.875 
Lymphocyte count at day 0 Non-rejecter 0.117 x109/ml [0.111, 0.123]  
 
 
Rejecter 0.110 x109/ml [0.101, 0.119]  0.197 
This study showed repopulation of lymphocytes following Campath induction following a cubic 
mathematical pattern. There was no statistically significant difference in baseline residual 
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lymphocyte counts between rejecters and non-rejecters. Furthermore, the rate and pattern of 
lymphocyte repopulation between the two groups were similar and not associated with acute 
rejection. 
10.6 Rejection and monocyte repopulation 
Monocyte repopulation followed a very similar pattern to lymphocyte repopulation, but was slightly 
more complex with a quartic pattern. The majority of monocytes depleted following Campath 
induction, but they recovered quickly and reached the plateau stage by around 10 weeks [Figure 
10-9]. 
 
Figure 10-9 Monocyte repopulation profiles between rejecters and non-rejecters 
Previous reports suggested that effect of Campath on leucodepletion were variable depending on 
the sub-type of leucocytes, of which monocytes were most resilient to the effect of Campath and 
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In this part of the study, I examined the effects of residual monocytes and the relationship between 
monocyte repopulation and later rejection. Similar to the lymphocyte repopulation model, I used a 
mixed-effect model to account for the nature of data. 
As with the lymphocyte repopulation, monocytes recover following a cubic manner and recovery 
was much quicker compared to lymphocytes. The rate of recovery was highest in the first 15 weeks 
and reached the plateau stage soon after. 
This model estimated that monocytes recover at 13.4% per week. My model did not detect a 
significant difference in the monocyte recovery rate between the groups. It estimated a 0.05% 
difference [95%CI -0.32%, 0.42%; p=0.801] in the rate between rejecter and non-rejecter. 
Residual monocyte counts were 0.180 x109/ml in the non-rejecter compared to 0.175 x109/ml in the 
rejecter and there was no statistically significant difference between the two groups [p=0.611]. 
Table 10-3 Mixed-effect model showing differences in monocyte repopulations  
  
 
 Mean 95% CI p value 
Time week 13.40% [12.63, 14.16]  <0.001 
 
week2 -0.63% [-0.6786, -0.5882]  <0.001 
 





Difference in rate of repopulation  0.05% [-0.32, 0.42]  0.801 
Monocyte count at day 0 Non-rejecter 0.180 x109/ml [0.170, 0.191]  <0.001 
Rejecter 0.175 x109/ml [0.158, 0.193]   
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10.7 Summary 
Campath is a powerful lymphopenic agent and the rates of repopulation of lymphocytes are variable 
depending on the lymphocyte subset. In this chapter, I examined 96,695 results reported from a 
routine haemological laboratory on 483 patients from transplantation to investigate the effect of 
Campath on long-term haematological profiles. 
My analysis showed that total white cell counts immediately increase following induction with 
methylprednisolone and they remained high during the 7-day course of oral prednisolone. Total 
white cell counts fall after withdrawal of steroids and they appeared to be lower than pre-transplant 
levels. Total white cell counts start to recover after 6 months and they reach the pre-transplant level 
at 12 months. 
Within the leucocyte compartments, lymphocytes were most strongly affected by Campath. Effects 
of Campath on lymphocytes were immediate and I demonstrated immediate lymphopenia following 
induction. Lymphocytes remained low: 99.8% of patients remain significantly lymphopenic in the 
first month, and they only started to recover after 3 months. I demonstrated that the proportion of 
patients in the cohort with lymphopenia decreases gradually from 96.8% at 3 months to 52.3% at 12 
months, and 75.6% of patients in this cohort had recovered their lymphocyte compartment by 2 
years. 
Although there was a suggestion that CD52 expresses on neutrophils and that activated CD52 results 
in neutrophil cell lysis in vitro (148), data obtained from a routine clinical haematological study did 
not demonstrate Campath incurring significant effects on neutrophils. There was a transient 
neutrophilia following administration of induction steroids in the first week following 
transplantation. The overall neutrophil profile appeared to be stable over time. There were 8 cases 
of neutropenia in this cohort and 5/8 cases were due to other medications, with the remaining 3 
cases recovering spontaneously, and there was no evidence to suggest that this transient 
neutropenia was associated with an increased risk of infection [Chapter 11.3]. 
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It had been previously demonstrated that Campath has a different degree of effects on leucocyte 
subsets. In particular monocytes, it was noted that monocytes are more resilient to Campath and 
the residual monocyte populations are resistant to a list of conventional types of 
immunosuppression apart from calcineurin inhibitors. Results from my data were similar to previous 
reports in literature: monocytes remained low in the first 4 weeks; however, monocytes recover 
earlier and faster compared to lymphocytes. Monocyte compartments recovered in 45% of patients 
in the first 6 months and 65% at 1 year. 
My data also demonstrated that Campath has little impact on haemoglobin and platelet counts, at 
large, although there were 11 cases of haematological disorder reported in this cohort: 7 idiopathic 
thrombocytopenic purpura, 1 autoimmune haemolytic anaemia and 3 cases of both AHA and ITP. 
Most patients responded to treatment and the majority of patients achieved total remission with 
treatment. 
Pearl et al. report that lymphopenia following Campath is incomplete and residual cells are mainly 
memory-effect T cells, which are only sensitive to calcineurin inhibitors (77). Therefore, there was a 
concern that repopulation of lymphocytes might trigger allograft rejection.  
In order to examine the effect of lymphocyte profiles accurately, I used a mixed-effect model to 
examine the rate of lymphocyte and monocytes change over time between rejecters and non-
rejecters. My study showed that neither the trajectories of lymphocyte nor monocyte recovery were 
different in patients who experienced rejection and in those who did not.  
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11 Risk  
11.1 Introduction  
Infection 
It has long been established that immunosuppression increases the risk of infection (107, 108) and 
that the pattern and nature of infection change over time after transplantation (108) and differ with 
immunotherapy used (109, 110). 
It was thought that the powerful lymphodepleting ability of Campath might result in a high risk of 
infection (42), in particularly CMV infection (65) although this was not supported by subsequent 
papers with short follow-up (52, 54-57, 98). There were previous reports suggested poor patient 
survival associated with its use in patients with multiply relapsed vasculitis exposed to Campath 1-H 
during the 1990s (94), as well as reports of fatal fungal infections in kidney/pancreas transplant 
recipients exposed to multiple doses (95-97). 
Infective risk in the long term following Campath use is unclear, mainly related to the lack of long-
term follow-up data in the literature, although the 5-year long-term follow-up pioneer study in 
Calne’s group did not show a substantial difference in the risk of infection in the Campath group 
(63). 
The effect of Campath on the risk of infection appears to be dose-related in both transplantation and 
rheumatological literatures, which used up to 400mg of Campath per treatment (79, 96, 99). The 
incidence of infection was higher in patients given a high dose of Campath 1M in the pioneer study 
in the 1980s (42). Nath et al. (96) reported a 5.6 percentage point increased risk of system fungal 
infection in patients receiving Campath as maintenance therapy in their pancreas programme , and 
systemic fungal infection in these patients was associated with high mortality – 3/8 [38%] (97, 98). A 
further report from Pittsburgh suggested that patients who received Campath as a supplement with 
concurrent treatment of rejection are associated with a 3.5-fold increase in the risk of opportunistic 
infection (99). 
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These data strongly suggest that Campath 1-H should not be used in repeated, multiple-dosing 
regimens or in individuals already carrying a heavy burden of immunosuppression. However, an 
extensive body of reports, both cohort studies and randomised prospective trials, is now available to 
show this when used at total cumulative doses of between 30 and 60 mg.  
Malignancy 
Chronic immunosuppression not only reduces the immune response of recipients to an allograft, but 
also reduces a recipient’s immune reaction to infection as well as the ability of immune surveillance 
that prevents growth and development of malignancies. It was also suggested that long-term 
immunosuppression reduces DNA repair at a molecular level and further increases risk in developing 
malignancy (102). A recent report analysing data from the UNOS registry suggested a cumulative 
incidence of malignancy of up to 7.5% at 3 years, of which skin cancer was the most prevalent (103). 
It was estimated that the rates of skin cancer and lymphoma in transplant recipients were 90 and 37 
times higher, respectively, compared to the general population after being adjusted for age. 
Furthermore, these findings were consistent throughout other registry data from Australia, New 
Zealand, Denmark and Norway. It was an interesting finding that long-term immunosuppression has 
a selective effect on skin cancer and lymphoma, which were both found to be linked to a viral 
pathology with human papilloma virus (104) and Epstein-Barr virus, respectively (105). 
An immunosuppression regimen also has a substantial impact on the risk of malignancies: recipients 
on a tacrolimus-based immunosuppressant regimen have a 35% reduced risk of non-melanoma skin 
malignancy, whereas those who received azathioprine maintenance increased the risk by 17%.  
The risk of skin malignancy is also 17% lower in recipients receiving induction antibodies; this might 
be confounded by the reduction in Azathioprine use following induction therapy (106).  
Post-transplant malignancy is related to an increased morbidity and mortality (149) and the risk of 
developing malignancy is correlated with intensity and duration of immunosuppression (150). 
Understanding the nature and risk factors of developing malignancy will add development of 
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screening and medical management to reduce the impact. However, there are no published data 
studying the risk of malignancy in Campath-treated patients. 
New Onset Diabetes After Transplantation [NODAT]  
New Onset Diabetes After Transplantation [NODAT] is a common complication following renal 
transplantation. It was reported that patients with NODAT have a higher cardiovascular risk and, 
therefore, a poorer long-term survival, as well as inferior allograft function (151-153). A single-centre 
study from the Norwegian group reported a long-term follow-up longitudinal study that examined 
the cardiovascular risk in patients with NODAT, suggesting that cardiovascular mortality and risk of 
myocardial infarction increase by 3.27 times from 7% to 20% at 8 years. Furthermore, overall all-
cause mortality increased from 20% to 37% in patients with NODAT (152). 
The true incidence of NODAT is unclear. It was reported that the NODAT rate was as high as 46% in 
the first year under a high-dose steroid regimen in 1979 (154), and the rate of NODAT falls as the 
steroid-sparing protocol becomes more popular with more powerful immunosuppression. It was 
reported that the incidence of NODAT ranged between 2% and 50% in the first 3 months after 
transplantation and that variables depended on the immunosuppressive protocol used (155). 
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Figure 11-1 Incidence of NODAT over time and immunosuppressant (155) 
Many risk factors had been identified as being associated with the increased risk of NODAT.  
Recipient Age. It was noted that NODAT patients were generally older recipients compared to the 
non-NODAT group. It estimated that recipients older than 45 years have a 2.2-fold increase in the 
risk of developing NODAT (156), as well as there being a further 2.5-fold increase in the risk of 
NODAT in recipients older than 65 (157). 
Obesity. It has long been established that obesity is associated with increased risk of type II diabetes 
mellitus and its effects appeared to be more pronounced in transplant recipients. In a large US study, 
it was reported that patients who have a BMI>30kg/m2 at transplantation have a 1.73 increased risk 
of NODAT post-transplantation (151, 157, 158). However, the effect of weight gain post-
transplantation is not well studied. 
Ethnicity. There is a substantial risk in developing NODAT between ethnicities. It had been reported 
consistently that Afro-Americans and Hispanics have a significantly increased risk of NODAT 
compared to Orientals and Caucasians (153, 157-159). Most of these studies are based on the UNOS 
US database, and the risk of NODAT in South Asians is not well documented in the literature . 
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Medications.  It is well known that long-term use of corticosteroids is associated with a high risk of 
diabetes, even with a small maintenance dose. Its effects on NODAT were first reported in 1949 and 
showed 46% of patients developing NODAT within the first year after 1 year of steroid exposure 
(154). Subsequent large epidemiological studies confirm the association of NODAT and steroid use in 
transplantation (153, 158, 159).  
There are consistent data in the literature suggesting that calcineurin inhibitors are also associated 
with an increased risk of NODAT (153, 158, 159) and that there is a significantly higher risk of NODAT 
with tacrolimus compared to cyclosporine. A 2004 meta-analysis reported a 7.1% increase in the risk 
of insulin-dependent diabetes in tacrolimus-treated patients compared to those treated with 
Cyclosporine (160). Furthermore, a large randomised controlled study reported a higher rate of 
NODAT in tacrolimus-treated patients compared to those treated with cyclosporine or Sirolimus 
(161). 
In terms of effects of induction agents, UNOS registry data showed that patients who received 
Campath induction have a 48% reduction in the risk of NODAT (21) which is most likely related to a 
spare use of steroids in immunosuppressant maintenance following Campath induction. 
There is little in the literature describing the precise nature and rate of infection, type and timing of 
malignancy and the risk of NODAT in recipients receiving this MMF-free, steroid-free 
immunosuppressive regimen following Campath induction. 
And in this chapter, I am going to address this issue with experience from the Imperial College 
Kidney and Transplant Centre.  
11.2 Patients and methods  
Patients  
This is a retrospective study based on data collected on subjects transplanted betwee Nov 2005 and 
March 2011 for the Imperial College Kidney and Transplant Centre transplant registry. The reason for 
the data range being up until 1st March 2011 is so all patients will have at least 12 months follow-up 
prior to data analysis. 
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The use of data was authorised by the Imperial College Kidney and Transplant Centre transplant 
research group. Patient data were anonymised to guarantee patient confidentiality. 
11.3 Infection 
11.3.1 Methods 
The purpose of this study is to examine the nature and trend of infection in our transplant patient 
cohort, who were treated with this simple minimalistic protocol consisting of Campath induction and 
tacrolimus monotherapy. 
Primary objectives of this study were: 
1. Incidence of infection over time following Campath induction 
2. Nature of infection over time following Campath induction 
3. Investigate the concern of Campath-induced lymphopenia and risk of infection 
4. Examine the effect of female gender, diabetes, reflux nephropathy and treatment of 
rejection on infection risk 
For the purpose of this study, all infections recorded with microbiological evidence over time in this 
cohort were included up until patient loss to follow-up or when a patient returns to dialysis. All 
infections were diagnosed based on microbiological evidence. Positive urine, bronchiolar lavage, 
drain fluid, ascites and blood cultures constituted significant episodes of bacterial infection. 
Cytomegalovirus PCR positivity [>1000 copies/ml] and biopsy-proven BK virus nephropathy  
[intranuclear inclusion bodies with positive staining for SV40] were considered to be significant 
markers of viral infections. 2  
In order to examine the effects of Campath-induced haematogical anomalies on the risk of infection, 
a subject-specific detailed profile on full haematological reports and infection incidences over 
transplant follow-up on all subjects were created. A random-effect longitudinal statistical model was 
then developed to analyse the effects of risk factors on infection risk. 
                                                                 
2
 Adapted from Horan et al ., Surveillance of nosocomial infections in Mayhall CG. Hospital epidemiology and 
infection control 2004:1659. 
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Furthermore, this analysis on the associations with infection risk and factors was stratified into a 
timeline following transplantation for the following reasons: 
 During the initial examination of data, it became clear that the risk of infection changes over 
time [Table 11-1].  
 The follow-up in the cohort differs depending on the transplant vintage. This might cause 
bias with the potential missing data and this would be best handled with stratification. 
 Lastly, one would argue that the effects of risk factors on infection risk differ over time. 
This piece of work was done in collaboration with Dr. Rawya Charif and I would like to acknowledge 
the help from Dr. Charif – she collected and permitted the use of data regarding the incidence of 
infection in this cohort for my work. My involvement comprised study development, collection of 
clinical data and haematology profiles on all transplant recipients, as well as data analysis and 
statistics modelling. 
11.3.2 Statistics  
All statistical analyses were performed using Stata 12 [StataCorp, Texas]. 
Allograft function and lymphocyte data were analysed using a mixed-effect model to account for the 
nature of repeat measurements over time, as well as allowing adjusting the effects of lymphocyte 
changes over time. Continuous variables were log-transformed into normal distributed data to 
improve adherence to model assumptions if needed. 
Incidences of infection were presented as the incidence per 100 patient years. Poisson was used to 
analyse rate and rate ratio; a Negative binomial model is used in cases when the underlying 
assumption of equal mean and variance with the Poisson model is violated. 
Association of risk factors [e.g. gender, lymphopenia] and infection was examined using a random-
effect logistic regression model to adjust for repeat measurements over time. Results were 
presented as odds ratios, which can be interpreted as the relative odds of developing the infection 
type of interest in the presence of the risk factors.  
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11.3.3 Results 
11.3.3.1 Overall infection risk 
Figure 11-2 (below) shows the overall rate of infections following Campath induction. Infection rates 
were shown in the incidence per 100 patient years to adjust for time of follow-up. The overall 
incidence of infection is highest in the first 6 months after transplantation. It was estimated that the 
rate of infection reached 141 incidences per 100 patient years [Table 11-1], gradually falling in the 
subsequent months, as expected: 50.1, 37.4, 32.2 and 19.4 incidences per 100 patient years at 6-12 
months, 12-24 months, 24-36 months and 36-48 months following transplantation, respectively. 
The nature of infections did not change substantially over time, and urinary tract infection was the 
commonest cause of infection throughout all timelines. It accounts for approximately 50% of all 
cases reported throughout follow-up. Despite the profound lymphopenia, the incidence of viral 
infection remains low late after transplantation. Details of the nature of infection will be examined 
in more detail in the latter part of this chapter. 
 
Figure 11-2 Incidence of infection after Campath induction 
Table 11-1 Rate [Incidences per 100 patient years] and nature of infection after Campath induction 
 6 months  6-12 months  12-24 months  24-36 months  36-48 months  
Surgical 31.3 [24.81,39.37]     
UTI 69.9 [59.88,81.56] 29.8 [23.27,38.12] 21.0 [16.42,26.91] 18.0 [12.80,25.33] 16.4 [10.03,26.73] 
Bacteraemia 21.7 [16.45,28.64] 8.5 [5.36,13.51] 5.3 [3.27,8.72] 4.9 [2.56,9.44] 1.0 [0.14,7.27] 






















6 12 24 36 48
Months after transplantation
Infection rate over time
UTI Bacteraemia BK CMV
Fungal Surgical Other Total
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CMV 3.5 [1.74,6.94] 3.3 [1.58,6.94] 0.0 [0.00,0.00] 0.5 [0.08,3.87] 0.0 [0.00,0.00] 
Fungal 0.9 [0.22,3.47] 0.5 [0.07,3.36] 0.7 [0.17,2.67] 1.1 [0.27,4.36] 0.0 [0.00,0.00] 
Other 10.9 [7.33,16.06] 7.1 [4.27,11.76] 9.7 [6.73,13.93] 7.1 [4.12,12.22] 2.0 [0.51,8.19] 
Total 141.1 [126.54,157.27] 50.1 [41.42,60.62] 37.4 [31.06,44.98] 32.2 [24.94,41.55] 19.4 [12.41,30.49] 
 
Risk factors 
First 6 months 
The overall infection rate was highest in the first 6 months following transplantation [Figure 11-2].  
Univariate analysis demonstrated that the risk of overall infection is time-dependent, with 
background diabetes, reflux nephropathy and female gender being positively associated with 
increased risk of infection [Appendix 14.1.1, Table 14-1]. 
A multivariable model was used to examine the combined effects of all these factors [Appendix 
14.1.1, Table 14-1]. Table 11-2, which consists of factors that have a significant impact on infection 
risk, confirms that infection risk is time-dependent. It estimated a reduction of 7% in risk in every 
week following transplantation. Patients with background diabetes have a 2.1-fold increase in the 
risk of infection [OR 2.12, 95%CI 1.31, 3.44; p=0.002], those with reflux nephropathy experienced a 
3.8-fold increased risk of infection [OR 3.8, 95%CI 1.81, 7.95; p<0.001], and women have an 80% 
increased risk of infection in the first 6 months after transplantation [OR1.80 95%CI 1.22, 2.68; 
p=0.003]. Interestingly, there is a suggestion that patients who had a change of immunosuppressant 
as a result of rejection experienced a 71% increased risk of infection, although it did not reach 
statistical significance [OR1.71, 95%CI 0.99, 2.96; p=0.054].  
Data did not suggest early lymphopenia or neutropenia being associated with an increased risk of 
infection.  
After 6 months 
After the initial 6 months after transplantation, patients with reflux nephropathy are persistently 
associated with an increased risk of infection. It was estimated that these patients have a 5.1-, 4.0-, 
3.0- and 3.3-fold increase in the risk of infection 6 months and annually afterwards [Table 11-2]. This 
is likely due to the higher incidence of urinary tract infection in this group [Table 14-3]. 
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Treatment changes after late rejection are associated with an increased risk of infection. Data 
suggest that patients treated for rejection 24 months after transplantation have a 4-fold increased 
risk of infection [OR 4.04, 95%CI 1.66, 9.87; p=0.002]. 
Despite the profound lymphopenia, defined as total lymphocyte counts less than 1 x 109 per 1mm, 
data did not show an increased risk of infection in the first 12 months after transplantation [0-6 
months: OR 0.65, 95%CI 0.38, 1.13; p=0.127, 6-12 months: OR 1.55, 95%CI 0.85, 2.83; p=0.150]. 
Although there is some evidence suggesting a 2.22-fold increased infection risk in the second year of 
post-transplantation with lymphopenia, data from the later years did not support this finding. 
Neutropenia is rare; it was not feasible to accurately estimate the effects of neutropenia on overall 
infection risk. However, it did not appear to have a clear association with neutropenia and infection 
in this cohort. 
Table 11-2 Final multivariable analysis on overall infection risk  
  Final model 
 Risk Factors Odds Ratio p value 
0-6 months Week 0.93 [0.91,0.94] 0.000 
 Lymphopenia   
 Neutropenia   
 Diabetes 2.12 [1.31,3.44] 0.002 
 Reflux nephropathy 3.80 [1.81,7.95] 0.000 
 Female gender 1.80 [1.22,2.68] 0.003 
 Post-rejection 1.71 [0.99,2.96] 0.054 
6-12 months Week 1.02 [0.99,1.05] 0.216 
 Lymphopenia   
 Neutropenia   
 Diabetes   
 Reflux nephropathy 5.13 [1.67,15.77] 0.004 
 Female gender   
 Post-rejection   
12-24 months Week 1.00 [0.99,1.02] 0.743 
 Lymphopenia 2.22 [1.24,3.96] 0.007 
 Neutropenia   
 Diabetes   
 Reflux nephropathy 3.96 [1.56,10.03] 0.004 
 Female gender   
 Post-rejection   
24-36 months Week 0.98 [0.96,1.00] 0.095 
 Lymphopenia   
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 Neutropenia   
 Diabetes   
 Reflux nephropathy 6.16 [1.99,19.10] 0.002 
 Female gender 3.01 [1.23,7.35] 0.016 
 Post-rejection 4.04 [1.66,9.87] 0.002 
36-48 months Week 1.00 [0.97,1.04] 0.884 
 Lymphopenia   
 Neutropenia   
 Diabetes   
 Reflux nephropathy 3.25 [0.95,11.03] 0.059 
 Female gender 3.19 [1.03,9.93] 0.045 
 Post-rejection   
 
11.3.3.2 Urinary tract infection 
Urinary tract infection was the commonest cause of infection following transplantation. It was 
estimated that there is an incidence of 69.9/100 patient years in the first 6 months and that 
accounts for approximately 50% of cases of infection observed throughout the timeline [Table 11-1]. 
Coliforms are the commonest pathogen; they account for 52.6% of all cases of urinary tract infection 
and the data did not suggest a change of pathogen over time. The rate of urinary tract infection 
being highest in the first 6 months might be related to the use of ureteric stents following 
transplantation in our centre.  
The incidence of urinary tract infection fell to 29.8 cases/100 patient years at the second 6 months 
post-transplantation and between 16.4 and 210 cases/100 patient years between 12 and 48 months 
after transplantation [Table 11-1]. 
Risk factors 
Reflux nephropathy and female gender were associated with a high risk of urinary tract infection 
independently [Section 14.1.3, Table 14-3]. The final adjust model suggested that patients with 
background reflux nephropathy are associated with a 3.7-fold increased risk of urinary tract infection 
in the first 6 months and that they remained raised throughout the subsequent 42 months 
thereafter.  
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Female patients also have a higher risk of urinary tract infection, as described in the literatures; it 
was estimated that female patients have a 2.7-3.95 times increased risk of urinary tract infection 
throughout the first 4 years after transplantation. 
Lymphopenia and neutropenia following Campath induction have a little effect on the risk of urinary 
tract infection [Table 11-3] 
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Table 11-3 Final multivariable analysis on urinary tract infection  
    Final model   
  Risk Factors Odds Ratio p value 
6 months Week 0.97 [0.95,1.00] 0.042 
  Lymphopenia 0.52 [0.28,0.98] 0.044 
  Neutropenia    
  Diabetes 1.90 [1.00,3.60] 0.049 
  Reflux nephropathy 3.65 [1.46,9.09] 0.006 
  Female gender 2.71 [1.61,4.58] 0.000 
  Post-rejection    
6-12 months Week 1.01 [0.97,1.04] 0.720 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy 4.94 [1.42,17.27] 0.012 
  Female gender 3.23 [1.46,7.14] 0.004 
  Post-rejection 3.26 [1.47,7.23] 0.004 
12-24 months Week 1.00 [0.98,1.02] 0.877 
  Lymphopenia    
  Neutropenia 10.57 [0.92,121.63] 0.059 
  Diabetes    
  Reflux nephropathy 5.82 [1.76,19.29] 0.004 
  Female gender 2.41 [1.01,5.75] 0.047 
  Post-rejection    
24-36 months Week 0.99 [0.96,1.03] 0.692 
  Lymphopenia 2.63 [0.99,7.04] 0.053 
  Neutropenia    
  Diabetes    
  Reflux nephropathy 13.08 [4.00,42.80] 0.000 
  Female gender 3.49 [1.16,10.52] 0.027 
  Post-rejection     
36-48 months Week 1.00 [0.97,1.04] 0.928 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy 3.44 [0.97,12.17] 0.055 
  Female gender 3.95 [1.16,13.43] 0.028 
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11.3.3.3 Surgical-related infections 
In the first 6 months, surgical wound-related infection also contributed to a substantial amount of 
infection incidences observed. Surgical wound-related infection accounts for approximately a 
quarter of infection observed. It was estimated that there is a rate of 31.3 incidences per 100 patient 
years [Table 11-1]. 
Risk Factors 
Surgical infection is highest in early post-transplantation; data confirms that surgical infection is 
strongly time-dependent and that risk falls by 34% per week following transplantation in Surgical 
infection [Section 14.1.2, Table 14-2]. After adjusting for time, the final model estimated that 
surgical infection was highest in those with diabetes – these patients experienced a 2.5-fold increase 
in the risk of wound infection [OR 2.49, 95%CI 1.43, 4.34; p=0.001] – as well as those who were 
treated for rejection [OR 2.89, 95%CI 1.29, 6.48; 0.010] [Table 11-4]. 
Apart from risk factors examined in this model, body habitus was also a significant risk factor for 
wound infection. We have demonstrated that patients in the highest body mass quadrant 
experienced a 2.1-fold increased risk of wound infection [Section 7.4.6]. 
Table 11-4 Final model on risk of surgical infection 
  Final model 
 Risk Factors Odds Ratio p value 
6 months Week 0.63 [0.56,0.71] 0.000 
 Lymphopenia   
 Neutropenia   
 Diabetes 2.49 [1.43,4.34] 0.001 
 Reflux nephropathy   
 Female gender   
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11.3.3.4 BK nephropathy 
There were 12 cases of biopsy-proven BK nephropathy in the cohort, with the highest rate of BK 
nephropathy being in the first 6 months after transplantation [Table 11-1]; the median time from 
transplantation to diagnosis of BK nephropathy was 24 weeks. Interestingly, 7/12 [58%] cases 
happened soon after treatment of rejection. This reflected in the final model that rejection is 
associated with a 4.2-fold increased risk of BK nephropathy in the first 6 months [OR4.15, 95%CI 
0.98, 17.56; p=0.053]. However, because of the little number of cases of late BK, it was difficult to 
accurately estimate the impact of rejection on the risk of BK nephropathy later after transplantation. 
This model did not show an association between lymphopenia, neutropenia, diabetes, reflux 
nephropathy and female gender with BK nephropathy at any time point.[Table 11-5] 
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Table 11-5 Final model on risk of BK nephropathy 
    Final model 
  Risk Factors Odds Ratio p value 
6 months Week 1.12 [0.99,1.25] 0.062 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Female gender    
  Post-rejection 4.15 [0.98,17.56] 0.053 
6-12 months Week 1.12 [0.99,1.25] 0.062 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection 4.15 [0.98,17.56] 0.053 
12-24 months Week 1.04 [0.94,1.15] 0.417 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection    
24-36 months Week 0.97 [0.84,1.12] 0.685 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection     
36-48 months Week   
  Lymphopenia   
  Neutropenia   
  Diabetes   
  Reflux nephropathy   
  Female gender   
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11.3.3.5 CMV disease 
All patients in our centre received 3 months of oral valganciclovir as CMV prophylaxis – a total of 14 
cases of CMV infection were noted in the cohort. The median time to CMV disease was 26 weeks 
after transplantation. There was 1 case of CMV infection noted within the 3-month prophylaxis 
period; this patient had the prophylactic antiviral stopped because of lymphopenia previously. All 
cases were successfully treated with intravenous ganciclovir and an antiviral-resistant strain was not 
detected. 
Almost all (but 1) cases were detected within the first year and the last case was detected at 105 
weeks after transplantation [Table 11-1]. 
Risk factors 
The overall risk of CMV disease remains low despite the profound lymphopenia, and the statistical 
model confirms the lack of correlation between lymphopenia and CMV disease.  
Our data showed that the risk of developing CMV disease was not increased following treatment of 
rejection, despite the increased immunosuppression burden following treatment of rejection. This 
might be related to the liberal use of CMV prophylaxis following immunosuppressant escalation in 
our unit. 
Furthermore, the model confirms that neutropenia, diabetes mellitus, reflux nephropathy and 
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Table 11-6 Final model on risk of CMV disease 
    Final model 
  Risk Factors Odds Ratio p value 
6 months Week 1.14 [1.02,1.27] 0.021 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection    
6-12 months Week 1.00 [0.90,1.11] 0.984 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection    
12-24 months Week  No cases   
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection    
24-36 months Week  NA   
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection     
36-48 months Week No cases   
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
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11.3.3.6 Bacteraemia 
The risk of developing bacteraemia was highest in the first 6 months following transplantation. It 
was estimated that there is an average of 21.7 episodes per 100 patient years in the first 6 months 
and that it falls to 8.5, 5.3, 4.9 and 1.0 episodes per 100 patient years at 6-12 months and annually 
afterwards [Table 11-1]. 
The high rate of bacteraemia is likely secondary to the high incidences of wound infection [Section 
11.3.3.3] and urinary tract infection [Section 11.3.3.2] in the first 6 months. 
A total of 133 episodes of bacteraemia were recorded. Coagulase Negative Staphylococcus and 
Coliforms were the commonest pathogens, and the nature of the common pathogens did not 
change over time.  
Risk Factors 
In the first 6 months after transplantation, initial multivariate analysis suggested that patients with 
diabetes mellitus and reflux nephropathy have an increased risk of bacteraemia [Section 14.1.6, 
Table 14-6]. However, the final model did not show these factors having any significant impact on 
bacteraemia after adjustment [Table 11-7]. 
Treatment of late rejection is associated with a 7.89-fold increase in the risk of bacteraemia at 2 
years after transplantation.  
The model didn’t show either lymphopenia or neutropenia following Campath induction increasing 
the risk of bacteraemia. There was no evidence suggesting diabetes, reflux nephropathy or female 
gender increasing the risk of bacteraemia in the long term. 
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Table 11-7 Final model on risk of bacteraemia 
    Final model   
  Risk Factors Odds Ratio p value 
6 months Week 0.94 [0.90,0.98] 0.005 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection    
6-12 months Week 1.02 [0.95,1.09] 0.623 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection     
12-24 months Week 1.01 [0.97,1.06] 0.488 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection     
24-36 months Week 0.99 [0.94,1.05] 0.841 
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection 7.89 [1.44,43.07] 0.017 
24-36 months Week    
  Lymphopenia    
  Neutropenia    
  Diabetes    
  Reflux nephropathy    
  Female gender    
  Post-rejection     
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11.3.3.7 Fungal infection 
There are reports from the literature suggesting that the use of Campath is associated with an 
increased risk of fungal infection, particularly when it is used as maintenance immunosuppression. In 
our study, fungal infections are rare. 
We observed 0.9 cases per 100 patient years in the first 6 months and 0.5 cases per 100 patient 
years between 6 and 12 months post-transplantation. Incidences of fungal infections were largely 
unchanged annually thereafter [Table 11-1]. 
20 cases of fungal infection were documented in this cohort. There were 4 cases of aspergillus 
pneumonia and 2 cases of Pneumocystis pneumonia, all of which were diagnosed by bronchial 
lavage or sputum. There had been 7 cases of candidaemia in 6 patients, and 2 cases of subcutaneous 
fungal infections with dematiaceous fungi and pyrenchaeta romoroi. 
The risk factor analysis did not show any association of fungal infection with lymphopenia, 
neutropenia, diabetes, reflux nephropathy, female gender or rejection [Section 14.1.7, Table 14-7]. 
11.3.3.8 Other infections 
For the purpose of this study, all infection that was not classified in the above category was pooled 
and classed as “other infection”. Chest pathogen was the commonest cause of infection in this 
category; it accounts for 27/109 [24.8%] of the cases observed. 22/109 [20.2%] infections were 
related to non-surgically related wound infection.  
Over the follow-up period, we observed 3 cases of H1N1 infection and 3 cases of Parovirus B19 
infection.  
Overall, we were not able to demonstrate any significant association between risk of development 
of other infection and lymphopenia or neutropenia [Section 14.1.8, Table 14-8]. 
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11.4 Malignancy 
11.4.1 Methods 
Primary objectives of this study were: 
1. Incidence and nature of malignancies over time following Campath induction 
2. Examine the effect of gender, ethnicity, previous immunosuppressive therapy and age on 
risk of developing malignancies. 
All malignancies were identified clinically and confirmed with histological diagnosis when possible. 
11.4.2 Statistics  
All statistical analyses were performed using Stata 12 [StataCorp, Texas]. 
Times to malignancies were analysed using an age-adjusted survival model to account for effects of 
age on malignancy risk. 
Effects of transplant vintage on malignancy risk were analysed using Nexus expansion to allow 
adjustment on patient levels. Risk factors were analysed using a Cox proportional hazard model, 
under an assumption that risk between groups within a factor was proportional throughout time. A 
Weilbull parametric model was used in cases where this assumption is violated. 
11.4.3 Results 
11.4.3.1 Incidence 
13 [2.2%] cases of malignancy were identified in the cohort of 602 patients [Table 11-8]. Figure 11-3 
(below) shows cumulative freedom from malignancy in the cohort from transplantation. Cumulative 
risk of developing malignancy in this cohort was 0.5%, 3.1% and 3.5% at 1, 3 and 5 years, 
respectively. 
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Figure 11-3 Malignancy-free survival 
11.4.3.2 Type of malignancies 
The commonest malignancy identified was skin in origin and accounted for 4/13 [30.8%] cases; there 
were 3 [23.0%] cases of malignancy related to the gastrointestinal system and 2 [15.4%] cases of 
renal cell carcinoma. There was one case of angiosacroma, one case of breast carcinoma, one case of 
post-transplant lymphoproliferative disorder and one case of prostate cancer. 











There was a total of 4 skin malignancies identified. All 4 recipients were Caucasians and were 
diagnosed at 4.3, 17.8, 18.7 and 34.7 months following successful living donor transplantation, 
respectively. Histological examination from 3 cases demonstrated squamous cell carcinoma and one 
case of basal cell carcinoma. All 4 cases were successfully treated, but one patient died with 
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GI 
3 cases of gastrointestinal malignancies were identified. 1 patient was diagnosed with spindle cell 
carcinoma in the stomach at 29.5 months following transplantation and was successfully treated. 1 
case of metastatic pancreatic cancer and 1 case of metastatic adenocarcinoma, possibly in the lower 
bowel origin, was diagnosed at 35.1 and 26.4 months following transplantation, respectively. 
Unfortunately, both patients with metastatic diseases died within 6 months of diagnosis.  
Renal 
2 cases of renal tumours were identified in this cohort. 1 case of multifocal papillary renal cell 
carcinoma in the native kidney at 11.7 months after transplantation was successfully treated with 
native nephrectomy. There was no clinical suggestion of recurrence at the last follow-up at 4 years 
after treatment. The second patient underwent bilateral nephrectomy for renal cell carcinoma and 
was presented late at 35.6 months after transplantation with metastatic disease, and died 2 years 
following diagnosis.  
Others 
A case of prostate carcinoma and a case of breast carcinoma was diagnosed at 10.7 months and 29.1 
months respectively. One case of EBV pos post-transplantation lymphoproliferative disorder was 
diagnosed at 19 months and was successfully treated with a course of intravenous rituximab. Lastly, 
one patient developed angiosacroma over a functional fistula at 36.3 months after transplantation 
and died with metastatic disease. 
11.4.3.3 Risk factors 
Table 11-9 (below) summarised the result of an age- and time lapse-adjusted univariable analysis on 
effects of ethnicity, previous immunosuppression with cyclophosphamide for vasculitis and gender 
on the risk of developing malignancy. All three models confirm the risk of malignancy increasing with 
time [p<0.05, not listed]. 
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The model did not show a statistically significant relationship between ethnicity, previous 
immunosuppressant exposure and gender to the risk of developing malignancy under this regimen.  
Table 11-9 Age and time-adjusted univariable analysis on risk factors for development of malignancy 
Risk factors HR 95%CI p 
Ethnicity Caucasian 1   
 Afro-Caribbean 2.6 0.75,8.73 0.135 
 South Asian 0.38 0.07,1.83 0.227 
 Others NA   
Vasculitis N 1   
 Y 3.1 0.39,25.32 0.282 
Gender F 1   
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11.5 New Onset Diabetes After Transplantation 
In this part of the thesis, I am going to report the incidence and timing of NODAT in this cohort of 
patients receiving a steroid-sparing maintenance regimen, as well as examine risk factors of 
developing NODAT, including the effect of South Asians and effects of weights after transplantation.  
11.5.1 Methods 
Primary objectives of this study were: 
1. Incidence of NODAT over time following Campath induction 
2. Examine the effect of gender, ethnicity, previous immunosuppressive therapy and age on 
risk of developing NODAT. 
NODAT is defined as the requirement of starting antiglycaemic medications post-transplantation. 
11.5.2 Statistics  
All statistical analyses were performed using Stata 12 [StataCorp, Texas]. 
Pre-transplant risk factors were analysed using a Cox proportional hazard model, under an 
assumption that risk between groups within a factor was proportional throughout time. A Weilbull 
parametric model was used in cases where this assumption is violated. 
Post-transplant risk factors, e.g. weight changes, were analysed using a time-adjusted logistic 
regression model in the same patient and risk on NODAT.  
11.5.3 Results 
433/602 [71.9%] non-diabetic patients in the whole study cohort were included in this analysis. 56 
patients developed NODAT during the study period. Cumulative NODAT survival is best depicted in 
Figure 11-4 below; 1-, 3- and 6-year NODAT survival was 92.2%, 86.2% and 84.2%, respectively.  
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Figure 11-4 NODAT-free survival 
There is a substantial difference in the incidence of NODAT between ethnicity origins. Caucasoid 
[6.1%] has a much lower incidence compared to Afro-Caribbean [27.7%] and South Asians [19.2%]. 
The groups developing NODAT have a higher mean age at transplantation compared to the group 
without NODAT [51.6 vs 46.0 yrs.].  
It did not appear to have a substantial difference between gender, donor group, donor age and HLA 
mismatch between the two groups. Interestingly, there is no substantial difference between pre-
transplant weights between the two groups [Table 11-10]. 
Table 11-10 Demographics - NODAT patients 
 
 
NODAT -ve  NODAT +ve 
Donor type Deceased 196 [86.7%] 30 [13.3%] 
 Living Donor 181 [87.4%] 26 [12.6%] 
Ethnici ty Afro-Caribbean 34 [72.3%] 13 [27.7%] 
 Asian 101 [80.8%] 24 [19.2%] 
 Caucasian 216 [93.9%] 14 [6.1%] 
 Other 26 [83.9%] 5 [16.1%] 
Gender Female 143 [87.2%] 21 [12.8%] 
 Male 234 [87%] 35 [13%] 
Recipient age  46.0+14.71 51.6+11.68 
Donor age  38.5+19.11 42.7+16.96 
HLA MM  3.5+1.78 3.7+1.91 
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Risk factors 
Univariant analysis showed that ethnicity and transplant age are significant factors associated with 
development of NODAT. Patients who are Afro-Caribbean and South Asian in origin have a 5.0- and 
3.4-fold increase in the risk of developing NODAT compared to Caucasoid. Moreover, there is a 3% 
increased risk of NODAT for every year increase in age at transplantation. Both factors appeared to 
be independent, and effect size did not change within a multivariant analysis. 
On the contrary to data reported in the literature, neither donor type nor pre-transplant weight 
have a significant impact on subsequent risk of NODAT. There is no significant association between 
gender, donor age and HLA mismatch to the risk of NODAT [Table 11-11]. 
Table 11-11 NODAT: Pre-transplant risk factors  
 Univariant model Multivariant model 
Factors HR 95%CI P value  HR 95%CI P value  
Donor type       
DD 1 
     LD 0.9 0.55,1.57 0.773 
   
Ethnicity       
Caucasian 1 
     Afro-Caribbean 5.0 2.36,10.69 0.000 5.3 2.49,11.33 0.000 
South Asian 3.4 1.77,6.61 0.000 3.4 1.77,6.63 0.000 
Other  3.3 1.17,9.07 0.023 4.0 1.42,11.16 0.009 
Gender       
Female 1 
     Male 1.1 0.62,1.83 0.827 
   
Age [per year] 1.03 1.01,1.05 0.004 1.03 1.01,1.05 0.002 
Donor age [per year] 1.0 0.97,1.01 0.337 
   
HLA MM 1.1 0.92,1.25 0.381 
   
Pre-transplant weight       
Under 62.3kg 1 
     62.3-73.3kg 1.2 0.57,2.50 0.645 
   73.3kg-86.0kg 1.0 0.49,2.26 0.903 
   Above 86.0kg 1.2 0.59,2.62 0.560 
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The model above only examined the risk factors before transplantation. A patient’s body habitus 
changes significantly following transplantation, mainly due to improvement in appetite because of 
the non-uremic states and lifting of dietary restrictions. Post-transplant factors incurred a substantial 
risk on development of NODAT; however, conventional medical literature did not examine these 
issues in a systemic and mathematically sound analysis. Therefore, I am going to examine the effects 
of the post-transplantation risk factors in this time-adjusted model. We have established that age at 
transplantation is a significant risk factor of developing NODAT and we examined the risk factor 
using an age-adjusted model.  
Univariant analysis confirmed age, ethnicity, post-transplant weight and steroids after rejection 
having had a significant impact on the risk of developing NODAT. Gender has little impact on the risk. 
In an age-adjusted multivariant model, we showed patients from an Afro-Caribbean background 
having an 8.1-fold increase in the risk of NODAT [95%CI 6.41, 10.19; p<0.001] compared to 
Caucasoid. South Asians persons and other patients from other ethnical backgrounds have a 6.9- 
[95%CI 5.56, 8.48; p<0.001] and 8.1- [5.91, 11.1; p<0.001] fold increased risk of NODAT.  
Although pre-transplant weight has a little effect on subsequent NODAT, obesity post-
transplantation posts a significant risk on NODAT. Patients who reached a weight of 90kg have a 50 
percent [HR 1.5, 95%CI 1.09, 1.94; p=0.011] increased risk and this is even higher in those reaching 
above 100kg – estimated at a 2.3-fold increase in risk of NODAT [HR 2.3, 95%CI 1.73, 3.06; p<0.001]. 
Apart from weight and ethnicity, the recommencement of steroids following rejection increased risk 
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Table 11-12 Risk factors of NODAT: Post-transplantation 
 Univariant model Multivariant model 
Factors HR 95%CI P value  HR 95%CI P value  
Age 1.03 1.03,1.04 0.000 1.04 1.03,1.04 0.000 
Ethnicity       
Caucasian 1      
Afro-Caribbean 6.7 5.36,8.34 0.000 8.1 6.41,10.19 0.000 
South Asian 5.5 4.51,6.65 0.000 6.9 5.56,8.48 0.000 
Others 5.2 3.86,6.96 0.000 8.1 5.91,11.10 0.000 
Current weight      
Below 65kg 1   1   
65-75kg 1.0 0.78,1.22 0.829 1.2 0.92,1.49 0.203 
75-90kg 0.9 0.74,1.10 0.320 1.0 0.78,1.24 0.895 
90-100kg 1.1 0.87,1.43 0.392 1.5 1.09,1.94 0.011 
Above 100kg 1.3 1.03,1.65 0.029 2.3 1.73,3.06 0.000 
Post-rejection      
No 1      
Yes 3.1 2.65,3.58 0.000 3.5 2.97,4.12 0.000 
Gender       
Female 1   1   
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11.6 Summary 
In this chapter, I examined the risk related to long-term immunosuppression exposure related to the 
use of this powerful immunosuppressive regimen. 
Campath induction is a powerful lymphopenia and its effects persist for months following 
transplantation; I have demonstrated the effects of Campath on leucocytes in the previous chapter 
[Section 10]. Lymphopenia recovers within the 12 months in 50% of patients. 
There were concerns about the increased risk of viral infection in Campath-treated patients. Our 
data showed the overall rate of infection being highest in the first 6 months, estimating it reached 
141 incidences per 100 patient years and fell gradually and plateaued after 12 months. Urinary tract 
infection was the highest cause of infection over time, although the risk of surgical-related infection 
was highest in the first 6 months.  
The time of post-transplantation is an important risk factor on infection; the risk of infection falls as 
time lapses following transplantation. The model estimated a 7% reduction in risk every week 
following transplantation.  
The backgrounds of diabetes mellitus, end-stage renal disease with reflux uropathy and female 
gender are all significant factors associated with a 2.1-, 3.8- and 1.8-fold increase in infection risk, 
respectively, using this simple Campath induction and tacrolimus monotherapy regimen. 
The incidence of infection remained low despite lymphopenia and I was not able to elicit a 
relationship between lymphopenia and infection risk in our centre. This is likely a result of the spare 
use of MMF; our data showed treatment of rejection by restarting corticosteroids, and MMF 
increased the risk of infection by 71%, albeit it just reached statistical significance. 
Despite the lymphopenia, the incidence of viral infection remained low late after transplantation. A 
total of 14 cases of CMV disease were reported in this cohort, with a median time to infection of 26 
weeks. 3.5 episodes per 100 patient years of CMV infection in the first 12 months and cases 
remained rare after 12 months. All cases occurred following stopping the 3-month valganciclovir 
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prophylaxis. All cases were successfully treated with intravenous ganciclovir and antiviral resistance 
was not detected.  
There were 12 cases of BK nephropathy overall and the risk of BK nephropathy is highest in the first 
6 months, with the median time to event of 24 weeks. Approximately 60% of cases occurred after 
the increment of immunosuppressants following rejection and this is equivalent to a 4.2-fold 
increased risk. 
Previous reports examining the risk of fungal infection in the Campath maintenance protocol in 
pancreas transplants suggested an increased risk of fungal infection in repeated and high-dose 
Campath-treated patients. My data from this large cohort showed 20 cases of fungal infection in 
total, equivalent to 0.9 cases per 100 patient years in the first 6 months and 0.5 cases per 100 
patient years between 6 and 12 months post-transplantation. Incidences of fungal infections were 
largely unchanged annually thereafter. There were 4 cases of aspergillus pneumonia and 2 cases of 
Pneumocystis pneumonia, of which all cases were diagnosed by bronchial lavarge or sputum. There 
had been 7 cases of candidaemia in 6 patients, and 2 cases of subcutaneous fungal infections with 
dematiaceous fungi and pyrenchaeta romoroi. 
My results showed that the incidence of infection in this simple regimen is similar to data published 
previously; the incidence of bacteraemia in the first 6 months was 21.7 episodes per 100 patient 
years and this fell to 8.5 episodes per 100 patient years after the first 6 months in our unit. This is 
similar to the report published by the Spanish RESITRA registry, showing incidences of bacteraemia 
of 24.8 and 7.31 episodes per 100 patient years in the first 6 months and between 6 and 12 months 
after transplantation, respectively (162). 
Chronic immunosuppression not only reduces the immune response of recipients to an allograft, but 
also reduces a recipient’s immune reaction to infection as well as the ability of immune surveillance, 
which prevents growth and development of malignancies. Therefore, the risk of developing 
malignancies with long-term immunosuppression should also be examined for a risk benefit balance.  
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13 [2.2%] cases of malignancy were identified in the cohort of 602 patients, and the cumulative risk 
of developing malignancy in this cohort was 0.5%, 3.1% and 3.5% at 1, 3 and 5 years, respectively. 
Skin cancer is the commonest malignancy identified and it accounted for 4/13 [30.8%] cases; there 
were 3 [23.0%] cases of malignancy related to the gastrointestinal system and 2 [15.4%] cases of 
renal cell carcinoma. There was one case of angiosacroma, one case of breast carcinoma, one case of 
post-transplant lymphoproliferative disorder and one case of prostate cancer. 
I examined the effects of ethnicity, previous use of immunosuppressants and gender on the risk of 
developing malignancy and I found no strong evidence supporting these factors incurring any 
substantial impact. 
One limitation of this analysis is that the follow-up from this study may be insufficient to delineate 
the effect of the Campath on future development of malignancy, because malignancy tends to 
develop late following transplantation (106, 118). 
Despite this potential shortcoming, it is worth noting that there is a low incidence of PTLD in this 
large cohort. A previous report from a large registry suggested that PTLD is commonest in the first 
year, with the incidence reaching approximately 0.3% and 0.7% at 1 and 5 years (163). Our results 
showed only 1 case of PTLD [0.17%] in this large cohort and it was unarguably substantially lower 
than published literatures (163, 164). This might be related to the spared use of antiproliferative 
agents [MMF] and the lymphopenic nature of Campath-destroyed EBV-harboured lymphocytes that 
could potentially evolve into PTLD (165). 
New Onset Diabetes After Transplantation [NODAT] is a common complication following renal 
transplantation and it is associated with a higher cardiovascular risk and poorer long-term graft and 
patient survival. It has long been established that long-term use of corticosteroids and calcineurin 
inhibitors is associated with an increased risk of diabetes, even with a small maintenance dose.  
Campath induction is associated with a 48% reduction in risk of NODAT (21), which is most likely 
related to a spared use of steroids in immunosuppressant maintenance following Campath 
induction.  
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Recipients' pre-transplant factors, e.g. obesity, being Afro-American and Hispanic in origin, and older 
age, are associated with a higher risk of NODAT. The effects of risk factors developed after 
transplantation, e.g. weight gain, treatment change following rejection, were not well studied. 
56 patients developed NODAT in our non-diabetic cohort consisting of 433 patients. I demonstrated 
1- and 6-year NODAT survival of 92.2% and 84.2%. My model confirms that Afro-Caribbean and 
South Asian have a 5.3- and 3.4-fold increased risk of NODAT and that age is also a significant risk 
factor, which increased the risk of NODAT by 3% for every year of a recipient’s age. 
I further developed this mathematical model to account for the changes in body habitus and events 
occurring following transplantation. My model showed that ethnicity has a similar effect on the risk 
of NODAT as the pre-transplant risk factor model. Afro-Caribbean and South Asian have an 8.1- and 
6.9-fold increase in risk of NODAT respectively.  
More importantly, although the pre-transplant weight has little impact on NODAT, weight gain after 
a transplant is a highly significant risk factor of NODAT. My data showed that patients who weigh 
above 90kg increase the risk of NODAT by 50%, as well as a further 180% if their weight reaches 
above 100kg. 
Treatment of rejection with recommencing steroids and MMF is also associated with an increased 
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12 Discussion 
The incidence of end-stage renal failure has gradually been rising over the last decade in the UK and 
renal transplantation has long been established as the treatment of choice. Renal transplantation 
not only improves a patient’s quality of life, it has been shown to be associated with a significant 
survival benefit. 
The key difficulties of renal transplantation is how to maintain the balance of immunosuppression to 
reduce an alloimmune response to an allograft and the associated risk of long-term 
immunosuppression, e.g. risk of infection, malignancy and metabolic side effects associated with 
immunosuppressants in the long term.  
The US UNOS registry confirmed the increased risk of malignancy in transplant recipients compared 
to the general population. It has long been established that the risk of acquiring infection is higher in 
transplant recipients and, in particular, the first 6 months following transplantation. And yet, 
allograft failure with rejection is inevitable without long-term immunosuppression. 
Long-term exposure to an immunosuppressant itself is associated with chronic allograft damage and 
other metabolic side effects. A previous report suggested that 100% of patients exposed to long-
term cyclosporine developed features of long-term allograft damage after 10 years. Furthermore, it 
is well known that long-term exposure of antiproliferative agents and oral steroids is associated with 
skin malignancies, raised cardiovascular risk and mortality. 
Therefore, the Imperial College Kidney and Transplant Centre aimed to develop an 
immunosuppression regimen to provide adequate alloimmune control, yet sparing patients from 
excessive risk of complications. This became possible with the development of Campath 1H.  
Campath 1H is a humanised monoclonal antibody that targets CD52 antigens. CD52 antigen is one of 
the most abundant antigens on human lymphocytes. Once CD52 antigen is stimulated, it causes 
profound lymphopenia by cell lysis and a marked cytokine release. It had been hypothesised that 
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this period of lymphopenia is crucial for development of immune tolerance and therefore facilitate s 
a lower intensity of long-term immunosuppression.  
Although it had been shown by Kirk et al. that Campath 1H on its own is insufficient to generate 
immune tolerance, maintenance immunosuppression is crucial for successful long-term survival 
following Campath induction. It had been shown that Campath 1H allowed a safe reduction in 
intensity of maintenance immunosuppressant. Calne et al. showed that a medium dose of 
cyclosporine maintenance following Campath induction is as efficacious as conventional triple 
therapy maintenance consisting of high-dose cyclosporine, steroids and azathioprine. 
This leads to the development of this simple minimalistic regimen in our unit consisting of Campath 
induction and medium-dose tacrolimus maintenance. Albeit tacrolimus and cyclosporine both exert 
their pharmacological property via a similar pathway and tacrolimus delivers similar therapeutic 
efficacy, it has been shown that tacrolimus has an improved risk profile in the long term. We hoped 
that this lower intensity of maintenance immunosuppressant would translate to improvements in 
long-term allograft function, patient and allograft survivals. 
Our unit converted to this Campath regimen in 2004; I described the results from the pilot study in 
chapter 3. The results showed that 1-year cumulative patient and graft survival were comparable to 
the historic cohort consisting of patients receiving daclizumab induction and tacrolimus and 
mycophenolate mofetil maintenance regimes with steroids at 1 year. This pilot study also showed a 
substantial reduction in rejection, albeit not statistically significant. The incidence of new onset 
diabetes after transplantation [NODAT] and calcineurin inhibitor toxicity remained low, likely as a 
result of spared use of steroids. This pilot study was a retrospective short cohort study and number 
of subjects were small, these small retrospective cohot studies was subjected to bias related to 
difference in patient characteristics between the two groups, as well as difference in practice 
between the control and test group eras. Neverthelss, the results from this cohort study was 
encouraging, this showed Campath was safe and delivers very similar if no better results in the short 
term.  
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In order to examine the effect of Campath induction in transplantation in more details, we have  
therefore proceeded to develop a formal randomised controlled study to compare the Campath and 
tacrolimus monotherapy regimes with daclizumab induction, tacrolimus and MMF maintenance 
regimes in 2005.  
This open-label RCT was designed as a non-inferior study, aimed at detecting a non-inferiority 
efficacy with a 10% inferiority margin in patient survival with a functioning graft with the Campath 
regimen at 1 year. Details of this trial are described in Chapter 4. I demonstrated the difference of 
survival between the two groups was in favour of the Campath-treated group with 2.6% 
improvement [95%CI -1.7%, 6.9%]. The results from this RCT supported our previous findings with 
the retrospective cohort study that graft survival and function in patients receiving the Campath 
regimen were comparable to the daclizumab-treated cohort. Rejection risk was once again slightly 
lower in the Campath-treated group; however, it did not reach statistical significance.  
Although this randomised controlled study supported our hypothesis that the Campath and 
tacrolimus monotherapy protocol was at least “as good as” the conventional daclizumab induction 
protocol. This supported our argument that this cheaper and miminalstic protocol were at least as 
good as the standard but substantially lower in cost. 
The study was designed to be a non-inferiority study, and therefore the interpretations of the results 
were limitations by trial design and the statistical power. We were not able to detect any potential 
superiority survival signals if that should exist. In order to detect a superiority signal, a considerable 
bigger study is required and is out of scope of resources on both participants and financially for a 
single centre. If resources were no restriction, I would propose a multicentre study to examine the 
risk benefit of this regime in more details. Benefit of a multicentre study does not only provide the 
number of subjects needed to produce the evidence to support the hypothesis of superiority with 
this regime, this also allow to results of the study be more applicable to a wider range of subjects 
and difference in practice across centres. Furthermore, a large study would also reduce the effects 
of confounder bias. In this RCT, there were a bigger proportion of sensitised subjects in the 
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daclizumab group compared to the study group. One would argue the results observed in this RCT 
could be confounded by the imbalance of sensitised subjects between groups. Small clinical studies 
are more prone to these confounder bias caused by randomness. A larger study and will balance the 
effect of randomness, as well as provide the statistical power for post hoc adjusted analysis if 
necessary. 
We were only able to report the results on 1-year outcome because of trial design. An extended 
follow up study is ongoing, this will take a longer follow up period to test if there is a true difference 
in the long term. We would have to rely on the results from the cohort study to provide us an idea 
on the long-term outcomes of this regime in the time being.  
I examined the medium-term outcomes in patients in our original cohort and reported the findings 
in Chapter 5.  Results from this medium-term follow-up cohort showed a comparable 5-year patient 
and graft survival in those receiving the Campath protocol. Unlike some of the reported studies, our 
cohort did not suffer a significant level of “catch-up” acute rejection episodes beyond 6 months. 
After correcting for risk of rejection in the first year, adjusted 5-year cumulative rejection-free 
survival was 86.7% and 92.0% in the Campath and daclizumab group. A time-adjusted risk model did 
not suggest an increased risk of late rejection. I also examined the trend of allograft function on 
individuals over time using a repeat-measurements model and confirmed that there were no overall 
net differences in function or rate of changes in function between the two groups. Another 
interesting finding was that incidences of CNI toxicity were low in both groups, compared to the 
incidence reported in the literature based on a cyclosporine regimen.  
This study was a long-term longitudinal cohort study and was subjected to issues with loss to follow-
up; however, thanks to the nature of our practice, the majority of patients within this cohort were 
followed up in our centre and were provided with an excellent source of data to examine the risk 
and benefit of this regimen.  
Furthermore, one should interpret the results with caution, as with any long term cohort study. The 
results were by the study’s retrospective nature and the difference in chronologies between the two 
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groups. The daclizumab control cohort consisted of mainly subjects transplanted between 2002 and 
2004, whereas the Campath group were transplanted after 2004. Therefore, the results were 
subjected to the change of practice over time. 
As discussed previously, a large long-term follow up study is needed in order to test the long-term 
effect of Campath. The choice of long-term outcome measure to examine is also crucial. Most 
transplant studies were designed with primary outcome measure of graft/patient survival or 
allograft function. These outcomes had substantially improved with advance in immunosuppressant 
maintenance in the last decade and therefore the outcome measures used in these study should 
reflect the concern with long-term allograft pathology, for example CNI toxicity or transplant 
glomerulopathy. Even if the right clinical measure was selected, the difference in these outcomes is 
often very small. Mathematically, it is very difficult to detect a difference in these outcomes without 
a large-scale clinical trial, and will require trial size similar to conventional cardiovascular studies – 
which is extremely hard in transplantation trial due to disease prevalence. One would argue these 
clinical trial design difficulties could be resolved using adaptive clinical trial design and Bayesian 
statistically methods. 
I have demonstrated the short- and long-term efficacies of Campath induction in Chapter 3-5. 
However, it was unclear as to what dosage of Campath would provide a most favourable benefit risk 
balance in transplant recipients. Studies in the literature described a dosage range from a body 
weight-adjusted dosage of up to 1.2mg/kg to a standard dosing of 30 to 60mg in total, and there was 
no clear evidence supporting a higher dose of Campath improving transplant outcomes. There was 
some anecdotal evidence suggesting that the risk of systemic fungal and mycobacterial infections 
was higher in patients who have received high or repeated doses of Campath as maintenance 
therapy. This supported the argument that Campath doses should be adjusted to avoid excess 
dosage and the associated infective complications. Therefore, I performed a dose-finding analysis on 
our cohort of Campath-treated patients and reported the findings in Chapter 6. 608 patients were 
included in the analysis and were divided into quadrants according to their Campath exposure per 
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weight [<0.35mg/kg, 0.35-0.40mg/kg, 0.40-0.48mg/kg and >0.48mg/kg]. The study showed there 
was an approximate 49.8% increased risk of rejection in the first 12 months with patients who 
received less than 0.35mg/kg of Campath and there was no evidence to suggest an additional 
protective effect against rejection with a higher-dose Campath. Alarmingly, patients who received 
the highest dose of Campath >0.48mg/kg appeared to have the highest risk of infection. Compared 
to the group who received an average dose of Campath, this group exposed to the highest dose of 
Campath have a 2.6-fold increased risk of infection in the first 6 months and this increased infective 
risk persisted after 2 years. The results did not change after adjusting the effect of gender difference 
between groups. This analysis showed that patients receiving less than 0.35mg/kg of Campath were 
subjected to an increased risk of rejection and a higher dose of Campath did not offer additional 
protection against rejection, yet raised infective risk. As a result of this study, we changed our 
immunosuppressive protocol to a weight-adjusted Campath induction dose at 0.40mg/kg followed 
by a targeted tacrolimus monotherapy in January 2012. 
Although this dose finding retrospective study was conducted using the objective evidence based on 
laboratory results, the results of this study were affected its study design – as discussed earlier.  
Moreover, the severity and seriousness of the events were not assessed.  
A large clinical trial is needed to confirm the beneficial risk balance of weight adjusting dosage of 
Campath. Apart from the standard clinical outcomes, one should examine the adverse events using 
the International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) guideline and reporting requirement. Defining events based 
on ICH definition of seriousness and causality assessment. This approach would provide an objective, 
repeatable assessment of seriousness and severity of events related to the treatment regime. 
Little data was available to examine the causes of graft loss in Campath-treated patients. In Chapter 
7, I examined the cause of graft loss in our Campath cohort. Patient death with a functioning graft 
remained the commonest cause of graft loss in our unit, accounting for 34% of graft losses, of which 
sepsis was the commonest cause of patient death. Contrary to previous UNOS reports, 
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cardiovascular death only accounted for a moderate portion of total patient deaths [8/33, 24.2%]. 
The reduction of cardiovascular death was likely because of a proactive cardiac screening prior to 
transplantation in our transplant recipients, and this was reported by my colleague, Dr. Nichola 
Kumar, in her MD thesis. Although data from my short- and long-term studies on Campath both 
showed a low risk of rejection, rejection remained an important cause of graft loss. This study once 
again highlighted the importance of patient compliance – 8 grafts were lost due to non-compliance 
despite the minimalistic maintenance regimen.  
As discussed earlier in this thesis, Campath is a powerful lymphopenic agent and the rates of 
repopulation of lymphocytes are variable depending on the lymphocyte subset. Therefore, I 
developed a study to examine the haematological profiles, the relationship between lymphocyte and 
monocyte repopulation and rejection, as well as examined the association of lymphopenia and 
infective risk on patients from the earlier study, based on 96,695 results collected from their routine 
haemological blood work. Details of the results and analysis were reported in chapters 8 and 9. Data 
from this large cohort confirmed previous results that lymphocyte repopulation differs between 
subsets. Lymphocyte repopulation starts weeks after Campath – 96.8% of patients remained 
lymphopenic at 3 months and this fell to 52.3% at 6 months. By 2 years, 75.6% of patients in this 
cohort had recovered their lymphocyte compartment. Interestingly, monocytes depleted 
immediately following Campath and their level remained suppressed for the first 4 weeks after 
transplantation. Monocytes repopulated substantially faster compared to the lymphocyte 
compartment. Monocyte counts in 45% of cohort patients reached a normal level within the first 6 
months and 65% of patients’ routine blood tests demonstrated a normalised monocyte level by 1 
year. There were a few cases of transient thrombocytopenia and neutropenia in the Campath 
cohort; however, there was no evidence to suggest an overall effect on either platelets or 
neutrophils, and this will be discussed in detail by my colleague, Dr. Rawya Charif, in her thesis 
concentrating on the complications of Campath.  
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It had been hypothesised that the recovery of a leukocyte compartment following Campath is 
associated with occurrences of rejection. I developed a mathematical model to examine the rate of 
lymphocyte and monocyte changes over time between rejecters and non-rejecters. The model 
showed that both lymphocyte and monocyte recovery follows a cubic trajectory and the trajectories 
on lymphocyte and monocyte recovery were not different in patients who experienced rejection and 
those who did not. Furthermore, the residual lymphocyte and monocyte counts were not 
statistically different between the two groups.   
This study was the first of it’s kind to examine the profiles of lymphocyte repopulations on 
individuals and its impact on rejection risk. This approach did take into account of changes in the 
individual profile over time and the effect of missing data between time points. However, this 
approach requires a heavy statistical input and mathematical modelling.  
The results of this study were indeed very interesting, the model was built using total lymphocyte 
counts. Therefore, we could not conclude whether lymphocyte subset repopulation has any effects 
on rejection.  
Long-term success in transplant immunosuppression is dependent on the balance between 
immunosuppressive effects to reduce an alloimmune response with the associated infection and 
malignancy risk and metabolic side effects. It was thought that the powerful lymphodepleting ability 
of Campath might result in a high risk of infection. Therefore, in Chapter 10, I examined the 
incidence and pattern of infection, malignancy and NODAT in Campath-treated patients over time, 
as well as tried to answer the question on whether lymphopenia induced by Campath is associated 
with an increased risk of infection. Data from the study showed that the infection rate was highest in 
the first 6 months after transplantation, and urinary tract infection was the commonest form of 
infection and remained high for 12 months. The incidence of infection remained low and I was not 
able to elicit a relationship between lymphopenia and infection risk in our centre. This was likely a 
result of the spared use of MMF; our data showed treatment of rejection by restarting 
corticosteroids, and MMF increased risk of infection by 71%, albeit it just reached statistical 
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significance. Despite the lymphopenia, the incidence of viral infection remained low late after 
transplantation. There were no evidence suggesting a high risk of CMV disease or fungal  infection  
Malignancy remained rare in this cohort, and the cumulative risk of developing malignancy in this 
cohort was 0.5%, 3.1% and 3.5% at 1, 3 and 5 years, respectively. Skin cancer was the commonest 
malignancy. A major limitation of this analysis was that the follow-up from this study might be 
insufficient to delineate the effect of the Campath on future development of malignancy, giving 
malignancy a tendency to develop late following transplantation. Despite the limitation, we were 
surprised to note the low incidence of post-transplant lymphoproliferative disorder in this cohort. It 
was estimated that there was a cumulative risk of 1% at 5 years and this is much lower than 
published literature. This low-risk PTLD is likely as a result of the spare use of antiproliferative agents 
as well as the lymphopenic nature of Campath-destroyed EBV-harboured lymphocytes that could 
potentially evolve into PTLD. 
The metabolic effect of this regime was best reflected by the low incidence of NODAT; 6-year 
NODAT survival of 84.2%. The statistical model suggested that ethnicity, recipient age, weight gain 
and treatment of rejection increase the risk of NODAT.  
In this thesis, I described the short- and medium-term clinical outcomes of this minimalistic regimen 
consisting of Campath induction and tacrolimus maintenance in renal transplantation. I was the 
junior investigator of the CamTac trial, which provided evidence to support clinical outcomes with 
this regimen being “as good” as the conventional regimen, consisting of daclizumab induction with 
tacrolimus and MMF maintenance. I also demonstrated that Campath dosage should be weight-
adjusted to maximise the immunosuppressive effect without risking an increased risk of over-
immunosuppression and related infection; as a result of my study, the immunosuppression regimen 
has changed from a standard dose to a weight-adjusted regimen in the Imperial College Kidney and 
Transplant Centre. I have also showed that patient death with a functioning graft remained the 
commonest cause of graft loss and that a transplant clinician should endeavour to reduce the risk of 
infection in the long term.  
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Regarding the long-term efficacy of this regimen, I demonstrated that the incidence of CNI toxicity, 
transplant glomerulopathy and recurrent disease remains low despite the reduction in the 
immunosuppression burden.  
I developed a mathematical model to examine the haematological profile in a large cohort of 
patients using their routine blood work; I confirmed previous finding that recovery varies between 
lymphocyte subsets. Importantly, I showed evidence that there were no differences in the patterns 
of lymphocyte recovery between rejecters and non-rejecters. 
Although there were limitations in the clinical studies included in this thesis because of study design, 
data from these study supported the notion that this minimalist regimen is efficacious and safe. 
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14  Appendix 
14.1 Risk factors for infection following Campath induction 
14.1.1 Risk of any infection 
Table 14-1 Risk factor analysis for any infection after Campath induction 
  Univariant model Adjusted model Final model 
 Risk Factors Odds Ratio p value Odds Ratio p value Odds Ratio p value 
0-6 months Week 0.93 [0.91,0.95] <0.001 0.94 [0.92,0.96] 0.000 0.93 [0.91,0.94] 0.000 
 Lymphopenia 1.24 [0.77,2.03] 0.370 0.65 [0.38,1.13] 0.127   
 Neutropenia NA 0.999 N/A 0.997   
 Diabetes 1.75 [1.07,2.88] 0.027 2.10 [1.30,3.39] 0.002 2.12 [1.31,3.44] 0.002 
 Reflux nephropathy 3.74 [1.76,7.95] 0.001 3.61 [1.73,7.54] 0.001 3.80 [1.81,7.95] 0.000 
 Female gender 1.88 [1.26,2.81] 0.002 1.70 [1.14,2.53] 0.009 1.80 [1.22,2.68] 0.003 
 Post-rejection 1.09 [0.63,1.87] 0.765 1.54 [0.90,2.63] 0.115 1.71 [0.99,2.96] 0.054 
6-12 months Week 1.02 [0.99,1.05] 0.197 1.02 [0.99,1.06] 0.114 1.02 [0.99,1.05] 0.216 
 Lymphopenia 1.74 [0.97,3.13] 0.065 1.55 [0.85,2.83] 0.150   
 Neutropenia NA 0.999 NA 0.999   
 Diabetes 1.22 [0.51,2.90] 0.656 1.60 [0.72,3.56] 0.247   
 Reflux nephropathy 5.17 [1.69,15.79] 0.004 4.28 [1.60,11.50] 0.004 5.13 [1.67,15.77] 0.004 
 Female gender 1.97 [1.02,3.78] 0.043 1.85 [1.00,3.42] 0.049   
 Post-rejection 3.28 [1.67,6.42] 0.001 1.53 [0.78,2.99] 0.212   
12-24 months Week 1.00 [0.98,1.01] 0.728 1.00 [0.99,1.02] 0.844 1.00 [0.99,1.02] 0.743 
 Lymphopenia 2.19 [1.22,3.94] 0.008 1.93 [1.06,3.51] 0.031 2.22 [1.24,3.96] 0.007 
 Neutropenia 2.84 [0.31,26.30] 0.358 2.67 [0.30,24.08] 0.382   
 Diabetes 1.36 [0.54,3.42] 0.518 1.78 [0.77,4.10] 0.176   
 Reflux nephropathy 4.72 [1.66,13.41] 0.004 4.59 [1.76,11.94] 0.002 3.96 [1.56,10.03] 0.004 
 Female gender 1.07 [0.53,2.16] 0.849 1.10 [0.58,2.10] 0.772   
 Post-rejection 4.58 [2.19,9.60] 0.000 1.79 [0.90,3.55] 0.098   
24-36 months Week 0.98 [0.96,1.01] 0.181 0.99 [0.97,1.02] 0.458 0.98 [0.96,1.00] 0.095 
 Lymphopenia 1.69 [0.71,4.03] 0.238 1.52 [0.66,3.49] 0.325   
 Neutropenia NA 0.999 NA 0.999   
 Diabetes 0.29 [0.05,1.65] 0.161 0.35 [0.07,1.74] 0.201   
 Reflux nephropathy 9.80 [2.59,37.13] 0.001 5.82 [2.12,15.95] 0.001 6.16 [1.99,19.10] 0.002 
 Female gender 3.92 [1.39,11.05] 0.010 2.65 [1.15,6.09] 0.022 3.01 [1.23,7.35] 0.016 
 Post-rejection 4.47 [1.53,13.01] 0.006 1.79 [0.75,4.27] 0.189 4.04 [1.66,9.87] 0.002 
36-48 months Week 1.00 [0.97,1.04] 0.812 1.00 [0.96,1.04] 0.968 1.00 [0.97,1.04] 0.884 
 Lymphopenia 1.38 [0.35,5.36] 0.643 1.33 [0.33,5.42] 0.689   
 Neutropenia 0.00 [0.00,0.00] 0.000 #VALUE! 1.000   
 Diabetes 1.66 [0.36,7.53] 0.513 2.22 [0.56,8.72] 0.255   
 Reflux nephropathy 4.73 [1.25,17.86] 0.022 3.09 [0.73,13.07] 0.125 3.25 [0.95,11.03] 0.059 
 Female gender 3.88 [1.24,12.14] 0.020 3.74 [1.19,11.77] 0.024 3.19 [1.03,9.93] 0.045 
 Post-rejection 1.52 [0.39,5.85] 0.546 1.33 [0.38,4.70] 0.657   
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14.1.2 Surgical infection 
Table 14-2 Risk factor analysis for surgical infection after Campath induction 
  Univariant model Adjusted model Final model 
 Risk Factors Odds Ratio p value Odds Ratio p value Odds Ratio p value 
6 months Week 0.64 [0.57,0.72] 0.000 0.63 [0.56,0.71] 0.000 0.63 [0.56,0.71] 0.000 
 Lymphopenia NA      
 Neutropenia NA      
 Diabetes 2.41 [1.42,4.10] 0.001 2.66 [1.51,4.68] 0.001 2.49 [1.43,4.34] 0.001 
 Reflux nephropathy 1.33 [0.47,3.78] 0.588 1.70 [0.57,5.01] 0.339   
 Female gender 1.18 [0.71,1.97] 0.524 1.24 [0.73,2.10] 0.426   
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14.1.3 Urinary tract infection 
Table 14-3 Risk factor analysis for urinary tract infection after Campath induction 
    Univariant model   Adjusted model   Final model   
  Risk Factors Odds Ratio p value Odds Ratio p value Odds Ratio p value 
6 months Week 0.95 [0.93,0.97] 0.000 0.97 [0.95,1.00] 0.061 0.97 [0.95,1.00] 0.042 
  Lymphopenia 0.72 [0.42,1.24] 0.240 0.53 [0.28,1.00] 0.052 0.52 [0.28,0.98] 0.044 
  Neutropenia NA  NA     
  Diabetes 1.49 [0.78,2.83] 0.225 1.90 [1.00,3.60] 0.049 1.90 [1.00,3.60] 0.049 
  Reflux nephropathy 4.82 [1.98,11.75] 0.001 3.54 [1.42,8.86] 0.007 3.65 [1.46,9.09] 0.006 
  Female gender 2.96 [1.77,4.97] 0.000 2.75 [1.62,4.65] 0.000 2.71 [1.61,4.58] 0.000 
  Post-rejection 0.72 [0.33,1.57] 0.404 0.77 [0.35,1.69] 0.520    
6-12 months Week 1.01 [0.98,1.05] 0.518 1.02 [0.98,1.06] 0.351 1.01 [0.97,1.04] 0.720 
  Lymphopenia 1.42 [0.70,2.88] 0.335 1.10 [0.54,2.24] 0.799    
  Neutropenia NA  NA     
  Diabetes 1.56 [0.54,4.50] 0.411 2.22 [0.85,5.80] 0.102    
  Reflux nephropathy 6.35 [1.62,24.93] 0.008 4.85 [1.45,16.15] 0.010 4.94 [1.42,17.27] 0.012 
  Female gender 4.06 [1.76,9.34] 0.001 3.27 [1.50,7.15] 0.003 3.23 [1.46,7.14] 0.004 
  Post-rejection 3.57 [1.55,8.22] 0.003 1.97 [0.87,4.46] 0.102 3.26 [1.47,7.23] 0.004 
12-24 months Week 1.00 [0.98,1.02] 0.956 1.00 [0.98,1.02] 0.815 1.00 [0.98,1.02] 0.877 
  Lymphopenia 2.13 [0.94,4.81] 0.070 1.79 [0.79,4.07] 0.164    
  Neutropenia 11.38 [0.94,137.72] 0.056 8.85 [0.77,101.89] 0.080 10.57 [0.92,121.63] 0.059 
  Diabetes 1.23 [0.35,4.33] 0.752 1.55 [0.46,5.18] 0.476    
  Reflux nephropathy 7.78 [2.14,28.29] 0.002 6.56 [1.89,22.78] 0.003 5.82 [1.76,19.29] 0.004 
  Female gender 2.50 [0.99,6.31] 0.052 2.33 [0.96,5.66] 0.061 2.41 [1.01,5.75] 0.047 
  Post-rejection 3.26 [1.47,7.23] 0.004 1.43 [0.56,3.66] 0.457    
24-36 months Week 0.98 [0.95,1.01] 0.181 0.02 [1.02,0.00] 0.960 0.99 [0.96,1.03] 0.692 
  Lymphopenia 3.01 [1.00,9.07] 0.051 2.57 [0.89,7.36] 0.080 2.63 [0.99,7.04] 0.053 
  Neutropenia NA  NA     
  Diabetes 0.16 [0.01,1.89] 0.144 0.22 [0.02,2.29] 0.203    
  Reflux nephropathy 14.71 [3.69,58.70] 0.000 10.04 [2.95,34.18] 0.000 13.08 [4.00,42.80] 0.000 
  Female gender 7.18 [1.88,27.39] 0.004 4.14 [1.28,13.39] 0.018 3.49 [1.16,10.52] 0.027 
  Post-rejection 4.47 [1.20,16.72] 0.026 1.78 [0.57,5.53] 0.319     
36-48 months Week 1.00 [0.97,1.04] 0.850 1.00 [0.96,1.04] 0.960 1.00 [0.97,1.04] 0.928 
  Lymphopenia 1.52 [0.37,6.20] 0.559 1.60 [0.38,6.68] 0.519    
  Neutropenia   NA     
  Diabetes 1.81 [0.37,8.82] 0.461 2.51 [0.62,10.22] 0.198    
  Reflux nephropathy 5.36 [1.30,22.13] 0.020 3.20 [0.74,13.95] 0.121 3.44 [0.97,12.17] 0.055 
  Female gender 4.86 [1.41,16.67] 0.012 4.50 [1.31,15.45] 0.017 3.95 [1.16,13.43] 0.028 
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14.1.4 BK nephropathy 
Table 14-4 Risk factor analysis for BK nephropathy after Campath induction 
    Univariant model Adjusted model   Final model 
  Risk Factors Odds Ratio p value Odds Ratio p value Odds Ratio p value 
6 months Week 1.13 [1.01,1.26] 0.040 1.12 [1.00,1.26] 0.056 1.12 [0.99,1.25] 0.062 
  Lymphopenia NA  NA     
  Neutropenia NA  NA     
  Diabetes 0.70 [0.09,5.69] 0.739 0.76 [0.09,6.36] 0.803    
  Reflux nephropathy  NA     
  Female gender 0.57 [0.12,2.85] 0.497 0.64 [0.12,3.36] 0.601    
  Post-rejection 5.23 [1.25,21.90] 0.024 4.12 [0.89,19.12] 0.071 4.15 [0.98,17.56] 0.053 
6-12 months Week 1.16 [0.82,1.64] 0.402 NA   1.12 [0.99,1.25] 0.062 
  Lymphopenia NA  NA     
  Neutropenia NA  NA     
  Diabetes NA  NA     
  Reflux nephropathy NA  NA     
  Female gender NA  NA     
  Post-rejection NA   NA   4.15 [0.98,17.56] 0.053 
12-24 months Week 1.04 [0.94,1.15] 0.417 1.04 [0.94,1.15] 0.427 1.04 [0.94,1.15] 0.417 
  Lymphopenia NA  NA     
  Neutropenia NA  NA     
  Diabetes NA  NA     
  Reflux nephropathy 14.42 [0.90,230.57] 0.059 14.15 [0.88,226.38] 0.061    
  Female gender NA  NA     
  Post-rejection NA  NA     
24-36 months Week 0.97 [0.84,1.12] 0.685 0.97 [0.84,1.12] 0.685 0.97 [0.84,1.12] 0.685 
  Lymphopenia NA  NA     
  Neutropenia NA  NA     
  Diabetes NA  NA     
  Reflux nephropathy NA  NA     
  Female gender NA  NA     
  Post-rejection NA   NA       
36-48 months Week No cases      
  Lymphopenia NA      
  Neutropenia NA      
  Diabetes NA      
  Reflux nephropathy NA      
  Female gender NA      
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14.1.5 CMV infection 
Table 14-5 Risk factor analysis for CMV disease after Campath induction 
    Univariant model Adjusted model Final model 
  Risk Factors Odds Ratio p value Odds Ratio p value Odds Ratio p value 
6 months Week 1.14 [1.02,1.27] 0.021 1.21 [1.06,1.38] 0.004 1.14 [1.02,1.27] 0.021 
  Lymphopenia 0.72 [0.09,5.88] 0.761 2.40 [0.27,21.14] 0.430    
  Neutropenia NA  NA     
  Diabetes 0.61 [0.08,4.90] 0.644 0.78 [0.09,6.52] 0.820    
  Reflux nephropathy 2.50 [0.31,19.98] 0.389 3.12 [0.35,27.87] 0.308    
  Female gender 1.38 [0.37,5.14] 0.632 1.60 [0.39,6.61] 0.517    
  Post-rejection 2.49 [0.52,11.99] 0.256 1.42 [0.26,7.63] 0.685    
6-12 months Week 1.00 [0.90,1.11] 0.984 1.02 [0.91,1.13] 0.778 1.00 [0.90,1.11] 0.984 
  Lymphopenia 1.57 [0.29,8.60] 0.601 2.01 [0.35,11.68] 0.437    
  Neutropenia NA  NA     
  Diabetes NA  NA     
  Reflux nephropathy 3.71 [0.43,31.81] 0.231 2.97 [0.34,26.28] 0.327    
  Female gender 0.34 [0.04,2.90] 0.323 0.28 [0.03,2.44] 0.250    
  Post-rejection 0.87 [0.10,7.45] 0.899 0.43 [0.05,3.96] 0.459    
12-24 months Week No cases           
  Lymphopenia NA       
  Neutropenia NA       
  Diabetes NA       
  Reflux nephropathy NA       
  Female gender NA       
  Post-rejection NA       
24-36 months Week No cases           
  Lymphopenia NA       
  Neutropenia NA       
  Diabetes NA       
  Reflux nephropathy NA       
  Female gender NA       
  Post-rejection NA           
24-36 months Week No cases       
  Lymphopenia NA       
  Neutropenia NA       
  Diabetes NA       
  Reflux nephropathy NA       
  Female gender NA       
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14.1.6 Bacteraemia 
Table 14-6 Risk factor analysis for bacteraemia after Campath induction 
    Univariant model   Adjusted model   Final model   
  Risk Factors Odds Ratio p value Odds Ratio p value Odds Ratio p value 
6 months Week 0.94 [0.90,0.98] 0.005 0.97 [0.92,1.02] 0.193 0.94 [0.90,0.98] 0.005 
  Lymphopenia 2.07 [0.55,7.85] 0.285 1.44 [0.35,6.02] 0.615    
  Neutropenia NA  NA     
  Diabetes 2.12 [0.78,5.82] 0.143 2.74 [1.12,6.73] 0.027    
  Reflux nephropathy 3.92 [0.91,16.93] 0.067 6.53 [1.77,24.13] 0.005    
  Female gender 0.98 [0.41,2.34] 0.961 0.72 [0.31,1.67] 0.441    
  Post-rejection 1.78 [0.57,5.49] 0.319 2.28 [0.77,6.71] 0.135    
6-12 months Week 1.02 [0.95,1.09] 0.623 1.03 [0.96,1.10] 0.486 1.02 [0.95,1.09] 0.623 
  Lymphopenia 3.94 [0.80,19.41] 0.092 3.27 [0.64,16.69] 0.153    
  Neutropenia NA       
  Diabetes 1.42 [0.19,10.37] 0.729 2.14 [0.36,12.79] 0.406    
  Reflux nephropathy 8.83 [0.74,104.71] 0.084 6.19 [0.75,50.90] 0.090    
  Female gender 1.90 [0.39,9.29] 0.430 1.41 [0.34,5.79] 0.632    
  Post-rejection 6.02 [1.18,30.74] 0.031 2.25 [0.50,10.12] 0.292     
12-24 months Week 1.01 [0.97,1.06] 0.488 1.02 [0.98,1.07] 0.267 1.01 [0.97,1.06] 0.488 
  Lymphopenia 3.16 [0.66,15.07] 0.149 3.74 [0.72,19.38] 0.116    
  Neutropenia 0.00 [0.00,0.00] 0.000 #VALUE! 0.998    
  Diabetes 1.51 [0.21,10.91] 0.685 2.12 [0.34,13.37] 0.424    
  Reflux nephropathy 1.75 [0.12,26.23] 0.686 1.66 [0.12,22.34] 0.704    
  Female gender 1.69 [0.36,7.85] 0.502 1.43 [0.31,6.68] 0.648    
  Post-rejection 3.32 [0.62,17.92] 0.163 0.90 [0.16,4.98] 0.908     
24-36 months Week 0.98 [0.96,1.01] 0.181 1.02 [0.95,1.09] 0.600 0.99 [0.94,1.05] 0.841 
  Lymphopenia 1.69 [0.71,4.03] 0.238 0.51 [0.05,5.40] 0.577    
  Neutropenia NA       
  Diabetes 0.29 [0.05,1.65] 0.161      
  Reflux nephropathy 9.80 [2.59,37.13] 0.001      
  Female gender 3.92 [1.39,11.05] 0.010 11.86 [1.15,122.62] 0.038    
  Post-rejection 4.47 [1.53,13.01] 0.006 13.65 [1.26,148.39] 0.032 7.89 [1.44,43.07] 0.017 
24-36 months Week Unable to estimate - 1 case only     
  Lymphopenia NA       
  Neutropenia NA       
  Diabetes NA       
  Reflux nephropathy NA       
  Female gender NA       
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14.1.7 Fungal infection 
Table 14-7 Risk factor analysis for fungal infection after Campath induction 
    Univariant model   Adjusted model   Final model   
  Risk Factors Odds Ratio p value Odds Ratio p value Odds Ratio p value 
6 months Week 1.19 [0.81,1.75] 0.376     1.19 [0.81,1.75] 0.376 
  Lymphopenia NA       
  Neutropenia NA       
  Diabetes NA       
  Reflux nephropathy NA       
  Female gender NA       
  Post-rejection NA           
6-12 months Week 1.20 [0.81,1.77] 0.358     1.20 [0.81,1.77] 0.358 
  Lymphopenia NA       
  Neutropenia NA       
  Diabetes NA       
  Reflux nephropathy NA       
  Female gender NA       
  Post-rejection NA           
12-24 months Week 0.99 [0.90,1.09] 0.806   0.99 [0.90,1.09] 0.806 
  Lymphopenia NA       
  Neutropenia NA       
  Diabetes NA       
  Reflux nephropathy NA       
  Female gender NA       
  Post-rejection NA           
24-36 months Week 1.03 [0.94, 1.13] 0.553     1.03 [0.94, 1.13] 0.553 
  Lymphopenia NA       
  Neutropenia NA       
  Diabetes NA       
  Reflux nephropathy NA       
  Female gender NA       
  Post-rejection NA           
24-36 months Week No cases       
  Lymphopenia NA       
  Neutropenia NA       
  Diabetes NA       
  Reflux nephropathy NA       
  Female gender NA       
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14.1.8 Other infections 
Table 14-8 Risk factor analysis: Other infections after Campath induction 
    Univariant model   Adjusted model   Final model   
  Risk Factors Odds Ratio p value Odds Ratio p value Odds Ratio p value 
6 months Week 0.94 [0.89,1.00] 0.069 0.95 [0.88,1.02] 0.151 0.94 [0.89,1.00] 0.069 
  Lymphopenia 0.85 [0.19,3.88] 0.835 0.48 [0.08,2.72] 0.405    
  Neutropenia NA       
  Diabetes 1.21 [0.35,4.20] 0.767 1.28 [0.36,4.52] 0.705    
  Reflux nephropathy 1.02 [0.11,9.90] 0.984 1.19 [0.12,11.57] 0.881    
  Female gender 1.48 [0.56,3.95] 0.429 1.35 [0.49,3.75] 0.561    
  Post-rejection 1.73 [0.43,6.98] 0.438 2.00 [0.48,8.43] 0.344     
6-12 months Week 1.05 [0.97,1.12] 0.213 1.07 [0.98,1.16] 0.122 1.05 [0.97,1.12] 0.213 
  Lymphopenia 3.55 [0.77,16.43] 0.105 3.57 [0.72,17.62] 0.119    
  Neutropenia NA 1.000      
  Diabetes 1.44 [0.40,5.16] 0.576 1.68 [0.34,8.20] 0.522    
  Reflux nephropathy 3.10 [0.69,13.87] 0.139 4.28 [0.86,21.30] 0.076    
  Female gender 0.68 [0.21,2.16] 0.512 0.78 [0.22,2.70] 0.693    
  Post-rejection 4.36 [1.53,12.45] 0.006 1.68 [0.48,5.86] 0.415     
12-24 months Week 1.00 [0.98,1.01] 0.728 0.99 [0.96,1.02] 0.445 0.98 [0.95,1.01] 0.163 
  Lymphopenia 2.19 [1.22,3.94] 0.008 1.31 [0.52,3.30] 0.570    
  Neutropenia 2.84 [0.31,26.30] 0.358      
  Diabetes 1.36 [0.54,3.42] 0.518 3.35 [1.10,10.24] 0.032 3.09 [1.00,9.56] 0.051 
  Reflux nephropathy 4.72 [1.66,13.41] 0.004 1.80 [0.29,11.04] 0.523    
  Female gender 1.07 [0.53,2.16] 0.849 0.30 [0.09,1.02] 0.054    
  Post-rejection 4.58 [2.19,9.60] 0.000 3.32 [1.16,9.51] 0.026 5.18 [1.85,14.50] 0.002 
24-36 months Week 0.98 [0.93,1.03] 0.366 0.97 [0.92,1.03] 0.310 0.98 [0.93,1.03] 0.366 
  Lymphopenia 0.65 [0.09,4.63] 0.670 0.61 [0.08,4.92] 0.646    
  Neutropenia NA       
  Diabetes 0.71 [0.07,7.62] 0.779 0.65 [0.07,6.26] 0.706    
  Reflux nephropathy NA       
  Female gender 0.55 [0.09,3.28] 0.508 0.65 [0.11,3.71] 0.623    
  Post-rejection 2.12 [0.39,11.38] 0.382 1.45 [0.26,8.16] 0.674     
36-48 months Week No cases       
  Lymphopenia NA       
  Neutropenia NA       
  Diabetes NA       
  Reflux nephropathy NA       
  Female gender NA       
  Post-rejection NA           
 
